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Salmonellae with reduced susceptibility to the fluoroquinolones have been 
reported to be responsible for treatment failure. The minimal inhibitory 
concentrations (MICs) of fluoroquinolones for these strains were lower than the 
recommended breakpoint concentrations for susceptible strains but were higher than 
those for the majority of susceptible strains. They also had a gyrA mutation that was 
present as one of the mutations in strains with high-level resistance. This study aimed 
to investigate the ability of six different fluoroquinolones to select fluoroquinolone-
resistance in two Salmonella serotypes, Salmonella enterica serotype Typhimurium 
and S. Hadar, by determining the mutant prevention concentration (MPC) of these 
fluoroquinolones; and to follow the accumulation of and characterize target gene 
mutations by in vitro stepwise selection and molecular methods, respectively. 
The MFCs of norfloxacin, ciprofloxacin, ofloxacin, levofloxacin, 
moxifloxacin and gemifloxacin for both Salmonella serotypes were similar although 
the MPC/MIC ratios for S. Typhimurium were higher than those for S. Hadar. All 
MFCs were below the achievable serum concentrations. 
S. Typhimurium 1^ -^step mutants that developed when the fluoroquinolone-
susceptible parent was first exposed to a fluoroquinolone usually haboured a gyrA 
mutation (Asp87 —>Asn/Gly/His/Tyr) and had MICs 4 - 16 times higher than those 
for the parent but lower than the breakpoints for susceptible strains. AgyrB mutation 
(Glu466一Asp) was detected in one mutant for which the MICs were 2 - 8 times 
higher. Second-step mutants that developed when r^-step gyrA or gyrB mutants were 
exposed to fluoroquinolones had a gyrA mutation, Ser83—Phe in addition to the one 
present in the parents or an Asp87—Gly in addition to the gyrB mutation in the 
parent. The MICs for all mutants were 2 - 16 times higher than those for 
their parents, most of which were below the susceptible breakpoints. All strains with 
one or more gyrA mutations were resistant to nalidixic acid. 
Mutations in parC (Glu51/Gly78—Asp, Ser80—Arg/Ile or Glu84—Gly/Lys) 
appealed in 3^^-step mutants. These mutants were resistant to most of the 
fluoroquinolones tested. No additional mutation was detected in step mutants 
although the MICs were 2 - 1 6 times higher than those for their 3^^-step parents. 
i 
Fewer mutations were detected in resistant strains that developed after 
stepwise selection of S. Hadar by fluoroquinolones. First-step mutants harboured a 
gyrA (Asp87—>Asn/Gly/Tyr or Ser83—>Phe) or a gyrB (Glu466-^Asp) mutation. No 
additional mutation was found in 2"^-step mutants although MICs were 2 - 3 2 times 
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Salmonellae are Gram-negative bacilli belonging to the family 
Enterobacteriaceae. They are non-fastidious, i.e. with simple nutritional requirements 
and are facultative anaerobes. 
1.1 Morphology 
Salmonellae resemble other enterobacteria in microscopic morphology. 
They are actively motile by peritrichous flagella and have adhesive fimbriae, but they 
usually do not form capsules. 
They form middle-sized, translucent smooth colonies on nutrient agar. 
Colonies can vary from smooth to rough (S-R). This change is due to loss of 
0-specific side chains of the smooth lipopolysaccharide, leaving the basal R core and 
lipid A. 
1.2 Antigenic structure 
Salmonellae possess two sets of antigens - somatic (O) antigens and 
flagellar (H) antigens. Some strains also form Vi antigen which is thought to be 
related to virulence. 
Somatic antigens are heat-stable polysaccharides which form part of the 
cell wall lipopolysaccharides and endotoxins. Many different O antigens, designated 
by Arabic numbers, are found among salmonella strains. A single bacterial strain may 
contain more than one O antigen. 
Flagellar antigens are proteins that make up the peritrichous flagellae. In 
1 
contrast to O antigens, H antigens are labile to heat. In most salmonellae, the 
flagellae exhibit diphasic variation, i.e. they appear in two alternative forms which 
are defined by two different sets of genes in the bacterial genome. When one of these 
sets is expressed, one or more phase 1 H antigens are produced and when the other 
set is expressed, two or more phase 2 H antigens are produced. Phase 1 H antigens 
are designated by lower-case letters while phase 2 H antigens are designated by both 
lower-case letters and Arabic numerals. 
The antigenic structure of a salmonella strain is usually designated by its O, 
phase 1 and phase 2 H antigens. For example, the antigenic structure of S. 
Typhimurium is 1, 4, 5, 12: i: 1, 2, where 1, 4, 5, 12 are the O antigens, i is the phase 
1 H antigen and 1, 2 are the phase 2 H antigens. 
1.3 Identification 
Salmonellae are identified biochemically and serologically. They are 
oxidase negative, non lactose-fermenting and urease negative. 
1.4 Nomenclature and classification 
The nomenclature and classification of Salmonella are very complex and 
have been constantly modified and revised (Brenner et al., 2000). Initially, every 
serotype was regarded as a separate species, e.g. S. enteritidis. However, by 
DNA-DNA hybridization analysis, Crosa et al. (1973) showed that nearly all 
serotypes of Salmonella and the former genus Arizona were highly related at the 
genomic level and should therefore belong to a single species named later as 
choleraesuis. Since “choleraesuis” is also the name of a serotype, it was changed to 
enterica to avoid confusion (Hohmann, 2001). 
2 
At present, the Centers for Disease Control and Prevention (CDC) divides 
the genus Salmonella into two species - the type species Salmonella enterica and 
Salmonella bongori (Brenner et al； 2000). Both species contain many serotypes. S. 
enterica contains six subspecies: S. enterica subsp. enterica (subspecies I)，S. enterica 
subsp. salamae (subspecies II), S. enterica subsp. arizonae (subspecies Ilia), S. 
enterica subsp. diarizona (subspecies Illb), S. enterica subsp. houtenae (subspecies 
IV) and S. enterica subsp. indica (subspecies VI). 
Serotypes are designated by their O and H antigens. More than 2000 
Salmonella serotypes have now been reported (Bopp et al., 1999; Brenner et aL, 2000; 
Gorman and Adley, 2003). Most of them belong to subspecies I and are mainly 
isolated from humans and warm-blooded animals. They are usually named after the 
place of first isolation. Since the full name oi Salmonella serotype is rather long, it is 
often abbreviated, e.g. S. enterica subsp. enterica serotype Typhimurium is referred to 
as S. enterica serotype Typhimurium or just S. Typhimurium. Serotypes of other 
subspecies of S. enterica and S. bongori are usually isolated from cold-blooded 
animals and the environment (rarely from humans) and are not given names but 
designated only by their antigenic formulae. 
1.5 Pathogenesis and virulence 
Salmonella infections can be classified into enteric fever and gastroenteritis. 
The former is a septicaemic type of illness while the latter is a diarrheal type. Both 
are initiated by ingestion of a sufficient number of organisms. The number of cells 
that must be swallowed in order to cause infection, i.e. the infective dose, is uncertain 




1.6.1 Enteric fever 
Enteric fever which includes typhoid and paratyphoid fever is caused by S. 
Typhi and S. Paratyphi A, B, C, respectively. These organisms are mainly human 
pathogens. The infection is acquired by ingestion of contaminated food or drink. 
After reaching the intestine, the organism penetrates the ileal mucosa and multiplies 
in the mesenteric lymph nodes. They then invade the blood stream via the thoracic 
duct. In this early period, symptoms are often nonspecific including a dry cough, a 
dull continuous headache, abdominal discomfort and fever. This primary bacteraemic 
phase usually lasts for 7-10 days when the gallbladder, liver, spleen, kidney and bone 
marrow are infected. The organism multiplies intracellularly in these organs and then 
passes into blood again causing specific clinical signs to develop which include 
relative bradycardia, hepatomegaly, splenomegaly and rose spots. 
Classic typhoid fever is a serious infection but may vary in its presentation 
from mild or asymptomatic to severe or even fatal. World Health Organization 
(WHO) reported that 16 million patients are infected resulting in 600,000 deaths 
worldwide annually (WHO, 1996; Crump et al., 2003). Up to 5% of typhoid patients 
who have recovered continue to excrete the organism and become chronic carriers 
(Lewis, 1997). 
1.6.2 Gastroenteritis 
The majority of Salmonella infections are gastroenteritis or food-poisoning 
caused by salmonellae which are primarily animal pathogens. The infection is 
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acquired by ingestion of contaminated food. The incubation period is short, usually 8 
- 4 8 hours and symptoms include vomiting, diarrhea and abdominal pain. Patients 
usually recover spontaneously within a few days. However, the organism can 
occasionally become invasive causing bacteraemia, meningitis, etc. Non-typhoid 
infections are prevalent in the world, even in the United States, where more than one 
million cases and 600 deaths are estimated annually (Mead et al., 1999). 
1.7 Treatment 
1.7.1 Enteric fever 
Antibiotics are essential in the treatment of typhoid fever. Untreated 
typhoid fever has a mortality approaching 20% (Lewis, 1997). In the 1940s, 
chloramphenicol was the drug of choice (Lewis, 1997). Since the development of 
plasmid-mediated chloramphenicol-resistance in S. Typhi in the 1970s (Herzog, 
1976), ampicillin and co-trimoxazole were used. However, simultaneous resistance 
to all three antibiotics has become increasingly common (CDC, 1972; Paniker and 
Vilma, 1972; Anderson, 1975; Rowe, Ward, and Threlfall, 1997). Fluoroquinolones 
such as ciprofloxacin are now the drugs of choice for the treatment of typhoid 
patients (Akalin, 1999; Ackers et al., 2000). 
However, it is more difficult to treat chronic carriers. Prolonged course of 
ampicillin, amoxycillin, co-trimoxazole or ciprofloxacin can only cure up to 80% of 
carriers (Lewis, 1997). 
1.7.2 Gastroenteritis 
Uncomplicated cases of Salmonella gastroenteritis require only supportive 
treatment such as fluid and electrolyte replacement. Antibiotic therapy should not be 
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given since it prolongs the carrier state and exacerbates symptoms. However, 
invasive salmonellosis, which is not common, does require prompt antibiotic 
treatment. 
1.8 Epidemiology and control 
1.8.1 Enteric fever 
Typhoid and paratyphoid bacilli are essentially human pathogens and the 
infection is transmitted by the faecal-oral route. Control thus depends on provision of 
clean drinking water and proper disposal of human excreta. In countries where 
typhoid fever is endemic, TAB (Typhi, Paratyphi A and B) vaccines have been used, 
but with variable efficiency. Recently, Ty21a, an oral live attenuated vaccine, has 
been developed and shown to be a potential candidate giving higher protection rates 
(Lewis, 1997). 
1.8.2 Salmonella food poisoning 
Salmonellosis is generally acquired by ingestion of foods of animal origin. 
Control thus depends on proper handling and adequate cooking of food to avoid 
contamination and cross-contamination. 
2. Fluoroquinolones 
Fluoroquinolones are a group of relatively new synthetic, orally absorbed 
antimicrobial agents. They mainly differ from the quinolones by an additional 
fluorine atom at position 6 of the main nucleus (Figure 1). As a result of this and 
other chemical modifications, they have wider antibacterial spectrum, better 
bioavailability and pharmacokinetic characteristics including better tissue 
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Figure 1 Chemical structure of nalidixic acid and fluoroquinolones. 
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penetration. 
2.1 History of fluoroquinolones 
The discovery of nalidixic acid in the 1960,s as a byproduct of the 
purification of chloroquine (an antimalarial drug) initiated the development of the 
quinolones (Lesher et al., 1962). Nalidixic acid and other first-generation quinolones 
(clinoxacin and oxolinic acid) have a narrow spectrum of activity and are active only 
against some Gram-negative bacteria (Yao and Moellering, 1999; Bearden and 
Danziger, 2001). 
In 1986, the first fluoroquinolone to be used clinically, norfloxacin, was 
developed. Subsequently, more fluoroquinolones such as ciprofloxacin (in 1987), 
ofloxacin (in 1991), lomefloxacin and temafloxacin (in 1992) were developed. These 
fluoroquinolones are also referred to as the second-generation quinolones and have 
much broader spectrum and pharmacokinetic properties (Scholar and Pratt, 2000; 
Bearden and Danziger, 2001; File Jr and Slama, 2001). 
Third-generation quinolones were developed in the 1990s. They are more 
active against Gram-positive bacteria and are also active against anaerobes and other 
bacterial species besides retaining activity against Gram-negative bacteria (Yao and 
Moellering, 1999; Scholar and Pratt, 2000). Levofloxacin is the L-isomer of 
ofloxacin (Walker, 1999; File Jr and Slama, 2001). Sparfloxacin and grepafloxacin 
are developed from ciprofloxacin by addition of a methyl and an amino group, 
respectively at position 5 (Walker, 1999). Trovafloxacin, with great anaerobic activity, 
was released into the market in 1998 (Spangler, Jacobes and Appelbaum, 1996). 
Although some fluoroquinolones (e.g. temafloxacin, grepafloxacin and 
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trovafloxacin) have been withdrawn or restricted for use due to toxic side effects, 
new members continue to be developed (Hooper, 2001a). Gatifloxacin and 
moxifloxacin have a methyl group and a methoxy group, respectively at position 8, 
as well as additional side groups at the C-1 and C-7 positions (Gootz and Brighty, 
1998). They are more active against atypical pathogens, e.g. Chlamydia sp., 
Mycoplasma pneumoniae and Legionella pneumophilia. Gemifloxacin is the newest 
fluoroquinolone to be developed and has enhanced activity against Gram-positive 
bacteria (Ball, 2000). 
2.2 Mechanisms of action 
Fluoroquinolones act by targeting the bacterial enzyme - DNA gyrase (also 
known as topoisomerase II) and topoisomerase IV (Hooper, 2001a & b). DNA gyrase 
consists of two A and two B subunits which are encoded by gyrA and gyrB genes, 
respectively (Gootz and Brighty, 1998). Topoisomerase IV consists of two parC and 
two parE subunits encoded by parC and parE genes, respectively and shows 
homology with DNA gyrase (Hooper, 2001a). In Staphylococcus aureus, the 
corresponding topoisomerase IV genes are grlA and grlB (Ince and Hooper, 2000). 
Both enzymes are essential for DNA replication, recombination and repair. DNA 
gyrase facilitates initiation of replication by removing positive supercoiling from 
closed-circular DNA while topoisomerase IV separates the catenated daughter DNA 
during the final phase of replication (Adams et al., 1992; Wang, 1996). 
Fluoroquinolones bind to and stabilize the DNA-DNA enzyme complex so that 
movement of the replication fork is blocked. As a result, DNA synthesis is inhibited 
and the bacterial cell dies (Drlica and Zhao, 1997; Hooper, 1998). 
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These two enzymes are not bound to the same extent by fluoroquinolones. 
In general, in Gram-negative bacteria such as Escherichia coli or Neisseria 
gonorrhoeae, DNA gyrase is the primary and topoisomerase IV the secondary target 
(Belland et al., 1994; Khodursky, Zechiedrich and Cozzarelli, 1995). In contrast, in 
Gram-positive bacteria such as S. aureus or Streptococcus pneumoniae, 
topoisomerase IV is the primary target (Ferrero et al., 1994; Choi, Lee and Lee, 
1998). In Mycobacterium tuberculosis, Helicobacter pylori and Treponema pallidum, 
topoisomerase IV genes are absent so that DNA gyrase is the only fluoroquinolone 
target (Tomb et al., 1997; Cole et al, 1998; Fraser et al., 1998). 
Interestingly, fluoroquinolones themselves show target preferences. In S. 
pneumoniae, ciprofloxacin, levofloxacin and norfloxacin act primarily on 
topoisomerase IV while moxifloxacin, clinafloxacin, gatifloxacin and sparfloxacin 
act primarily on DNA gyrase (Pan and Fisher, 1997; Chauvel and Courvalin, 1999; 
Fukuda and Hiramatsu, 1999; Hooper, 2000a; Houssaye, Gutmann and Varon, 2002). 
3. Antimicrobial resistance 
Antimicrobial resistance is a serious problem worldwide and its 
development compromises the efficiency of antimicrobial actions. It is a complicated 
phenomenon resulting from interactions of the drug, the microorganism and the 
environment. 
3.1 Microorganism-mediated resistance 
Microorganism-mediated resistance is defined as resistance that results 
from genetically encoded characteristics of the microorganism (Quintiliani Jr, Sahm 
and Courvalin, 1999; Forbes, Sahm and Weissfeld, 2002). It can be classified into 
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two groups - intrinsic resistance and acquired resistance. 
3.1.1 Intrinsic resistance 
Intrinsic resistance is the natural resistance or insensitivity to antimicrobial 
agents of a bacterial species without any genetic alteration that results from the 
normal genetic, structural or physiologic state (Towner, 1997; Quintiliani Jr, Sahm 
and Courvalin, 1999; Forbes, Sahm and Weissfeld, 2002; Henriques-Normark and 
Normark, 2002). 
For example, Klebsiella sp. are resistant to ampicillin due to production of 
/5 -lactamases (Forbes, Sahm and Weissfeld, 2002). Hydrophobic antibiotics do not 
penetrate the outer membrane of some bacteria so these bacteria are less susceptible 
to hydrophobic antibiotics (Nikaido, 2001). Pseudomonas aeruginosa is the bacterial 
species that has intrinsic resistance to various antibiotics due to presence of 
multidrug efflux pumps, restricted permeability in outer-membrane and P-lactamase 
(Li, Nikaido and Poole, 1995; Hancock and Speert, 2000). Mycoplasma sp. has no 
peptidoglycan in the cell wall and is thus resistant to P-lactam antimicrobial agents 
(Nikaido, 2000). 
Since intrinsic resistance is a natural trait of certain bacterial species, it can 
be used as a guide in treatment when only the identity of the microorganism is 
known or in the preliminary identification of bacteria. 
3.1.2 Acquired resistance 
Acquired resistance refers to resistance which results from gene mutations 
or horizontal gene transfer causing altered cellular structure and physiology (Towner, 
1997; Quintiliani Jr, Sahm and Courvalin, 1999; Forbes, Sahm and Weissfeld, 2002; 
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Henriques-Normark and Normark, 2002). Theoretically, this type of resistance can 
occur in any bacterial species. 
Resistance to antibiotics can be due to 1) alterations of drug target; 2) 
decreased permeability leading to decreased intake; 3) overexpression of efflux 
pumps leading to decreased uptake; 4) production of enzyme to destroy or inactivate 
the drug; 5) production of new target(s) insensitive to the drug; or 6) alteration of 
metabolic pathways (Quintiliani Jr, Sahm and Courvalin, 1999; Henriques-Normark 
and Normark, 2002). 
3.2 Resistance due to environmental factors 
Such resistance occurs as a result of a change in the physical or chemical 
characteristics of the environment so that the activity of an antibiotic or the normal 
physiologic response of bacteria to the antibiotic is altered (Quintiliani Jr, Sahm and 
Courvalin, 1999; Forbes, Sahm and Weissfeld, 2002). 
For example, a high pH increases the activities of aminoglycosides and 
erythromycin while decreases those of tetracycline. Aminoglycoside activities 
diminish when cation (such as Ca^^ or Mg2+) concentration increases (notably against 
P. aeruginosa) or in the absence of oxygen. Antibacterial activity can also be affected 
by certain nutrients or metabolites (Forbes, Sahm and Weissfeld, 2002). 
Information on environmental factors affecting antimicrobial activity is 
important towards designing of various conditions for in vitro susceptibility testing. 
3.3 Biological and clinical resistance 
Biological resistance is defined as any changes resulting in a 
microorganism being less susceptible to an antimicrobial agent than before. If its 
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susceptibility to an antimicrobial agent decreases to the extent that the drug has no 
clinical efficiency, the microorganism is regarded as resistant to the drug clinically 
(Forbes, Sahm and Weissfeld, 2002). 
Clinical resistance is closely associated with treatment outcome. Strains 
with biological resistance but not clinical resistance may play an important role in the 
development of resistant mutants (Molbak et al., 1999; Parry, 2003). 
3.4 Breakpoints 
Breakpoint concentration is a concentration whereby an organism is 
categorized as susceptible, intermediate or resistant and can be used to guide 
therapeutic choice and predict treatment outcome (MacGowan and Wise, 2001; 
Mouton, 2002; NCCLS, 2002). 
When an organism is regarded as susceptible to a certain drug, it will be 
killed by the drug with normal dosage and the patient will respond favorably to 
treatment. An organism that is categorized as intermediate will have its MICs 
approaching achievable serum or tissue concentration and can be inhibited clinically 
if it is at a site where the drug concentrates or if a higher dosage is used. An organism 
that is resistant to an antibiotic will not be eradiated clinically if a normal dosing 
regimen is used and the drug should not be used to treat infections caused by this 
organism (NCCLS, 2002). 
Different countries use their own standards to determine breakpoint 
concentrations (MacGowan and Wise, 2001). The two more commonly used 
standards are those set by the National Committee for Clinical Laboratory Standards 
(NCCLS) and the British Society for Antimicrobial Chemotherapy (BSAC). 
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Establishment of breakpoints depends on microbiological (e.g. the distribution of 
susceptibilities), pharmacokinetic/pharmacodynamic (e.g. peak serum levels, time 
above the minimum inhibitory concentration (MIC), area under the serum 
concentration time curve (AUG), different dosing regimens) and clinical outcome 
data (Ferraro, 2001; MacGowan and Wise, 2001; Phillips, 2001). 
Strains that are susceptible to breakpoint concentration of an antibiotic for 
susceptible strains have been reported to be causes of treatment failure of that drug 
(Piddock, Whale and Wise, 1990; Wain et al., 1997; Vasallo et al., 1998). Mouton 
(2002) suggested that microbiological breakpoints to detect microorganisms which 
do not belong to the natural population should be established. This can help to detect 
resistance emergence, predict clinical outcome accurately and restrict spread of 
resistant mutants. Therefore, breakpoints should be reevaluated regularly (Ferraro, 
2001; Phillips, 2001). Recently, the need for reevaluating fluoroquinolone 
breakpoints for Salmonella has been suggested (Crump et al., 2003; Parry, 2003; 
Poutanen and Low, 2003). 
4. Fluoroquinolone-resistance 
4.1 Increasing fluoroquinolone-resistance in bacteria 
Fluoroquinolones are active, broad-spectrum antimicrobial agents and they 
are commonly used to treat many infections. Fluoroquinolone consumption rates 
have increased markedly in recent years (Neuhauser et al., 2003). For example, for 
invasive pneumococcal disease, fluoroquinolone prescriptions in the United States 
increased from 3.1 to 4.6 prescriptions/100 persons/year during 1993 - 1998 though 
the overall prescriptions of antimicrobial agents decreased (CDC, 2001). Ho et al 
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(2001) have also reported that fluoroquinolone prescriptions increased from 66.8 to 
91.8 daily defined doses per 1000 persons per year during 1994 - 2000 in Hong Kong. 
Fluoroquinolones account for 11% of antimicrobial prescriptions worldwide and 
become the drugs of choice for treating various human infections (Eager and 
Helmuth, 2001). 
Unfortunately, the widespread use of fluoroquinolones results in an 
increasing prevalence of resistance (Goldstein and Garabedian-Ruffalo, 2002). 
Studies have shown a positive correlation between fluoroquinolone use and bacterial 
resistance (Chen et al., 1999; CDC, 2001). 
Resistance to fluoroquinolones develops in S. aureus (especially in 
methicillin-resistant S. aureus [MRSA]) and P. aeruginosa shortly after these 
antibiotics are introduced for clinical use (Blumberg et al, 1991; Acar and Goldstein, 
1997; Hooper, 2000b). Some investigations showed that more than 90% of S. aureus 
isolates in hospital-acquired infection were ciprofloxacin-resistant (Acar and 
Goldstein, 1997; Schimitz et al,, 1999). Neuhauser et al (2003) reported that 
ciprofloxacin susceptibility in aerobic Gram-negative bacilli decreased from 89% in 
1990 - 1993 to 86% in 1994, and to 76% in 2000. 
Chen et al (1999) reported that pneumococci with decreased 
fluoroquinolone susceptibility increased from 0% in 1993 to 1.7% in 1997 and 1998 
in Canada. In the United States, the prevalence of ofloxacin non-susceptible strains 
increased from 2.6% to 3.8% in 1995 - 1997 (CDC, 2001). In Hong Kong, the 
overall prevalence was 13.3% and 27.3% among penicillin-resistant isolates in 2000 
(Ho et al., 2001). Fluoroquinolone-resistance in S. pneumoniae has also been 
reported from other places in the world (Jorgensen et al., 2000; Whitney et al., 2000; 
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Empey et al., 2001; Urban et al., 2001; Weiss et al., 2001). 
Increasing prevalence of fluoroquinolone-resistance has been reported in E. 
coli (Aguiar et al., 1992; Pena et al., 1995; Webber and Piddock, 2001). In Beijing, 
about 50% and 60% of ciprofloxacin-resistant E. coli have been isolated from 
community- and hospital-acquired infections, respectively. Fluoroquinolone-resistant 
N. gonorrhoeae has been reported in the United States and a sustained outbreak has 
been documented (Knapp et al., 1997). Such N. gonorrhoeae strains with 
ciprofloxacin MIC >1.0 iig/ml and/or ofloxacin MIC >2.0 |ig/ml are responsible for 
treatment failure in many parts of the world including Hong Kong, Australia, Canada, 
the United Kingdom and the Philippines (Knapp et al., 1997; Pato-Mesola et al., 
1997). 
Fluoroquinolone-resistance has also been detected in C. jejuni of human 
and animal origin (Endtz et al. 1991; Smith et al., 1999). Nachamkin and his 
colleagues (2002) have reported that fluoroquinolone-resistance has increased from 
nil to 41% during 1992 - 2001. Hakanen et al (2003) also found that of the 376 
strains collected during 1995 - 2000, 174 (46%) were resistant to ciprofloxacin. 
Fluoroquinolone-resistance has also developed in Mycohacterum tuberculosis 
(Ginsburg, Grosset and Bishai, 2003). 
4.2 Mechanisms of resistance to fluoroquinolones 
Since the widespread use of fluoroquinolones, many bacteria have become 
resistant to them (Walker, 1999). There are three mechanisms of resistance to 
fluoroquinolones: mutations of target genes, active drug efflux and decreased 
membrane permeability (Hooper, 1999; Van Bambeke, 1999; Hooper, 2001b). Of 
16 
these, target gene alteration is the most common mechanism. 
4.2.1 Mutations of target genes 
Mutations most frequently occur in the QRDR (quinolone-resistance-
determining region) of the genes coding for DNA gyrase and topoisomerase IV 
(Yoshida et al., 1990). QRDR is a conserved region encoding residues 67 to 106 and 
is close to the catalytic Tyr-122 site on the GyrA sequence or a conserved region 
encoding amino acids 426 - 447 in gyrB (Yoshida et al., 1991). In S. aureus, the 
corresponding QRDR region on gyrA is between residues 68 and 107 (Margerrison, 
Hopewell and Fisher, 1992). 
It has been suggested that quinolones bind to a pocket that consists of the 
QRDR of gyrA and DNA (Heddle et al., 2000). These mutations cause structural 
changes to the target enzymes, thereby reducing binding of the drug to this pocket 
with subsequent decreased activity of the drug. 
The most common mutations in gyrA identified in E. coli and other 
Gram-negative bacteria include those at codons 83 and 87 (Drlica and Zhao, 1997). 
Substitution of serine for leucine, tryptophan, isoleucine, valine or alanine at codon 
83 and substitution of aspartate for asparagine, glycine or tyrosine at codon 87 have 
been reported (Yoshida et al., 1990; Tavio et al, 1999). Mutations in parC, the 
secondary target site of Gram-negative bacteria, leading to Ser80—Arg or lie and 
Glu84—>Val or Lys that are responsible for decreased fluoroquinolone susceptibility 
have also been reported (Vila et al., 1996). Simultaneous mutations in gyrA at Ser83 
and j^arC at Gly78 lead to moderate resistance while double gyrA mutations at Ser83 
and Asp87, together with a parC mutation at SerSO or Glu84, are responsible for 
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high-level resistance (Heisig, 1996). However, dual mutations in gyrA gene only 
have also been reported to be responsible for high-level resistance in some strains 
(Conrad et al., 1996). 
Recently, Heddle and Maxwell (2002) demonstrated that residues of GyrB 
too are present in the binding pocket and that mutation in gyrB leads to decrease in 
the binding ability of quinolones to gyrase-DNA complex. Mutations inparE are less 
common, however, a single change from T to A (leading to an amino acid change of 
leucine to histidine) at codon 445 of parE in E. coli is found to be related to 
fluoroquinolone-resistance (Breines et al., 1997). 
Similar mutations have been found in other Gram-negative bacteria such as 
P. aeruginosa, N. gonorrheae and Haemophilus influenzae (Deguchi et al., 1996; 
Georgiou et al., 1996; Nakano et al., 1997). Thus, in Gram-negative bacteria, DNA 
gyrase is the primary target since mutations in gyrA play an important role in 
resistance and are also the first to appear while topoisomerase IV is the secondary 
target since subsequent mutations in parC and/or parE lead to further increase in the 
level of resistance. 
That Gram-positive bacteria have topoisomerase IV as their primary target 
is demonstrated by the fact that mutations in topoisomerase IV genes leading to 
fluoroquinolone-resistance precede those in gyrase genes. In S. aureus, SerSO—>Tyr 
and Glu84^Lys in grlA occur before Ser84—Leu and Glu88^Lys in gyrA (Ferrero, 
Cameron and Crouzet, 1995). Other grlA mutations that have been reported include 
Alall6—Glu, Arg43->Cys, Asp69—Tyr, Prol57—Leu and Alal76—Thr (Ince and 
Hooper, 2000). Other than grlA and gyrA, grlB and gyrB have also been shown to 
play a role in fluoroquinolone-resistance. Mutations such as Asp437—>Asn, 
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Arg458—>Gln and Pro456—Ser in gyrB and Asp432^Val in grlB have been shown 
to result in fluoroquinolone-resistance (Ito et al, 1994; Takahashi et al., 1998). 
Different fluoroquinolones have been shown to vary in their primary 
targets. In S. pneumoniae, resistance to sparfloxacin and gatifloxacin is due to 
mutations initially in gyrA (Ser83—Phe/Tyr) followed by those inparC (Ser79—>Tyr 
or Asp83^Asn) (Pan and Fisher, 1997; Hooper, 2000a; Fukuda et al, 2001). In 
contrast, for norfloxacin, ciprofloxacin, levofloxacin and trovafloxacin, mutations 
occur first in parC (Fukuda and Hiramatsu, 1999). Other fluoroquinolones, such as 
clinafloxacin and sitafloxacin, target both enzymes equally well (Pan and Fisher, 
1998; Morrissey and George, 1999). Pan and Fisher (1998) have found that only 
when mutations occur in both gyrA and parC can S. pneumoniae become resistant to 
high levels of the drugs while strains with mutations in gyrA only have their MICs of 
clinafloxacin minimally increased. 
Fluoroquinolone-resistance has been shown so far to be due to 
chromosomal mutations of target genes. Plasmid-mediated resistance to quinolones is 
apparently not present because these drugs eliminate plasmids by inhibiting their 
replication and transfer between organisms (Weisser and Widemann, 1985, 1986 & 
1987; Courvalin, 1990). The report by Munshi et al (1987) of an isolate of Shigella 
dysenteriae that is resistant to nalidixic acid due to a transferable plasmid is later 
confirmed to be erroneous. 
However, a transferable plasmid (pMG252) coding for resistance to 
quinolones is recently confirmed to be present in a ciprofloxacin-resistant isolate of 
Klebsiella pneumoniae (Martinez-Martinez, Pascual and Jacoby, 1998). The 
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quinolone-resistance gene, qnr, is subsequently cloned from this plasmid and is 
shown to code for a protein belonging to the pentapeptide repeat family that acts by 
protecting target enzymes from inhibition by quinolones (Tran and Jacoby, 2002). 
Although the exact mechanism of the protection remains to be determined, qnr 
increases the effect of other mutations as well as enhances the development of 
organisms with high-level quinolone-resistance under selection pressure. 
4.2.2 Active efflux systems and decreased membrane permeability 
Fluoroquinolone-resistance can also be due to expression or 
overexpression of energy-dependent efflux pumps that actively exclude drugs from 
the cell so that accumulation of drugs is reduced (Nikaido, 1996; Poole, 2000a & b). 
Decreased membrane permeability as a result of deficiency of outer membrane porin 
OmpF or alterations of lipopolysaccharide is another mechanism of resistance to 
fluoroquinolones (Rajyagum and Muszynski, 1997; Ruiz, 2003). 
AcrAB is the efflux pump in E. coli that removes quinolones from the cell. 
Overexpression of the coding gene acrAB leads to high-level resistance (Giraud et al., 
2000; Mazzariol et al., 2000; Jellen-Ritter and Kem, 2001). Since the outer 
membrane porin, OmpF, is responsible for transporting drugs into the cell, lack of 
this porin due to chromosomal mutations contributes to low-level resistance. 
Mutations in the marRAB and soxRS loci can also confer resistance to quinolones and 
other unrelated antibiotics (Piddock, 1995). 
The efflux systems of P. aeruginosa are different from those of E. coli. 
MexCD-OprJ, MexAB-OprM, MexEF-OprN, MexAB-OprK and MexCD-OprM 
have been proposed to be the efflux systems of this organism, and mutations in the 
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coding genes are responsible for drug-resistance (Piddock, 1995; Kohler et al., 
1997). 
Mutations in nor A, the gene that codes for transmembrane efflux pump in S. 
aureus, lead to higher levels of resistance to hydrophilic quinolones such as 
norfloxacin and ciprofloxacin than to hydrophobic quinolones such as gatifloxacin 
and sparfloxacin (Ng, Trucksis and Hooper, 1994; Fukuda, Hori and Hiramatsu, 
1998). However, Takenouchi et al. (1996) found that the high-level resistance of 
norA mutants was also due to the bulkiness and/or hydrophobicity of C-7 and C-8 
substituents. PmrA, which is related to norA, has been identified in other 
Gram-positive cocci (Gill, Brenwald and Wise, 1999). 
5. Fluoroquinolone-resistance in Salmonella 
5.1 Prevalence of fluoroquinolone-resistant salmonellae 
in man and animals 
5.1.1 Prevalence in the world 
Salmonellosis is a major foodbome infection and multiply-resistant 
salmonellae have remained a public health concern (Kiessling et al., 2002). The use 
of ampicillin, chloramphenicol and trimethoprim-sulfamethoxazole in chemotherapy 
is limited because of increasing resistance to these agents (Cohen and Tauxe, 1986; 
Lee et al., 1994). Fluoroquinolones are now drugs of choice for Salmonella infection 
(Shah, 1989; Bamass, Franklin and Tabaqchali, 1990; Cherubin and Eng, 1991; Reid, 
1992). 
Although fluoroquinolone-resistance is still uncommon in salmonellae 
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(Piddock et al., 1993; Pers, Sogaard and Pallesen, 1996), strains that are resistant to 
nalidixic acid and exhibit decreased susceptibilities to fluoroquinolones are 
increasing in many parts of the world (Brown, Thomson and Amyesm, 1996; 
Cormican et al., 1998; Murphy et al., 2001; Threlfall and Ward, 2001; Asna, Haq and 
Rahman, 2003; Gorman and Adley, 2003; Parry, 2003; Threlfall et al., 2003). 
In England and Wales, ciprofloxacin-resistant salmonellae increased from 
0.3% to 2% during 1991 - 1994, among which S. Hadar with ciprofloxacin-resistance 
increased from 2% to 40% (Frost, Kelleher and Rowe, 1996). Multiresistant S. 
Typhimurium DT 104 with ciprofloxacin MIC >0.125 |ig/ml increased from 0% in 
1993 to 7% in 1995 and 14% in 1996 (Threlfall et al., 1996; Threlfall et al., 1997b; 
Threlfall, Ward and Rowe, 1997). Heurtin-Le Corre et al (1999) reported that 
resistance to nalidixic acid of S. Typhimurium strains from humans and animals 
increased from 9% to 19% during 1995 - 1996. These isolates are also resistant to 
low concentrations of ciprofloxacin (MIC 0.125 - 1 jug/ml) and are responsible for 
treatment failures (Threlfall et al., 2003; Threlfall, 2002). 
In the United States, only several cases of quinolone-resistance are 
reported with 0.1% resistance in 1989 - 1991 and 0.5% in 1994 - 1995 (Glynn et al., 
1998; Vasallo et al., 1998; Herikstad et al., 1997). However, there has been a report 
of an outbreak of fluoroquinolone-resistant Salmonella between 1996 and 2000 
(Olsen et a/., 2001b). 
Hakanen et al (1999 & 2001) reported that in Finland during 1995 - 1997, 
domestic Salmonella isolates with ciprofloxacin MIC >0.25 |ig/ml constituted 0% -
2.2% of the total salmonellae isolated while foreign isolates constituted a higher 
percentage of2.5% - 8.4% and up to 23.5% in 1999. 
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Between 1986 and 1990, the resistance to nalidixic acid of veterinary 
Salmonella isolates in Germany is alarming (0.2% to 14.8%). These isolates are 
mainly S. Typhimurium. In 1994, 14.4% of salmonellae that were resistant to 64 
jig/ml of nalidixic acid were mainly S. Hadar isolates (Malomy, Schroeter and 
Helmuth, 1999). Nalidixic acid-resistant strains continue to be prevalent in Germany 
during 1998 - 2001 and these strains have decreased susceptibility to ciprofloxacin 
(MICs = 0.125 - 2 jig/ml) (Malomy et al., 2003). Moreover, Salmonella strains with 
nalidixic acid-resistance and reduced susceptibilities to ciprofloxacin from the 
food-bome outbreak in Denmark in 1998 and from food animals in Canada during 
1998 - 1999 (ciprofloxacin MIC 0.125 - 0.5 ^ig/ml) caused treatment failures or 
deaths (Molbak et al,, 1999; Allen and Poppe, 2002). 
Other countries which have reported nalidixic acid-resistant strains isolated 
from humans and food animals include Vietnam, India, Pakistan, Bangladesh and 
Tajikistan (Wain et al., 1997; Jesudason, Malathy and John, 1996; Murdoch et al., 
1998; Asna, Haq and Rahman, 2003). These strains usually have decreased 
susceptibility to fluoroquinolones. 
High-level resistance to fluoroquinolones has also occurred in salmonellae. 
S. Typhimurium strains that are resistant to 16 |ig/ml of ciprofloxacin predominate in 
Germany and neighboring countries (Heisig, 1993; Heisig et al., 1995; Guerra et al., 
2003). More recently, high-level fluoroquinolone-resistance in S. Typhimurium in 
France and Japan, S. Choleraesuis in Taiwan and S. Schwarzengrund in USA has 
been reported (Olsen et al., 2001b; Chin et al., 2002; Casin et al., 2003; Nakaya et al., 
2003). 
It is important to note that Salmonella with resistance to fluoroquinolones 
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has been isolated from both man and food animals (Griggs et aL, 1994; Heurtion-Le 
Corre, 1999; Malomy, Schroeter and Helmuth, 1999; Wiuff et al., 2000; Allen and 
Poppe, 2002; Threlfall, 2002; Piddock, 2002; Gorman and Adley, 2003). Several 
Salmonella outbreaks have been related to food animals (Molbak et al., 1999; 
Aarestrup, 1999). Therefore, the use of fluoroquinolones in veterinary medicine is 
also a cause for concern (Piddock, 1998; Camevale et al., 2000). 
Among Salmonella serotypes, S. Typhimurium is one of the most common 
in animals and humans in many parts of the world (Hedberg et al., 1993; Desenclos 
et al., 1996; Malomy, Schroeter and Helmuth, 1999; Mhand et al., 1999; Olsen et al., 
2001a; Chiappini et al., 2002; Ling et al., 2003). It is also the serotype where 
antibiotic-resistance is most commonly found (Cruchaga et al., 2001). 
Antibiotic-resistant S. Hadar has also been found to be prevalent in Italy and Spain 
(Fantasia et al., 1997; Cruchaga et al., 2001). 
5.1.2 Increasing resistance trend in Hong Kong 
All salmonellae isolated in Hong Kong before 1998 were susceptible to the 
breakpoint concentrations of fluoroquinolones for susceptible strains as 
recommended by the NCCLS and BSAC (Ling et al., 1998 & 2000; Ling, Koo and 
Cheng, 2001). However, it was found that of the 200 S. Typhimurium strains isolated 
during 1989 - 1996, 6% and 9% were resistant to 0.12 |ig/ml of ciprofloxacin and 
ofloxacin, respectively (Ling, Koo and Cheng, 2001). Although these strains are still 
considered fluoroquinolone-susceptible, the MICs are higher than those for most of 
the susceptible strains isolated. The first high-level resistant clinical Salmonella 
strain was isolated in 1998. Six Salmonella strains resistant to up to 64 |ag/ml of 
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ciprofloxacin, ofloxacin, levofloxacin, sparfloxacin, moxifloxacin and gemifloxacin 
have so far been reported from Hong Kong (Ling et al., 2003). 
5.2 Clinical outcome 
Since treatment failure has been reported to be due to strains that are 
resistant to nalidixic acid, less susceptible to fluoroquinolones, and harbour a gyrA 
mutation, Poutanen and Low (2003) suggested that strains resistant to 0.06 [ig/m\ of 
ciprofloxacin or to 16 |ig/ml of nalidixic acid should be regarded as having reduced 
susceptibility to fluoroquinolones and such strains are likely not to respond to 
treatment by fluoroquinolones. Since the present breakpoints of fluoroquinolones can 
not reflect clinical outcome accurately while nalidixic acid susceptibility can be a 
sensitive and specific indicator of fluoroquinolone susceptibilities, the latter should 
be used as a screening test and fluoroquinolone breakpoints should be reevaluated 
(Hakanen et al., 1999; Kapil, Renuka and Das, 2002; Aarestrup et al., 2003; Crump 
et a/., 2003). 
5.3 Mechanisms of fluoroquinolone-resistance in 
Salmonella 
5.3.1 Target gene mutations 
Most point mutations of gyrA in Salmonella have been found to cluster in a 
region between amino acids 67 and 106, and near the catalytic site — Tyr-122 
(Yoshida et al, 1990; Giraud et al, 1999; Walker et al., 2001). GyrA mutations that 
have been reported in Salmonella serotypes resistant to nalidixic acid and with 
decreased susceptibility to ciprofloxacin are usually at serine 83 and aspartate 87 
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(Brown et al., 1996; Piddock et al., 1998; Giraud et al., 1999; Ruiz et al, 1999, 
Wiuffet al, 2000; Cloeckaert and Chaslus-Dancla, 2001). 
These gyrA mutations include S er 8 3 —>Phe/Tyr/Ala and 
Asp87—>Asn/Gly/Tyr (Heisig et al., 1995; Brown, Thomson and Amyes, 1996; 
Griggs, Gensberg and Piddock, 1996; Ouabdesselam, Tankovic and Soussy, 1996; 
Ruiz et al., 1997b & 1999; Ridley and Threlfall, 1998; Tankovic et al., 1999; Wiuff 
et al, 2000; Walker et al., 2001; Piddock, 2002; Ling et al； 2003). Several workers 
have found Asp87—Asn to be the most common mutation in S. Typhimurium DTI04 
and other Salmonella serotypes (Ridley and Threlfall, 1998; Piddock et al., 1998; 
Walker et al., 2001) in contrast to reports by other workers that mutation at the Ser83 
site is most common (Reyna et al., 1995; Griggs, Gensberg and Piddock, 1996). 
Both these mutations, however, have been associated with resistance to 
nalidixic acid and low-level resistance/reduced susceptibilities to the 
fluoroquinolones (Ruiz et al； 1997b; Piddock et al., 1998; Wiuff et al., 2000). 
Double mutations at both these sites are associated with high-level resistance instead 
(Heisig et al. 1995). These mutations, except Ser83—Ala, have also been 
demonstrated to occur in spontaneous quinolone-resistant mutants by in vitro 
selection (Reyna et al, 1995; Giraud et al., 1999; Hirose et al., 2002; Hansen and 
Heisig, 2003). 
Other gyrA mutations that have been reported include Ala67—>Pro, 
Gly81—Ser/Cys and Alall9^Glu/Val (Reyna et al., 1995; Griggs, Gensberg and 
Piddock, 1996; Piddock, 2002; Giraud et al., 2003). Reyna et al (1995) reported a 
double mutation (Ala67^Pro and Gly81—Ser) in Salmonella mutants that have 
ciprofloxacin MIC of 0.5 |ig/ml, which is the same as that for other mutants with a 
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single Ala67—>Pro mutation so that they suggested that Gly81-^Ser does not 
contribute to resistance. 
GyrB mutations are much rarer than gyrA mutations (Heisig, 1993; Heisig 
et al., 1995). GyrB mutations that have been reported include Ser463—Tyr and 
Ser464—>Phe (Gensberg, Jin and Piddock, 1995; Baucheron et al., 2002; Casin et al., 
2003; Hansen and Heisig, 2003). However, since Ser464-^Phe is present together 
with gyrA and parC mutations in high-level resistant strains, the exact role of gyrB 
mutations in development of quinolone-resistance is still unclear. 
ParC mutation in Salmonella is first reported in 2003 (Ling et al, 2003). 
The mutation SerSO^Arg is present together with gyrA mutations Ser83-^Phe and 
Asp87—Asn in a clinical S. Typhimurium isolate with high-level resistance to 
fluoroquinolones (MICs of ciprofloxacin, levofloxacin and norfloxacin 8 - 1 6 |Lig/ml, 
MIC of nalidixic acid >512 |ig/ml). Other parC mutations that have been reported in 
Salmonella include Ser80一lie and Glu84->Lys (Baucheron et al., 2002; Hirose et 
al., 2002; Casin et al., 2003; Guerra et al, 2003). 
Triple and quadruple mutations including parC mutations have been 
detected in Hong Kong Salmonella strains isolated after 1998 (Ling et al., 2003). The 
SerSO^Arg parC mutation is always found together with gyrA and/or parE 
mutations while Thr57—Ser parC mutation is present alone in seven isolates. 
However, the fluoroquinolone MICs for these strains are lower than those for strains 
with other mutations so that its contribution to fluoroquinolone-resistance is 
doubtful. 
Up to now, there is only one report of parE mutation, Ser458—>Pro, in 
fluoroquinolone-resistant Salmonella isolates (Ling et al., 2003). The mutations 
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occur simultaneously with a double gyrA mutation (Ser83—Phe and Asp87^Gly) 
and a parC mutation (Ser80—Arg). Whether both parC and parE mutations 
contribute to high-level fluoroquinolone-resistance remains to be determined. 
5.3.2 Other resistance mechanisms 
Mechanisms other than mutations in target genes including activation of 
efflux pumps and decreased permeability due to a lack of porin OmpF and 
lipopolysaccaride (LPS) have been reported in fluoroquinolone-resistant Salmonella 
(Poole, 2000a; Cloeckaert and Chaslus-Dancla, 2001). 
The AcrAB-TolC efflux systems have been proposed to be present in 
Salmonella (Cloeckaert and Chaslus-Dancla, 2001; Piddock, 2002; Ruiz, 2003). 
Giraud and colleagues (2000) demonstrated overexpression of AcrA in S. 
Typhimurium with decreased susceptibility to ciprofloxacin. Piddock et al (2000) 
reported increased expression of acrB, but not that of tolC in multiple 
antibiotic-resistant S. Typhimurium. Salmonella acrB gene is also important in 
resistance to detergents and bile salts (Lacroix et al., 1996). However, no difference 
in AcrAB expression levels between Salmonella susceptible strains and resistant 
mutants after passages has been found (Giraud et al., 2003). Since TolC has been 
suggested to be responsible for Salmonella virulence in mice, the exact role of 
AcrAB-TolC efflux systems in fluoroquinolone-resistance remains unclear (Stone 
and Miller, 1995). 
The AcrAB-TolC efflux systems and the synthesis of outer membrane 
porins are controlled by the regulatory systems marRAB and soxRS (Cohen, 
McMurry and Levy, 1988; Okusu, Ma and Nikaido, 1996). The mar locus in S. 
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Typhimurium contributes to low-level antibiotic-resistance and cyclohexane-
resistance while the soxRS regulon contributes to elevated levels of multiple 
antibiotic-resistance (Sulavik, Dazer and Miller, 1997; Pomposiello and Dample, 
2000; Koutsolioutsou et al., 2001; Randall and Woodward, 2001). However, Giraud 
and colleagues (2000) failed to demonstrate increased expression of marA or soxS in 
resistant Salmonella by Northern blot analysis. 
Reports of decreased permeability due to lack of OmpF and LPS in 
fluoroquinolone-resistant Salmonella are rare. Several workers noted that some 
quinolone-resistant Salmonella strains lack OmpF, however, they could not 
demonstrate a relationship between lack of OmpF and decreased accumulation of 
quinolones in these strains (Piddock et al., 1993; Griggs et aL, 1994; Piddock et al., 
1998). There is no difference in outer membrane porins and LPS in 
quinolone-sensitive and quinolone-resistant clinical S. Typhimurium isolates (Ruiz et 
al., 1997b). There is also no modification of porin expression in resistant mutants as 
compared to the sensitive parent (Giraud et aL, 2003). 
5.3.3 In vitro development of Salmonella resistant mutants 
Investigation of development of resistant mutants by in vitro selection 
studies can help to understand the in vivo development of resistance. Most studies to 
follow the in vitro development of fluoroquinolone-resistance have been done on S. 
pneumoniae (Davies et aL, 1999; Pestova et al., 1999; Nagai et al., 2000 & 2001; 
Houssaye, Gutmann and Varon, 2002), S. aureus (Ferrero, Cameron and Crouzet, 
1995； Ince and Hooper, 2001; Noguchi et al., 2002; Pan et al., 2002) and E. coli 
(Heisig and Tschomy, 1994; Kem et al., 2000) although other organisms such as N. 
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gonorrhoeae (Yasuda et al., 2000; Ruiz et al., 2001), P. aeruginosa (Le Thomas et al., 
2001), Legionella pneumophila (Jonas et al., 2003) and Citrobacter freundii (Tavio et 
al., 2000) have also been investigated. 
There are few reports on the in vitro demonstration of sequential 
development of gene mutations contributing to fluoroquinolone-resistance in 
salmonellae. Reyna and colleagues (1995) showed that spontaneous S. Typhimurium 
mutants selected by nalidixic acid or pefloxacin have a single Ser83一Phe/Tyr or 
Asp87—Asn mutation or a double mutation (Ala67—Pro and Gly81—Ser) on gyrA 
gene, resulting in decreased susceptibilities to fluoroquinolones. Giraud and 
colleagues (1999) subcultured fluoroquinolone-susceptible S. Typhimurium in the 
presence of enrofloxacin and detected only gyrA mutation at codon 81, 83 or 87 but 
no mutations in gyrB, parC andparE genes. These mutants have ciprofloxacin MICs 
of 0.06 - 0.5 |ig/ml. When these mutants are continuously grown in increasing 
concentrations of the drug, high-level resistant mutants (ciprofloxacin MIC = 4 - 1 6 
jig/ml) are obtained and these have double gyrA mutations. 
S. Typhi and S. Paratyphi A have also been similarly studied (Hirose et al., 
2002). Strains with high-level resistance to ciprofloxacin are obtained in vitro and 
these have mutations in both codons 83 and 87 on gyrA gene while parC mutation 
(Glu84-^Lys) is detected in only one S. Paratyphi A strain. Since parC mutation has 
not been reported in clinical isolates at that time, the authors suggested that parC 
G1u84 mutation might appear in the near future. Hansen and Heisig (2003) also 
found that I'^-step mutants have only a single gyrA mutation at position 83 or 87 
while and S'^ -^step mutants develop additional mutations including those at Asp 
87 of gyrA gene, Ser464 oi gyrB gene and Gly78 of parC. However, Cebrian et al 
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(2003) have found that gyrA mutation may not always develop in strains that are 
repeatedly exposed to various fluoroquinolones, but have reduced susceptibilities to 
the fluoroquinolones. 
6. Restricting the development of resistant 
mutants 
6.1 Mutant prevention concentration (MPC) 
6.1.1 Definition 
Mutant prevention concentration (MPC) is a concept recently developed by 
Dong et al. (1999). It is defined as the minimal concentration of an antibiotic at 
which no mutants will develop when more than colonies are applied to agar 
containing this concentration of antibiotic and represents a threshold above which 
selection of mutants should occur rarely. 
6.1.2 Development of MPC concept 
Due to the widespread development of resistant bacteria, restricting the 
development of resistant mutants is a more pressing issue clinically (Drlica and 
Schmitz, 2002). Many workers have investigated the various factors that contribute 
to development of resistance. Craig (2001) found that there is an association between 
pharmacokinetic/pharmacodynamic parameters of an antibiotic and the emergence of 
resistance. It is also found that antimicrobial compounds have different abilities to 
restrict the development of resistant mutants (Zhao et al., 1997; Dong et al., 1998). 
To investigate the relationship of bacteria and the drug, the effect of 
fluoroquinolone concentration on the development of resistant mutants was first 
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examined for M. bovis BCG and S. aureus (Dong et al., 1999). Selection of resistant 
mutants greatly depends on the concentration of a drug (Figure 2). Although 
susceptible strains are inhibited or killed at the MICs (the first sharp drop in the 
fraction of cells that formed colonies on fluoroquinolone-containing agar), 1^ -^step 
mutants will develop gradually until the drug reaches a concentration that is able to 
block the growth of these mutants. 
First-step mutants can only grow at a higher concentration if they attain 
two or more simultaneous mutations. However, the chance for this to occur is very 
rare since mutation occurs at a frequency of about 10"^  and a double mutation will 
therefore occur at a frequency of lO]* (Ng, Trucksis and Hooper, 1996; Pan et al, 
1996; Zhao et al, 1997). If there are approximately cells at the site of infection 
(Feldman, 1976; Mitchison，1984; Bingen et al., 1990), the chance that strains 
develop two mutations and thus become resistant would be very slim. 
Determination of MFC is technically similar to that of MIC except that the 
number of cells applied to antibiotic agar is cells or more (Blondeau et al., 2001). 
If more than cells are used as the inoculum, the number of cells used is added as 
a subscript to MPC (Dong et al., 1999). 
MPC of fluoroquinolones has been determined for bacterial species such as 
M. smegmatis, M. tuberculosis, S. pneumoniae and E. coli (Dong et al., 2000; 
Sindelar et al., 2000; Blondeau et al, 2001; Li, Zhao and Drlica, 2002; Zhao and 
Drlica, 2002; Hansen et al, 2003). MPC of other antimicrobial agents such as 
chloramphenicol, tobramycin, rifampin or penicillin G has also been determined for 
these microorganisms (Dong et al., 2000; Zhao and Drlica, 2002; Lu et al., 2003). 
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Figure 2 Development of resistant mutants in the presence of increasing 
concentrations of fluoroquinolones. Double-headed arrow represents mutant 
selection window (MSW). (Modified from Zhao and Drlica, 2001). 
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microorganisms many vary (Drlica and Malik, 2003). MPC of rifampin, 
streptomycin and kanamycin for M. tuberculosis and of rifampin for E. coli could not 
be determined probably because concentration higher than those tested are required 
to prevent resistant strains to develop (Dong et aL, 2000; Zhao and Drlica, 2002). 
Whether this infers that these drugs should not be used alone to treat M. tuberculosis 
or E. coli infection since resistance will develop remains to be determined. 
MPC of different fluoroquinolones to the same strain is also different 
indicating that individual fluoroquinolone has different potential to limit 
development of resistance. C-8-methoxy fluoroquinolones are more potent for M. 
bovis BCG and S. aureus than C-8-hydrogen or C-8-fluorine fluoroquinolones. Their 
potency can be increased by an additional methyl or ethyl group at position C-7-ring 
(Dong et aL, 1999; Sindelar et al., 2000). The MPC values of C-8-methoxy 
derivatives for M. tuberculosis and S. pneumoniae are also low (Dong et al., 2000; 
Blondeau et al., 2001). 
6.1.3 Significance 
The MPC concept is important towards restricting development of resistant 
mutants. MPC is the concentration above which no resistant strains can grow. It is 
therefore a measure of the ability of an antibiotic to restrict selection of resistant 
mutants (Sindelar et al., 2000; Drlica and Malik, 2003). 
If the MPC of a drug is below the achievable serum concentration, 
administering the drug at a concentration exceeding the MPC can theoretically 
restrict the growth of resistant mutants. For example, since the MFCs of both 
gatifloxaicn and moxifloxacin for mycobacteria and S. pneumoniae are below the 
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maximum concentration achievable with doses as recommended by the 
manufacturers, these drugs can be used alone for the treatment of infections caused 
by these organisms (Dong et al., 2000; Sindelar et al., 2000; Blondeau et al, 2001). 
In contrast, several workers found that the MPC of rifampin for M. tuberculosis 
exceeds the maximum drug concentration achievable in the body and thus 
recommended that rifampin should not be used as a monotherapy (Dong et al., 2000; 
Drlica, 2000). However, application of MPC-based strategy to clinical use requires 
confirmation in animal and clinical studies (Zhao, 2003). 
6.2 Mutant selection window (MSW) 
6.2.1 The concept of mutant selection window (MSW) 
Mutant selection window (MSW) is the concentration range between the 
MIC of wild-type strains to the MPC (Figure 2). In this window, the sensitive 
bacterial population is inhibited but resistant mutants multiply and grow rapidly 
(Zhao and Drlica, 2001 & 2002; Drlica, 2003). 
Drug concentrations that are below the MICs can not inhibit the growth of 
susceptible strains. Those that are higher but within the MSW can not kill resistant 
mutants that develop subsequently. In an individual with a normal immune system, 
these mutants can be finally eradiated but in immunocompromised patients, resistant 
mutants will flourish, resulting in treatment failure (Drlica, 2003). 
Several workers have shown that resistant mutants of mycobacteria，S. 
pneumoniae, S. aureus and E. coli are selectively enriched in the MSW (Dong et al., 
1999 & 2000; Zhou et al., 2000; Blondeau et al., 2001; Zhao and Drlica, 2002; 
Drlica，2003). It is therefore important to keep drug concentrations above the MSW, 
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such as by decreasing dosing interval (Blondeau et al., 2001; Zhao and Drlica, 2001; 
Drlica and Malika, 2003). In vitro phamacodynamic models have also proved the 
importance of the MSW hypothesis (Allen, Kaatz and Rybak, 2003; Firsov et al., 
2003). When moxifloxacin concentrations fall inside the MSW (AUC24/MIC from 24 
to 47 h ) � S . aureus and S. pneumoniae become less susceptible and the frequency to 
develop resistance increases (Zinner et al., 2003). 
The size of MSW of antimicrobial agents for bacteria is different and the 
MPC/MIC ratio can be used as an index to predict the size. For S. aureus and E. coli, 
the MPC/MIC ratio of C-8-methoxy fluoroquinolones is much lower than that of 
rifampicin (Zhao and Drlica, 2001). The ratio of the C-8 methoxy fluoroquinolones 
for S. aureus is much lower than that of C-8 hydrogen fluoroquinolones while that of 
the C-7 piperazinyl ring fluoroquinolones is higher than that of the C-7 diazo bicyclo 
fluoroquinolones. 
6.2.2 Significance 
The MSW concept is derived from the MFC concept and is a better 
concept since it is a basis for designing better strategies to limit resistance 
development (Zhao, 2003). The size of MSW can be used to evaluate antimicrobial 
agents (Zhao and Drlica, 2002). A high MPC/MIC ratio, i.e. the MSW is wide, 
indicates that the drug can easily select resistant mutants while a low ratio, i.e. the 
MSW is narrow, indicates that the drug has great potential to restrict selection of 
resistant mutants. 
Doem (2001) and Zhao & Drlica (2001) suggested that the ability of an 
antibiotic to restrict the development of resistance is more important than a low MIC 
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in determining its potency since potent drugs may not always have low MICs. Thus, 
the MICs of C-8-methoxy fluoroquinolones for E. coli is high as compared to those 
of ciprofloxacin, however, their MSW is narrower than that of ciprofloxacin (Zhao et 
al., 1997). Thus, it is important to decrease the time in the MSW and increase the 
time above the MSW (Baquero and Negri, 1997; Zhao and Drlica, 2002). However, 
this hypothesis awaits confirmation by in vivo studies. 
7. Detection of gene mutations 
In order to detect gene mutations, DNA from mutants were amplified by 
polymerase chain reaction (PCR) using primers specific for target genes and the 
mutations were sceened by multiplex PCR amplimer conformation (MPAC) analysis. 
MPAC analysis is developed from single-strand conformational 
polymorphism (SSCP) analysis which is a method based on the principle that 
different electrophoretic mobility of DNA results from conformational changes of 
different nucleotide sequences (Gasser and Chilton, 2001; Kane et al., 2002; 
Mcllhatton et al., 2002; Ling et al., 2003). The only difference between MPAC and 
the conventional SSCP method is the samples used for analysis which is the mixture 
of PCR products of test strain sample and the control strain sample (Ling et al., 
2003). It is more sensitive in detecting gene mutations by comparing mobility of 
DNA with controls and is a powerful molecular tool for efficient screening of large 
quantities of samples. 
8. Objectives 
The objectives of my project were 
1) To determine the MFCs of fluoroquinolones for salmonellae; 
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2) To investigate the development of fluoroquinolone-resistant salmonellae 
in vitro; and 
3) To characterize the sequential accumulation of target gene mutations 
leading to high-level fluoroquinolone-resistance. 
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Materials and methods 
1. Materials 
1.1 Bacterial strains 
1.1.1 Bacterial strains used for this study 
A total of 41 out of 43 strains of S. Typhimurium and 18 out of 19 strains 
of S. Hadar that were isolated from stools of patients in the Prince of Wales Hospital 
(PWH) during the period of 2000 - 2001 and 1995 - 2002, respectively, identified by 
standard microbiological techniques (Bopp et al., 1999) and survived were tested for 
susceptibilities to six fluoroquinolones. Eight S. Typhimurium and nine S. Hadar 
clinical isolates with the lowest fluoroquinolone MICs were used for this 
investigation. A standard strain, S. Typhimurium, American Type Culture Collection 
(ATCC) 13311, was also used. 
The control strains used in the susceptibility tests included E. coli ATCC 
25922 and National Collection of Type Culture (NCTC) 10418, S. aureus ATCC 
29213, and/^ aeruginosa ATCC 27853. 
1.1.2 Storage of bacterial strains 
All Salmonella strains isolated from patients' specimens were stored on 
nutrient agar slants in the routine microbiology laboratory. After subculture and 
re-identification, they were stored on nutrient agar slants at room temperature and in 
glycerol broth at -70°C for further studies. In vzYro-selected strains and standard 
strains were similarly stored. 
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1.2 Materials 
All materials used in this study are listed in Table 1. 
2. Methods 
2.1 Identification 
Bacterial strains were identified by the API20E system and serotyped by 
slide agglutination with Salmonella specific antisera. 
2.2 Microbiological methods 
2.2.1 Determination of minimal inhibitory concentration (MIC) 
The susceptibilities of all the strains to nalidixic acid and six 
fluoroquinolones (norfloxacin, ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin 
and gemifloxacin) were tested by determining the minimum inhibitory concentration 
(MIC) using an agar dilution method (NCCLS, 1997). 
2.2.1.1 Preparation of antibiotic plates 
A. Antibiotic powder was weighed (the amount calculated according to the 
equation below) and dissolved in appropriate solvents (IN NaOH for nalidixic acid; 
O.IN NaOH for norfloxacin, ciprofloxacin, ofloxacin and levofloxacin, and distilled 
water for moxifloxacin and gemifloxacin). Serial 10-fold dilutions were made as 
appropriate in distilled water. 
Volume {ml) x Concentration (jug丨ml� 
Potency (jug/mg) 
B. Agar plates containing fluoroquinolones at serial two-fold concentration 
were prepared by adding suitable volumes of fluoroquinolones into molten 
Mueller-Hinton (MH) agar. 
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Table 1 List of materials used in this study 
Media MacConkey agar (without salt) (Oxoid, Basingstoke, England) 
Mueller-Hinton agar (Oxoid) 
Nutrient broth (Oxoid)  
Antibiotics Ciprofloxaicn (Bayer, Connecticut, USA) 
Gemifloxacin mesylate (Glaxo SmithKline, Uxbridge, UK) 
Levofloxacin (Hong Kong Medical Supplies LTD., HK SAR) 
Moxifloxacin (Bayer, Wuppertal, Germany) 
Nalidixic acid (Sigma, Missouri, USA) 
Norfloxacin (Sigma) 
Ofloxacin (Sigma)  
Kits API20E system (BioMerieux, RCS Lyon, France) 
ExcelGel® DNA analysis Kit (Pharmacia, Uppsala, Sweden) 
PlusOne™ DNA silver staining kit (Amersham Biosciences AB, 
Uppsala, Sweden) 
Silver Sequence™*^ DNA sequencing reagents (Promega, 
Wisconsin, USA) 
Silver Sequence™ DNA staining reagents (Promega)  
Chemicals Absolute ethanol (Merck, Darmstadt, Germany) 
Acrylamide (Boehringer Mannheim Corporation, Indianapolis, USA) 
Bind silane (Promega) 
Boric acid (Merck) 
Bromphenol blue (Sigma) 
DNA Typing Grade™ agarose (GibcoBRL, Life Technologies, New 
York, USA) 
Ethidium bromide (Sigma) 
Ethylenediamine tetraacetic acid, EDTA (Sigma) 
Formamide (Sigma) 
Gel-loading buffer (Sigma) 
Glacial acetic acid (Merck) 
PlusOne™ methylenebisacrylamide (Pharmacia) 
PlusOne™ ammonium persulphate (Pharmacia) 
Sodium chloride (Merck) 
TEMED (LKB-prodekter AB, Bromma, Sweden) 
Tris-base (Sigma) 
Urea (Boehringer Mannheim GmbH, Mannheim, Germany)  
Xylene cyanol (BDH Chemicals Ltd, Poole, England)  
(To be cont，d) 
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Cont，d 
Table 1 List of materials used in this study  
Instruments Automatic inoculator MIC-2000 (Dynatech, Virginia, USA) 
Electrophoresis power supply-EPS 3500 (Pharmacia) 
Eppendorf centrifuge 5415D (Eppendorf, Hamburg, Germany) 
Freezer (General Electric., New York.，USA) 
Gel electrophoresis apparatus GNA-100 (Pharmacia) 
GibcoBRL sequencing system (Life Technologies, New York., USA) 
Gyrotory® shaker model G2 (New Brunswick Scientific Co. Inc. 
New Jersey, USA) 
Incubator (Memmert, Schwabach, Germany) 
Magnetic stirrer (Franz Morat KQ Eisenbach, Germany) 
Model 500/200 power supply (Bio-Rad Laboratories, California, 
USA) 
Multiphor II (Pharmacia) 
MultiTempIII (Pharmacia) 
Petri dish (Greiner bio-one, Castle Hill NSW, Australia) 
PTC-100™ programmable thermal controller (MJ Research Inc., 
Wisconsin, USA) 
Image master VDS (Amersham Phamacia Biotech, New Jersey, 
USA) 
2017 Microread light table (LKB, Bromma, Sweden) 
2303 Multidrive XL 3.5kv power supply (LKB)  
PGR reagents Buffer (Amersham Biosciences, New Jersey, USA) 
DNA polymerization mix (Amersham Phamacia Biotech) 
Primers (Invitrogen, Life Technologies, HK, SAR) 
Tag DNA polymerase (Amersham Biosciences)  
Others ^X1 lAJMPJHae III markers (Promega) 
Micro Spin S-300 HR columns (Amersham Biosciences) 
Salmonella antisera (Murex Biotech Ltd., Dartford, England)  
The identification software (BioMerieux)  
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2.2.1.2 Preparation of inoculum 
Several overnight colonies on MH agar were emulsified in 1 ml sterile 
g 
saline to a turbidity equivalent to 0.5 MacFarland standard (equivalent to 1.5x10 
cfu/ml). A 10-fold dilution of this suspension was made and was used as the 
inoculum. 
2.2.1.3 Inoculation of antibiotic plates 
The diluted suspension was inoculated onto MH agar containing antibiotics 
at serial two-fold dilution (concentration range as shown in Table 2) using an 
MIC2000 inoculator. The final inoculum was about lO* cfu per spot. Results were 
read after the plates were incubated at 37�C overnight. MIC is the lowest 
concentration that inhibits bacterial growth on the inoculation spot. All four standard 
strains (section 1.1) were included as control strains in every test. 
2.2.2 Determination of mutant prevention concentration (MPC) 
2.2.2.1 Preparation of bacterial suspension 
A single overnight colony on MH agar was inoculated in 500 ml Nutrient 
broth (NB), incubated at 37°C with shaking for about 5 h, and then adjusted to a 
turbidity matching that of MacFarland 1 (equivalent to 3x10^ cfu/ml). The cells were 
centrifuged at 12,000 g for 30 min at 4°C and were resuspended in 3 ml NB. 
2.2.2.2 Inoculation of bacterial suspension 
About 200 |il of this bacterial suspension (containing more than lO^^cfu) 
were spread onto plates containing antibiotics at serial two-fold concentrations 
starting from 0.5x MIC. 
2.2.2.3 Determination of the size of the inoculum 
43 
Table 2 Concentration range of antibiotics tested 
Antibiotics Concentration range (|ig/ml) 
Norfloxacin 0.015 - 128 
Ciprofloxacin 0.00375 - 64 
Ofloxacin 0.015 - 128 
Levofloxacin 0.0075 - 64 
Moxifloxacin 0.015 - 128 
Gemifloxacin 0.00375 - 128 
Nalidixic acid 1- 512 
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The size of the inoculum was determined by plating 100 jil of 10 ,^ 10^ and 
IQIO dilution of the bacterial suspension prepared in 2.2.2.1 above in duplicate on 
MH agar plates without antibiotics. The number of colonies growing on these plates 
was counted after 24 h incubation at 37°C and the total cell count per ml was 
calculated according to the following formula: 
Total cell count per ml = (the number of colonies X 1(f) X10 
n — times of 10-fold dilution 
2.2.2.4 Reading of results 
After 48 h of incubation at 37°C, colonies growing on the fluoroquinolone-
containing plate were purified by plating out on MacConkey agar containing the 
same fluoroquinolone at the MIC and identified as described in section 2.1. MPC 
was taken as the lowest concentration that inhibited all bacterial growth. Mutation 
frequency was calculated as the ratio of the number of resistant mutants to the 
number of cells in the original inoculum. 
2.3 Molecular methods 
2.3.1 Polymerase chain reaction (PCR) 
The QRDR of gyrA, gyrB, parC and parE genes was amplified by PCR. 
The primers used are shown in Table 3. To increase the sensitivity of MPAC analysis 
for detection of gyrA mutations, two pairs of gyrA primers were used to amplify the 
QRDR of the gyrA gene for MPAC analysis. 
Several overnight colonies on MH agar were emulsified in 200 |li1 of 
distilled water, heated at 100°C for 10 min and centrifuged at 12,000g for 2 min in an 
Eppendorf centrifuge. The supernatant was used as DNA template. The PCR mixture 
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Table 3 Primers used for the amplification of QRDR of 
gyrA, gyrB, parC and parE genes 
Product 
Gene Primer sequence (nucleotide position) (bp) 
gyrAr F 5'-TACACCGTCGCGTACTTTACGCCA-3'(19-42) 276 
R 5 ’ -CCATCAGTTCGTGGGCGATTTTCG-3 ’ (294-271) 
gyrA2^ F 5 ‘-TACCGTCATAGTTATCCACG-3' (21123-21142) 347 
R 5‘-TGTCCGAGATGGCCTGAAGC-3‘ (21469-21450) 
gyrB' F 5'-GTCCGAACTGTACCTGGTGGA-3' ( 1251-1271) 210 
R 5 ‘-TTGTCCGGGTTGTACTCGTCG-3 ‘ (1460-1440) 
parC^ F 5'-ATGAGCGATATGGCAGAGCG-3' (14-33) 347 
R 5'-GCGAATGACTTCGGATCATC-3' (360-341) 
parE' F 5‘-GACCGAGCTGTTCCTTGTGG-3' (1285-1304) 273 
R 5,-AGCAGAGTAGCGATATGCAA-3’ (1557-1538) 
F - forward primer R - reverse primer 
"according to Genbank accession no. X78977 
^according to Genbank accession no. AE008801 
""according to Genbank accession no. Y07916 
"according to Genbank accession no. M68936 
^according to Genbank accession no. L05544 
46 
in a total volume of 50 jil was prepared according to Table 4. Amplification was 
carried out at 95�C for 3 min, followed by 33 cycles of 94�C，52�C and 72�C for 40 s 
each and a final extension at 72°C for 3 min. 
2.3.2 Agarose gel electrophoresis 
Amplified products were prepared on agarose gel electrophoretically using 
a GNA 100 horizontal gel electrophoresis apparatus. 
A 1% agarose gel in 0.5x TBE buffer (0.045 M Tris-borate, 0.001 M EDTA) 
was prepared in an electrophoresis tray with a comb in it. When the gel was 
completely solidified, the comb was removed and the gel was placed in an 
electrophoresis tank. Buffer (0.5x TBE) was added to the tank until the gel was 1 mm 
under the liquid. 
DNA template (3 |il) was mixed with 0.3 [i\ lOx gel-loading buffer before 
loading into wells of the gel. 4/Haelll was used as the size marker. 
Electrophoresis was performed at 120 V, 400 mA and 200 W using a Bio-Rad 
500/200 power supply for about 40 min. 
After electrophoresis, the gel was stained in ethidium bromide (0.5 |Lig/ml) 
for about 30 min, washed thoroughly in running tap water and visualized under 
ultraviolet light. 
2.3.3 Multiplex PGR amplimer conformation (MPAC) analysis 
2.3.3.1 Preparation of samples 
The ExcelGel was placed on the Multiphor II cooling plate. One anodic 
and one cathodic buffer strips were applied on the appropriate sides of the gel. 
For gyrA MPAC analysis, 2 |il each of gyrA PGR products of test sample 
47 
Table 4 Components of PCR mixture 
Reagent Volume (|il) 
lOx buffer 5.0 
dNTP (10 mM) 1.5 
Forward primer (25 mM) 1.0 
Reverse primer (25 mM) 1.0 
Taq polymerase (5000 U/ml) 0.5 
DNA template 0.5 
Distilled water  
Total 50 
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amplified by two pairs of primers and 1 [d of gyrA PCR products of reference control 
{S. Typhimurium ATCC 13311 or S. Hadar 1739) were mixed with 2.5 |il denaturing 
solution (2.375 |il of 99% formamide, 0.125 |il of 1% xylene cyanol solution and 10 
|ig of bromophenol blue). For gyrB, parC and parE MPAC analysis, 2 |il each of the 
PCR product of the test sample, control strain and denaturing solution were mixed. 
2.3.3.2 Electrophoresis 
The mixtures were denatured at 95�C for 5 min and then immediately 
chilled on ice to prevent reannealing of single stranded products. Then 3.5 |il of 
mixture were loaded into each well. Electrophoresis was carried out at 600 V, 50 mA 
and 30 W for about 1.5 h or until the bromophenol blue migrated to the anodic buffer 
strip. The running temperature was kept at 4 � C for gyrA amplimer and 15°C for gyrB, 
parC and parE. 
2.3.3.3 Silver staining 
All steps were performed on a shaker. The gel was soaked in fixing 
solution (25 ml 5x fixing solution in 100 ml 24% ethanol) for at least 30 min, and in 
staining solution (25 ml 5x staining solution in 100 ml distilled water) for 30 min. 
After staining, the solution was poured off and the gel was washed with water for 1 
min. The gel was then placed in developing solution. This was prepared by adding 25 
ml 5x sodium carbonate solution to 100 ml distilled water and then adding 125 jil 
sodium thiosulphate and 125 |il formaldehyde just before use. 
Once the bands were distinct, the solution was immediately changed to 
stopping and preserving solution (25 ml 5x stopping and preserving solution in 100 
ml distilled water) to stop the reaction. Different DNA patterns could be examined 
after at least 30 min. 
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2.3.4 DNA Sequencing 
This was performed by using Silver Sequence™*^ DNA Sequencing 
Reagents and Silver Sequence™ DNA Staining Reagents according to the 
manufacturer's instructions. 
2.3.4.1 Purification of PCR products 
PCR products were purified using the Micro Spin S-300 HR columns. 
Resin was resuspended in the column by vortexing and then the bottom closure was 
snapped off. After 2 min of centrifugation at 3,000 rpm, the column was transferred 
to a new tube. About 35 [i\ of test samples were applied to the top center of the resin. 
Finally, the purified products were collected after spinning the column at 3,000 rpm 
for 3 min. 
2.3.4.2 Sequencing reactions 
Four tubes each containing 2 |il of one of the four d/ddNTP and 4 [il of the 
master mix (Table 5) were prepared. The primers used were the same as those in 
PCR. A drop (about 10 [i\) of paraffin oil was applied to each tube to prevent 
volatilizing. 
The tubes were briefly spinned down to gather the component to the 
bottom and then put in a thermal cycler. Amplification was carried out at 95°C for 3 
min, followed by 50 cycles of 95�C, 54�C and 70�C each for 40 s and then at 70°C 
for 3 min. After amplification, 3.8 i^l of DNA sequencing stop solution was added to 
each tube to terminate the reaction. They were stored at -20°C or used immediately. 
2.3.4.3 Electrophoresis 
A. Preparation of gel mold 
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Table 5 Components of master mix for sequencing reaction 
Reagent Volume (|il) 
DNA sequencing buffer, 5x 5.0 
Primer (10 |iM) 0.5 
Template 7.0 
Taq DNA polymerase, sequencing grade 1.0 
Distilled water 3.5 
Total 17 
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The clean short glass plate was evenly covered with binding solution 
(containing bind silane 3 pi, absolute ethonal 1 ml and 0.5% glacial acetic acid 5 |LI1). 
It was then placed on the clean long glass plate with two spacers at the two edges 
between the plates. 
B. Preparation of gel 
Urea (33.6 g) was dissolved in a mixture containing 4.8 ml of lOx TBE 
buffer, 24 ml of 20% acrylamide solution (acrylamide: bisacrylamide = 19:1) and 20 
ml distilled water in a beaker on a hot plate at 200�C and stirred by a magnetic stirrer. 
After filtering the mixture, 350 [i\ of 10% ammonium persulphate and 130 |LI1 
TEMED were added and mixed with shaking for about 10 s. The gel solution was 
immediately poured into the gel mold and allowed to solidify. 
C. Electrophoresis 
The glass plates together with the gel were placed in an electrophoretic 
machine and 0.5x TBE buffer was poured into the tank. Each sample (4 |al) was 
heated at 73°C for 2 min before loading into the wells. Electrophoresis was carried 
out at 1700 V for about 1.5 h. 
2.3.4.4 Silver staining 
After electrophoresis, the short glass plate was separated from the long 
glass plate and placed in a plastic tray. The fix solution (100 ml glacial acetic acid in 
900 ml distilled water) was poured onto it and was shaken for 20 min. The gel was 
rinsed with distilled water for 3 times of 2 min each, and then immersed in staining 
solution and shaken for 30 min. Staining solution was prepared by dissolving one 
package of silver nitrate in 2 L distilled water and one vial of formaldehyde was 
added just before use. 
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The gel was placed in distilled water for 10 s without shaking. Distilled 
water was replaced by developing solution and shaken until bands became visible. 
The stop solution (100 ml glacial acetic acid in 900 ml distilled water) was then 
added to stop the reaction. The gel was rinsed with distilled water twice (each for 2 
min) and dried at room temperature. Then it was placed on a light box to visualize 
the bands. 
2.4 Stepwise selection and characterization of mutants 
In order to select high-level resistant mutants and to investigate the 
sequential development of resistant mutants, mutants were selected by in vitro 
stepwise selection and characterized. S. Typhimurium ATCC 13311 (ST13311) and S. 
Hadar 1739 (SH1739) were the parent strains used for selection. 
2.4.1 In vitro selection of first-step strains 
Approximately 10^  to colonies were plated onto MH agar plates 
supplemented with increasing serial 2-fold dilutions of fluoroquinolones (ranging 
between MIC and MPC). They were incubated at 37°C for 48 - 72 h. Colonies 
growing on the antibiotic plates were picked and replated on MacConkey agar 
containing the same fluoroquinolone concentration used for selection. After 
purification and identification, the colonies with decreased susceptibility to the 
selecting drug were stored. 
2.4.2 Characterization of selected strains 
These selected strains were tested for susceptibilities to nalidixic acid, 
norfloxacin, ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin and gemifloxacin. 
Strains with different MICs were amplified by PCR and mutations in target genes 
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were screened by MPAC analysis and confirmed by DNA sequencing as described in 
sections 2.3.3 and 2.3.4, respectively. 
2.4.3 Subsequent selection of stepwise mutants 
After presence of mutation(s)/additional mutation was detected in mutants, 
they were subjected to another round of selection. They were plated on agar plates 
containing increasing two-fold dilutions from the MIC to 128 jig/ml. This was 
repeated until no additional mutation was found. 
3. Research Plan 
To achieve the research objectives, we planned to 
(1) Determine the MIC and MPC of norfloxacin, ciprofloxacin, ofloxacin, 
levofloxacin, moxifloxacin and gemifloxacin for clinical isolates of S. Typhimurium 
and S. Hadar and a standard strain S. Typhimurium ATCC 13311; 
(2) Select fluoroquinolone-resistance in these two serotypes by in vitro 
stepwise selection; and 
(3) Characterize target gene mutations in the developed resistant mutants 
by PGR, MPAC analysis and DNA sequencing. 
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Results 
1. Identification and fluoroquinolone MICs of 
Salmonella strains 
1.1 Identification of Salmonella strains 
All strains were confirmed by the API20E system to be Salmonella species. 
S. Typhimurium was confirmed by slide agglutination by the presence of 1, 4, 5, 12 
O antigens and i: 1, 2 H antigens while S. Hadar was confirmed by the presence of 6, 
8 O antigens and zio: e, n, x H antigens. 
1.2 Fluoroquinolone MICs for Salmonella strains 
1.2.1 Salmonella Typhimurium 
The MIC of ciprofloxacin and gemifloxacin was 0.0075 |ig/ml for S. 
Typhimurium ATCC 13311, that of levofloxacin was 0.015 |ig/ml, that of ofloxacin 
and moxifloxacin was 0.03 |ig/ml and that of norfloxacin was 0.06 |ig/ml (Table 6). 
The MICs of ciprofloxacin and gemifloxacin for the eight clinical isolates 
selected for this study were 0.015 |ig/ml and 0.015 - 0.03 |ig/ml, respectively, those 
of ofloxacin and levofloxacin were 0.06 |ig/ml, and those of norfloxacin and 
moxifloxacin were 0.06 - 0.12 |ig/ml (Table 6). 
The geometric mean (GM) MIC of ciprofloxacin and gemifloxacin for 
clinical isolates was similar, being 0.015 |ig/ml and 0.016 }ig/ml, respectively while 
that of norfloxacin and moxifloxacin was 0.078 |ig/ml and 0.085 |ig/ml, respectively. 
All MICs were 8- to 64-fold lower than the sensitive breakpoints for sensitive strains 
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Table 6 Minimal inhibitory concentrations of fluoroquinolones for Salmonella Typhimurium 
MICs (|Lig/ml) of 
Strain no.  
Nor Cip Of] Lev Mox Gem 
Standard strain 
ATCC 13311 0.06 0.0075 0.03 0.015 0.03 0.0075 
Clinical strains 
289 0.06 0.015 0.06 0.06 0.12 0.03 
1176 0.12 0.015 0.06 0.06 0.12 0.015 
1277 0.12 0.015 0.06 0.06 0.06 0.015 
2219 0.06 0.015 0.06 0.06 0.06 0.015 
2220 0.06 0.015 0.06 0.06 0.06 0.015 
2232 0.06 0.015 0.06 0.06 0.12 0.015 
2701 0.06 0.015 0.06 0.06 0.12 0.015 
4176 0.12 0.015 0.06 0.06 0.06 0.015 
Range 0.06-0.12 0.015 0.06 0.06 0.06-0.12 0.015 -0.03 
GMb 0.078 0.015 0.06 0.06 0.085 0.016 
aNor-norfloxacin, Cip-ciprofloxacin, Ofl-ofloxacin, Lev-levofloxacin, Mox-moxifloxacin, 
Gem-gemifloxacin 
^GM-geometric mean MIC of fluoroquinolones for clinical strains 
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(NCCLS, 2002; BSAC, 2004). 
1.2.2 Salmonella Hadar 
S. Hadar clinical isolates could be inhibited by 0.015 - 0.03 jig/ml of 
ciprofloxacin and gemifloxacin (GM = 0.03 ^ig/ml), but could only be inhibited by 
0.06 jig/ml of levofloxacin. Norfloxacin, ofloxacin and moxifloxacin inhibited these 
isolates at 0.06 -0.12 |ig/ml (GM = 0.10-0.11 jig/ml) (Table 7). 
All MICs were also 8- to 64-fold lower than the sensitive breakpoints for 
sensitive strains (NCCLS, 2002; BSAC, 2004). 
2. Mutant prevention concentration (MPC) 
2.1 Salmonella Typhimurium 
2.1.1 MPC value 
The MPC of ciprofloxacin and gemifloxacin for S. Typhimurium ATCC 
13311 was 0.12 |ig/ml, that of levofloxacin and moxifloxacin was 0.25 jig/ml, while 
that of ofloxacin and norfloxacin was 0.5 |ig/ml and 1 |ig/ml, respectively (Table 8). 
The MFCs of ciprofloxacin for clinical isolates were 0.25 - 0.5 jag/ml (GM 
=0.27 |ig/ml) and those of the other five fluoroquinolones were 0.5 - 1 |ig/ml (GM of 
levofloxacin, moxifloxacin and gemifloxacin 二 0.65 |ig/ml, GM of norfloxacin = 
0.77 ^ig/ml, GM of ofloxacin = 0.92 |ig/ml). 
2.1.2 MPC/MIC ratio 
The MPC/MIC ratio of moxifloxacin for S. Typhimurium ATCC 13311 was 
8 while that of the other five fluoroquinolones was 16 (Table 8). 
The MPC/MIC ratio of moxifloxacin for clinical isolates was 4 - 8 (GM = 
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Table 7 Minimal inhibitory concentrations of fluoroquinolones for Salmonella Hadar 
MICs (|ig/ml) of 
Strain no. — 
Nor Cip Of] Lev Mox Gem 
1739 0.12 0.03 0.12 0.06 0.12 0.03 
107 0.12 0.03 0.12 0.06 0.12 0.03 
1462 0.12 0.03 0.12 0.06 0.12 0.03 
1566 0.12 0.03 0.12 0.06 0.12 0.03 
2121 0.12 0.03 0.12 0.06 0.12 0.03 
2305 0.12 0.03 0.12 0.06 0.12 0.03 
3377 0.12 0.03 0.12 0.06 0.12 0.03 
3746 0.12 0.03 0.06 0.06 0.12 0.03 
4778 0.06 0.015 0.06 0.06 0.06 0.015 
Range 0.06-0.12 0.015 -0.03 0.06-0.12 0.06 0.06-0.12 0.015 -0.03 
GMb 0.11 0.03 0.10 0.06 0.11 0.03 
^Nor-norfloxacin, Cip-ciprofloxacin, Ofl-floxacin, Lev-levofloxacin, Mox-moxifloxacin, 
Gem-gemifloxacin 



























































































































































































































































































































































































































































































































































































































































































7.3), that of norfloxacin, levofloxacin and ofloxacin was 8 - 16 (GM = 9.5, 10 and 15, 
respectively), and that of ciprofloxacin and gemifloxacin was 16 - 32 (GM = 17) and 
16 - 64 (GM = 38), respectively (Table 8). 
2.1.3 Cmax/MPC ratio 
The Cmax/MPC ratio of norfloxacin and ofloxacin for S. Typhimurium 
ATCC 13311 was less than 10 (1.3 and 9.0, respectively) while that of moxifloxacin, 
levofloxacin, ciprofloxacin and gemifloxacin was higher (13 - 50) (Table 8). 
For clinical isolates, the Cmax/MPC ratio of norfloxacin and gemifloxacin 
was similar (1.3 - 2.6 and 1.6 - 3.2, respectively). The ratio of ofloxacin and 
moxifloxacin was the same (4.5 - 9.0), and that of levofloxacin and ciprofloxacin 
ranged from a low of 5.2 to a high of 24, respectively (Table 8). 
2.1.4 Frequencies of development of resistant strains 
First-step resistant strains of S. Typhimurium developed in the presence of 
fluoroquinolones at Ix - 32x MIC at a frequency ranging from to 10"^  (Table 9). 
Except for strain 289 in the presence of moxifloxacin, all six 
fluoroquinolones could select resistant strains at Ix, 2x and 4x MIC. Frequencies 
also decreased from 10"^  - 10"^  on plates containing Ix MIC of the drug to - 10'^  
on plates containing 4x MIC of drug. 
No resistant strains developed in the presence of 8x MIC of moxifloxacin, 
while three and four resistant strains developed in the presence of 8x MIC of 
norfloxacin and levofloxacin, respectively. Only one strain was unable to produce 
resistant progenies in the presence of 8x MIC of ofloxacin. Resistant strains still 
developed from seven strains when they were grown in 16x MIC of gemifloxacin, 
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Table 9 Frequencies of development of resistant strains from Salmonella Typhimurium in the  
presence of fluoroquinolones  
Frequencies of resistance development in the presence of 
Strain no. Drug'' concentration of fluoroquinolones ange 
IxMIC 2xMIC 4xMIC 8xMIC 16xMIC 32xMIC xMIC Frequency 
13311 Nor 5.7X10.7 2.2X10.8 2.6X10.9 9.3X10"'° lx-8x 9.3X10''°-5.7X10"^  
Cip >5.4X10-7 1.7X10-8 3.2X10-9 I.SXIO"^  Ix - 8x 1.3X10"^ ->5.4X10-"^  
Ofl >3.6X10-7 >1.0X10-7 6.8X10-9 1.2X10"^  Ix - 8x 1.2X10"^ ->3.6X10"^  
Lev >3.6X10-7 >2.0X10"^  3.0X10"^  4.3X10"'° lx-8x 4.3X10"''^ ->3.6X10"'^  
Mox >3.6X10-7 >6.6X10—8 3.8X10"^  lx-4x S.SXIO"^ ->3.6X10"^  
Gem 9.0X10-^  2.9X10'^  S-OXIO"^  3.0X10—9 Ix - 8x 3.0X10-^ -9.0X10-^  
289 Nor >2.2X10-7 >1.6X10"^  5.8X10"^ ° Ix - 4x 5.8X10"'°->2.2X10"^  
Cip >4.3X10.7 >2.1X10—8 1.1X10.9 3.5X10"'° lx-8x 3.5X10"^ °->4.3X10"^  
Ofl >2.3X10-7 >4 3X10-8 >4.6X10-9 2.2X10-'® Ix - 8x 2.2X10"'®->2.3X10-'^  
Lev >2.2X10-7 >5 4x10—9 2.0X10"'° lx-4x 2.0X10"'°->2.2X10"^  
Mox >1.1X10-7 3.9X10-9 lx-2x 3.9X10-^ ->1.1X10"^  
Gem >1.9X10-7 >1.2X10-^  >6.5X10-'^  S-OXIO'^ " Ix - 8x S.OXIO]�->1.9X10-7 
1176 Nor >5.4X10-8 8.2X10"'° 2.1X10"'® lx-4x 2.1X10-^ °->5.4X10'^  
Cip >2.6X10.7 >2.1X10-8 4 0X10-9 2.8X10"'° Ix - 8x 2.8X10"'°->2.6X10"^  
Ofl >3.6X10-7 >5 4X10-8 8.2X10-9 13x10—10 Ix - 8x I.SXIO"^ ®->3.6X10"^  
Lev >2.6X10—7 >6.9X10"^  5.1X10—10 lx-4x 5.1X10"'°->2.6X10"^  
Mox >2.1X10-7 4 1X10-10 5 1x10-11 lx-4x S.IXIO"^ '- >2.1X10"' 
Gem �1.0X10-6 >5.1X10-7 >7.7X10-' >6.6X10'' 6.2X10-1� Ix - 16x 6.2X10-'"->1.0X10'' 
1277 Nor >5.2X10"' 1.3X10.9 37x10-1� lx-4x S.VXIO"''->5.2X10"' 
Cip >4.7X10-7 >4.7X10-8 2.4X10-9 15X10—9 14x10—10 Ix - 16x 1.4X10"^ °->4.7X10"'^  
Ofl >2.3X10-7 >8 4X10-9 >1.9X10-9 4.7X10-'^  lx-8x 4.7X10"''- >2.3X10"^  
Lev >2.3X10.7 >2.7x10"^  >1.7X10.9 1.2X10'® Ix - 8x 1.2X10-'®->2.3X10'^  
Mox >1.9X10-7 2.3X10-9 7.9x10-10 lx-4x 7.9X10"^ ®->1.9X10"' 
Gem >1.0X10-6 >4 7x10-^  >2.3X10-^  5.6X10—9 V.OXIQ-'" 1.9X10—10 Ix - 32x 1.9X10-^ "->1.0X10-^  
2219 Nor >2.5X10-' 1.2X10-' 1.4X10.9 lx-4x 1.4X10"'->2.5X10-' 
Cip >2.8X10-7�2.3X10-8 4.7X10—9 4 8X10"^ ° IX - 8X 4.8X10-^ ° - >2.8X10"^  
Ofl >2.9X10-7 >13X10—8 3 6X10-9 lx-4x 3.6X10"^ ->2.9X10"^  
Lev >3.0X10-' >1.6X10-8 5 4x10—10 lx-4x 5.4X10-'° - >3.0X10-' 
Mox >2.9X10-7 5.7X10-9 6.5X10.1� lx-4x 6.5X10-'° - >2.9X10"' 
Gem >1.0X10-6 >5.7X10-7 >5.7X10-8 >6.0X10-9 1.0X10-9 Ix - 16x 1.0X10"^  - >1.0X10"^  
2220 Nor I.IXIO"' 4.0X10"' S.OXlO—io lx-4x 3.0X10-'° - 1.1X10"' 
Cip >6.5X10-7 >1 (5X10-' 5.1X10-9 5 8X10"^ ° lx-8x 5.8X10-'° - >6.5X10-' 
Ofl >6.3X10-7 >3.3X10-8 >1.1X10-8 1.6X10-' Ix - 8x 1.6X10-'- >6.3X10 ' 
Lev >6.7X10-7 13x10—8 7.8X10-'® 2.6X10"^ ° lx-8x 2.6X10"'® - 6.7X10-' 
Mox >6.7X10-7 2.2X10-8 1 jxiO'^  lx-4x 1.3X10—9 - >6.7X10—7 
Gem >1.0X10-6 >6.0X10-7 >6.7X10-8 9.7X10-9 3 7x10.9 Ix - 16x S.TXIO"'- >1.0X10"' 
(To be cont'd) 
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Cont 'd 
Table 9 Frequencies of development of resistant strains from Salmonella Typhimurium in the  
presence of fluoroquinolones  
Frequencies of resistance development in the presence of „ 
Strain no. Drug^  concentration of fluoroquinolones 呂 
IxMIC 2xMIC 4xMIC 8xMIC 16xMIC 32xMIC xMIC Frequency 
2232 Nor >1.5X10"^  >5.3X10"^  3.5X10.9 4.3X10"'° Ix - 8x 4.3X10"'°->1.5X10"^  
Cip >3.1X10-^  >1.5X10—8 3.3X10-9 6.5X10—1� Ix - 8x 6.5X10"^ ° - >3.1X10"^  
Ofl >3.1X10-7 >2.3X10.8 >1.5X10.9 2.3X10''° lx-8x 2.3X10'^ ° - >3.1X10"^  
Lev >1.5X10-7�8 9X10-9 >1.4X10"^  7.7X10-" Ix - 8x 7.7X10"" - >1.5X10"^  
Mox >7.1X10-8 1.3X10-9 4.6Xl(r�i lx-4x 4.6X10"" - >7.1X10"^  
Gem >1.0X10-6 >3.5X10-7 >4.6X10-8 >3.2X10"^  1.3X10"^  1.5X10"^ '^  Ix - 32x 1.5X10"'° - >1.0X10"® 
2701 Nor >1.8X10-7 >5 jxiO"^  4.2X10"^  1.4X10"^® Ix - 8x 1.4X10-^ ° - >1.8X10-^  
Cip >3.4X10-7 >8.7X10-8 >4 jxiO"^  1.1X10"^  Ix - 8x 1.1X10"^  - >3.4X10"^  
Ofl �2.0X10-7 >3.5X10-8 >9 4x10"'® 1.4X10—i® lx-8x 1.4X10"'° - >2.0X10-'^  
Lev >1.8X10.7 >9.5X10-9 2.3X10.10 lx-4x 2.3X10"^ ° - >1.8X10"^  
Mox >3.9X10-8 2.8X10—9 1 zxiO—i� lx-4x 1.2X10-^ ° - >3.9X10"^  
Gem >1.0X10-6 >3 5x10.7 >5.3X10—8 >4 2X10.9 ^ X^W^ 3.7X10"^® Ix - 32x 3.7X10"'° - >1.0X10"^  
4176 Nor >9.1X10"^  1.0X10"^  1.6X10"'° lx-4x 1.6X10"^® - >9.1X10"^  
Cip �4.1X 0-7 >4.1X10-8 4.4X10"^  3.7X10"^ ® IX - 8X 3.7X10"'® - >4.1X10"^  
Ofl >4.0X10—8 >2.0X10-9 >2.1X10-9 >2.2X10"^ ° Ix - 8x >2.2X10"^ ®->4.0X10"^  
Lev >2.0X10—7 >1 1X10—8 2.0X10"^® lx-4x 2.0X10"'° - >2.0X10"^  
Mox >1.0X10-7 10X10-9 I.6XIO-10 lx-4x 1.6X10"'° - >1.0X10-' 
Gem >1.0X10-6 >4.1X10-7 >2.0X10-8 4 5x10-9 4.5X10"'° Ix - 16x 4.5X10"^® - >1.0X10"^  
ALL XT >5.2X10-8-8.2X10-10- 1.6XIO-1O- 14X10-10- 1 ZIVIN-IO >^7VIN-7 
All Nor >5 7X10-7 i X^lO'^  4.2X10"^  9.3X10—10 lx-8x 1.4X10 ->5.7X10 
>2.6X10-7->1.5X10-8-1.1X10—9- 2.8X10-10-10 16x 1 4X10-'° >6 5X10"^  
CiP >6.5X10-7 >8.7X10-8 >6.8X10-9 15x10-^  1.4X10 Ix-16x1.4X10 ->6.5X10 
Ofl >4.0X10-；- >2.0X10-- >9.4X10-；- 4.7X10-- - 8x 4.7X10- - >6.3X10^  
>6.3X10-7�i 0X10-7 >1 1X10-8 1 6X10-9 
T >1.5X10-7->5.4X10-9-2.0X10-10- 7 7x10-"- 7 7Yin-u tvio-^ 
Lev >6.7X10-7 >2.7X10-8 >3.0X10-9 4 3x10—10 Ix-8x7.7X10 ->6.7X10 
Mox �3.9X10-;- 4-1X10-- 4.6X10-- . 4x 4.6X10-->6.7X10-�6.7X10-7 >6.6X10-8 3.8X10"^  
^ >1.9X10-7->1.2X10-8-�6.5X10-IO-3.0X10-IO- 4.5X10-10- 1.5X10-10- 1 sYiryio >1 
Gem >1.0X10-6 >6.0X10-7 >7.7X10-8 >9.7x10-^  3.7X10-^  3.7X10-^ ° lx-4x 1-5X10 ->i-OXiU 
''Selecting drugs: Nor-norfloxacin, Cip-ciprofloxacin, Ofl-ofloxacin, Lev-levofloxacin, Mox-moxifloxacin, 
Gem-gemifloxacin 
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but from only one strain when grown in 16x MIC of ciprofloxacin. 
2.2 Salmonella Hadar 
2.2.1 MPC value 
The MFCs of ciprofloxacin and ofloxacin for S. Hadar strains were 0.12 -
0.25 |ig/ml and 0.5 - 2 jig/ml, respectively, while those of the remaining four 
fluoroquinolones were 0.25 - 1 |ig/ml (Table 10). 
The MPC of ciprofloxacin was the lowest (GM = 0.18 jig/ml) and that of 
ofloxacin was accordingly the highest (GM = 0.93 jiig/ml). Although the MPC range 
of the other four fluoroquinolones was the same, the GM MPC ranged from a low of 
0.40 |ig/ml of levofloxacin to a high of 0.79 |ag/ml of norfloxacin (Table 10). 
2.2.2 MPC/MIC ratio 
The MPC/MIC ratio of norfloxacin, ciprofloxacin and moxifloxacin for S. 
Hadar isolates was 4 - 8, that of levofloxacin and ofloxacin was similar (4/8 - 16) 
while that of gemifloxacin was the highest (16 - 32). However, the GM of MPC/MIC 
ratio varied from 5.4 of moxifloxacin to 6.4 of ciprofloxacin and levofloxacin, 6.9 -
8.6 of norfloxacin and ofloxacin, and 24 of gemifloxacin (Table 10). 
2.2.3 Cmax/MPC ratio 
The Cmax/MPC ratio of norfloxacin and gemifloxacin for S. Hadar isolates 
were similar (1.3 - 5.2 and 1.6 - 6.4, respectively) while that of ofloxacin, 
moxifloxacin and levofloxacin differed by about 2-fold (ranging from 2.3 - 5.2 to 9 -
21). The ratio of ciprofloxacin was the highest (24 - 50). 
Similarly, the GM of the Cmax/MPC ratios of norfloxacin and gemifloxacin 








































































































































































































































































































































































































































































































































































































































levofloxacin was 4.9, 7.1 and 13, respectively. The GM of C^JMPC of 
ciprofloxacin was at a high of 33 (Table 10). 
2.2.4 Frequencies of development of resistant strains 
First-step resistant strains of S. Hadar could develop in the presence of 
fluoroquinolones at Ix - 16x MIC at a frequency ranging from to 10"^  (Table 
11). 
All six fluoroquinolones could select resistant strains on plates containing 
O 
up to 2x MIC. Frequencies were higher on plates containing Ix MIC of the drug (10" 
-10-6) than on plates containing 2x MIC ( lO]�- 10"^ ). 
However, five strains were unable to produce resistant strains in the 
presence of 4x MIC of moxifloxacin, four strains in the presence of 4x MIC 
levofloxacin, three and two strains in the presence of 4x MIC of ciprofloxacin and 
norfloxacin, respectively. Only one strain produced resistant strains in the presence 
of 8x MIC of either ofloxacin or levofloxacin while all produced resistant strains in 
the presence of 8x MIC of gemifloxacin. No resistant strains developed in the 
presence of 8x MIC of the other three fluoroquinolones. At 16x MIC of gemifloxacin, 
five strains were still able to produce resistant strains while at these concentrations of 
the other five fluoroquinolones, no resistant strains appeared. 
3. Stepwise selection of resistant mutants 
S. Typhimurium ATCC 13311 (ST13311) and S. Hadar 1739 (SH1739) 
were used for stepwise selection to follow the sequential development of resistant 
strains (Figures 3 and 4). Overnight colonies of each strain were inoculated in 
nutrient broth to a turbidity matching that of Macfarland 1, centrifuged and 
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Table 11 Frequencies of development of resistant strains from Salmonella Hadar in the presence 
of fluoroquinolones  
Frequencies of resistance development in the presence of „ 
Strain no. Dmg^  concentration of fluoroquinolones  
IxMIC 2xMIC 4xMIC 8xMIC 16xMIC xMIC Frequency 
1739 Nor 7.1X10—7 1.3X10"^  5.9X10"'° lx-4x 5.9X10—1° - 7.1X10—7 
Cip 5.6X10-7 2.1X10-8 8.2X10-1� lx-4x 8.2X10-'®-5.6X10"^  
Ofl 5.9X10—7 1.0X10"^  1.4X10—9 lx-4x 1.4X10-^ -5.9X10"^  
Lev 2.2X10-6 I.SXIO'^  lx-2x 1.5X10-^ -2.2X10"^  
Mox 4.6X10—7 1.2X10—8 1.2X10''° lx-4x 1.2X10-'° - 4.6X10-^  
Gem 1.2X10—6 2.8X10—7 1.6X10—8 i 5x10-9 lx-8x 1.5X10-^ -1.2X10'^  
107 Nor 3.4X10—7 1.6X10"^  7.1X10"^ ° lx-4x 7.1X10"'° - 3.4X10"^  
Cip 3.4X10-7 >2.6X10-8 >1.6X10"^  lx-4x >1.6X10-^ -3.4X10"^  
Ofl 2.0X10-7 >3.6X10-9 2.9X10—10 lx-4x 2.9X10"'° - 2.0X10"^  
Lev 3.8X10-7 1.8X10"^  3.2X10-9 lx-4x 3.2X10-^ -3.8X10"^  
Mox 3.8X10-7 2.6X10-8 3 2XIO"'® lx-4x 3.2X10"'° - 3.8X10"^  
Gem >4.1X10—7 >6.5X10-8 >2.7X10—8 >9.7X10-9 g.lXlQ-^ " Ix- 16x S-IXIO''" - >4.1X10'^  
1462 Nor 2.6X10.7 2.5X10"^  4.2X10"^ ° lx-4x 4.2X10"'° - 2.6X10"^  
Cip 1.7X10-7 8.3X10-9 1.6X10-9 lx-4x 1.6X10"'- 1.7X10'' 
Ofl 3.4X10-7 1.8X10-9 1.6X10-10 lx-4x 1.6X10-'° - 3.4X10"' 
Lev 3.7X10-7 2.8X10"^  3.2X10"'° lx-4x 3.2X10"'° - 3.7X10"' 
Mox >2.6X10-7 3.2X10-9 Ix - 2x 3.2X10-'->2.6X10"' 
Gem 1.1X10—6 41x10—8 >2.2X10—9 9.0X10-^ ° Ix - 8x 9.0X10-1�- 1.1X10-6 
1566 Nor 7.6X10"^  8.9X10"^  I.SXICT川 lx-4x LSXIO"'® - 7.6X10"' 
Cip 5.0X10-7 3.4X10-9 5 9X10.10 lx-4x 5.9X10-^ ® - 5.0X10"' 
Ofl 1.4X10-6 >5.5X10-9 11X10—10 lx-4x 1.1X10"'°-1.4X10"' 
Lev 1.1X10-6 2.0X10-8 Ix - 2x 2.0X10"'- 1.1X10"' 
Mox >1.9X10-7 2.5X10-9 lx-2x 2.5X10"'- >1.9X10-' 
Gem >7.4X10-7 4 5x10—7 >3.6X10'^  I-OXIO'^  1.9X10-'° Ix- 16x 1.9X10'^ ° - >7.4X10'^  
^ 7.5X10-7~~8.0X10_9 IX - 2 X 8 . 0 X 1 0 " ' - T-SXIO"' 
Cip 6.4X10-7 1.9X10-9 lx-2x 1.9X10"'- 6.4X10-' 
Ofl 6.2X10-7 >5.0X10-9 i oxiO-10 lx-4x LOXIO"'® - 6.2X10"^  
Lev 6.2X10-7 4 8X10"' lx-2x 4.8X10-'- 6.2X10-' 
Mox >2.5X10—7 2.5X10-9 Ix - 2x 2.5X10-'- >2.5X10-' 
Gem 4.5X10-6 2.IXIO-' >2.5X10"' 2.5X10"^  2.5X10"^ ° Ix - 16x 2.5X10-'°-4.5X10"' 
^ ^ 1.3X10-72.6X10-^3.3X10-1� lx-4x3.3X10-10 - IJXIO-? 
Cip 5.9X10-8 >8.3X10-' 2.8X10-9 lx-4x 2.8X10"'- 5.9X10-' 
Ofl 2.5X10—7 >2.0X10-8 >9.8X10-9 40x10—9 lx-8x 4.0X10-^ -2.5X10-^  
Lev >1.9X10-7 >7 3X10-8 >99x10"^  2.0X10"^  lx-8x 2.0X10-^ ->1.9X10"^  
Mox 1.6X10-7 1.1X10-8 11x10-9 lx-4x 1.1X10"'- 1.6X10-' 
Gem >4.0X10-7 >4 0x10-8 >13x10'^  >5.5X10-^  9.0X10-'" Ix - 16x 9.0X10-'° - >4.0X10 ' 
3m N^ 2.8X10-76.8X10-1�1.4X10-'° lx-4x1.4X10-'° - 2.8X10-' 
Cip 2.1X10-7 1.3X10-9 lx-2x 1.3X10-9-2.1X10-7 
Ofl 4.9X10-7 1.2X10"' 9.1X10-1° lx-4x 9.1X10-'° - 4.9X10"' 
Lev 1.1X10-6 3.1x10-8 14X10-10 lx-4x 1.4X10-'° - LIXIO"' 
Mox 2.1X10-7 2.7X10-9 Ix - 2x 2.7X10-^ -2.1X10-' 
Gem 1.3X10—6 2.7X10—7 3.2XIO-' 8.6X10-^ ° Ix - 8x 8.6X10-^ ° - 1.3X10'' 
(To be cont ’d) 
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Table 11 Frequencies of development of resistant strains from Salmonella Hadar in the presence  
of fluoroquinolones  
Frequencies of resistance development in the presence of 
Strain no. Druga concentration of fluoroquinolones  
IxMIC 2xMIC 4xMIC 8xMIC 16xMIC xMIC Frequency 
3746 Nor 5.5X10—7 7.7X10—9 7.7X10-'^  lx-4x 7.7X10-" - 5.5X10"^  
Cip 4.5X10-7 2.2X10-9 lx-2x 2.2X10"^  - 4.5X10"^  
Ofl >7.7X10-7 3 8X10—7 >3.8X10-10 lx-4x >3.8X10"'®- >7.7X10"^  
Lev 5.1X10-7 4.9X10-8 LIXIO''® lx-4x 1.2X10"^® - 5.1X10"^  
Mox >3.8X10-7 7.7X10—9 7.7X10"^ ^ lx-4x 7.7X10-" - >3.8X10"^  
Gem �7.7X10-7 >3.8X10-7 >15x10-8 1.5X10'^  1.2X10-^ " Ix - 16x 1.2X10-^ " - >7.7X10"^  
4778 Nor 5.9X10-7 3.8X10"^  lx-2x 3.8X10"^  - 5.9X10"^  
Cip 4.8X10-7 1.9X10-8 2.5X10]� lx-4x 2.5X10"^ ° - 4.8X10-^  
Ofl 4.6X10-7 1.4X10—7 3.1X10—9 lx-4x 3.1X10-^ -4.6X10'^  
Lev 2.6X10—7 8.2X10"^  lx-2x 8.2X10-^ -2.6X10"^  
Mox >8.5X10-8 2.1X10-9 lx-2x 2.1X10-'->8.5X10"' 
Gem >3.6X10-7 >19x10—7 >7.1X10'^  3.6X10-'° Ix - 8x 3.6X10-'°->3.6X10"^  
All Nor -^SXIO -^ 7.7X10-- lx-4x 7.7X10--7.6X10-Au 7.6X10-7 38X10—8 7.1X10-'° 
Cip 5.9X10-:- 1.3X10-9 5.9X10-10- ix-4x 5.9X10--6.4X10-
P 6.4X10-7 >2.6X10-8 >2.8X10-9 
Ofl 2.0X10-�1.8X10-�l.OXlO-iO- 4似10-9 Ix - 8x 1.0X10-'°-1.4X10-^  
1.4X10—6 3.8X10—7 >9.8X10-9 
Lev �1.9X1(^ -7- 8.2X10-9- LiXlO" '^- .^QXIO"^  IX - 8X 1.2X10-'° - 2.2X10"^  
2.2X10-6 >7.3X10-8 >99X10-9 
Mox >8.5X10-:- 2.1X10-:- 7.7X1=- ix-4x 7.7X10-- >4.6X10-
>4.6X10-7 2.6X10' 1.1X10—9 
广 >3.6X10-7- >4 0X10-8- >2.2X10-9- 3.6X10"^ °- 1.2X10"''- , . . . ovin-io . cvin-6 
Gem 4.5X10-6 >4.5x10-^  >2.7X10-^  >9.7X10"^  9X10.� lx-16x 1.2X10 -4.5X10 


















































































































































































































































































































































































































































































































































































































































































i > Hnor-4 > Hnor-4-1 





> Hcip-2 > Hcip-2-1 
-Hcip-2-2 
> Hofl-1 
—> Hofl-2 > Hofl-2-1 
7 7 — - Hofl-2-6 
> Hofl-3 
SH1739 „ « . 
^ Hofl-4 > Hofl-4-1 
-Hofl-4-3 
> Hlev-1 
> Hlev-2 > Hlev-2-1 
> Hlev-3 _ Hlev-2-2 
> Hmox-1 
> Hmox-2 





> Hgem-3 > Hgem-3-1 
-Hgem-3-6 
Figure 4 Schematic representation of and step Salmonella Hadar resistant 
strains and their respective parents. 
69 
resuspended in broth and were spread onto agar plates containing each of the six 
fluoroquinolones at increasing 2-fold concentrations starting at MIC. 
3.1 Salmonella Typhimurium 
3.1.1 Characterization of I'^-step strains 
Any colonies growing on the agar plates were referred to as I'^-step strains. 
They usually appeared 48 - 72 h after incubation and varied from pin-point colonies 
to approximately 1.5 mm in diameter (microscopic morphology of bacteria before 
and after selection by fluoroquinolones is shown in Figure 5). They were irregular in 
shape, being longer, thinner and curved, as compared to the short rod-shaped 
structure of their parent. After biochemical and serological identification, they were 
confirmed to be S. Typhimurium. Colonies on the plates containing fluoroquinolones 
at MIC or above were picked (all if they were <30 but only 6 - 7 of each type of 
there were >30) and replated on plates containing the same fluoroquinolone 
concentration for purification and the MICs of the fluoroquinolone used for selection 
were determined. Those with MICs higher than those of the parent and different from 
individual colonies were selected for further study. The same procedures and 
selection were used for selection of n-step mutants. 
A total of 20 ist-step strains of ST 13311 that developed in the presence of 
each of the six fluoroquinolones were characterized (Table 12). They were named as 
Txxx-n, where T stands for ST13311, xxx the abbreviation for the fluoroquinolone 
used for selection and n the number of strain. 
3.1.1.1 Antimicrobial susceptibilities 
The susceptibilities of 1^ -^step strains that developed in the presence of one 
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Figure 5 Microscopic morphology of Salmonella Typhimurium. a) before selection by 










































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































fluoroquinolone to all six fluoroquinolones and nalidixic acid were tested by 
determining the MICs. 
A) Susceptibilities of 1^ -^step strains 
a) First-step norfloxacin strains 
First-step strains that developed in the presence of norfloxacin are referred 
to as ist-step norfloxacin strains (Tnor-1 - Tnor-3). The same nomenclature will be 
used for strains developed in the presence of the other fluoroquinolones. 
The MICs of all fluoroquinolones were 4- to 16-fold higher for 1^ -^step 
norfloxacin strains than those for their parent (Table 12). They ranged from a low of 
0.03 jig/ml of gemifloxacin (4-fold higher) to a high of 1 jig/ml of norfloxacin 
(16-fold higher). In contrast, the MIC of nalidixic acid (the precursor of 
fluoroquinolones) was much higher, being 128 jug/ml, representing a 64-fold increase 
over that for the parent. 
b) First-step ciprofloxacin and ofloxacin strains 
The MICs of all fluoroquinolones increased 2- to 16-fold for both 1^ -^step 
ciprofloxacin and ofloxacin strains (Table 12). They ranged from a low of 0.015 
fig/ml of gemifloxacin (2-fold higher) to a high of 0.5 jig/ml of norfloxacin (8-fold 
higher) and levofloxacin (16-fold higher), respectively. The MICs of all 
fluoroquinolones tested except norfloxacin and moxifloxacin, for Tcip-3 and Tofl-3, 
were 16-fold higher than those for their parent (0.12 - 0.5 |ig/ml), while those of 
nalidixic acid were 128-fold higher (256 |ig/ml). 
c) First-step levofloxacin strains 
Fluoroquinolone MICs were 2- to 16-fold higher for 1^^ -step levofloxacin 
strains than those for their parent and ranged from a low of 0.015 |ig/ml of 
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gemifloxacin (2-fold higher) to a high of 0.50 |Lig/ml of ofloxacin and moxifloxacin 
(16-fold higher) (Table 12). The MIC of levofloxacin for Tlev-2 was also 16-fold 
higher (0.25 |ig/ml) than that for the parent. 
The MIC of nalidixic acid for these strains was 4- to 32-fold higher than 
that for the parent (8 - 64 jig/ml). 
d) First-step moxifloxacin strains 
All ist-step moxifloxacin strains showed only 2- to 8-fold decreased 
susceptibilities to the fluoroquinolones tested except Tmox-1 for which the MIC of 
norfloxacin and ciprofloxacin was the same as that for the parent. The increase in 
MIC of moxifloxacin and gemifloaxcin for two of these strains (Tmox-3 and 
Tmox-4) was highest (8-fold) (Table 12). 
e) First-step gemifloxacin strains 
The level of increase in MIC of norfloxacin (2-fold) and ofloxacin and 
levofloxacin (4-fold) was the same for all the three 1^ -^step gemifloxacin strains. 
However, the MIC of ciprofloxacin was 2- to 4-fold higher for strains than that for 
the parent and that of moxifloxacin and gemifloxacin was 4- to 8- fold higher than 
that for the parent (Table 12). The MIC of nalidixic acid for all these strains was 8 
|ig/ml which was 4-fold higher than that for the parent. 
B) Activities of fluoroquinolones against 1^ -^step strains 
First-step strains that developed in the presence of moxifloxacin were most 
susceptible to all six fluoroquinolones. The MICs ranged from 0.0075 - 0.03 昭/ml of 
ciprofloxacin (the same or 2- to 4-fold higher) to 0.06 - 0.25 ing/ml of moxifloxacin 
(2- to 8-fold higher). 
In contrast, 1^^ -step strains that developed in the presence of norfloxacin 
74 
were least susceptible to norfloxacin (MICs = 0 .5-1 jig/ml) and ciprofloxacin (MICs 
二 0.06 - 0.12 ！ig/ml). The MICs of these two fluoroquinolones were 8- to 16-fold 
higher than those for the parent. Besides, I'^-step ofloxacin strains were also least 
susceptible to ciprofloxacin. 
3.1.1.2 Characterization of gene mutations 
A) Multiplex PCR amplimer conformation (MPAC) analysis 
The QRDR of gyrA, gyrB, parC and parE genes in all 20 1^ -^step strains 
was characterized by PCR (Figures 6 and 7) followed by MPAC analysis. 
Five different patterns (Type I - V) were observed after amplimers of the 
gyrA gene of these strains were subjected to MPAC analysis (Figure 8). Fourteen 
strains had the same pattern (Type V) as ST 13311 while the other six strains showed 
four different patterns (Type I - IV). 
For the gyrB gene, only one strain (Tlev-3) exhibited an MPAC pattern that 
was different from that of the parent (Figure 9). The MPAC patterns of both parC 
and parE genes in all strains were the same as those of the parent. 
B) Gene mutations 
In order to confirm the presence of mutation as indicated by MPAC 
analysis, DNA sequence of the QRDR of gyrA, gyrB, parC and parE genes of all 20 
strains was determined by manual sequencing and repeated by automated sequencing. 
No mutation was detected in the gyrA gene of the 14 strains that had the 
same gyrA MPAC pattern as the parent (type V) while mutations were detected in the 
other six that had different gyrA MPAC patterns. Asp87—Gly (GAC—GGC) 
mutation was detected in three mutants (Tnor-2, Tnor-3, Tcip-2) of Type I; 
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Figure 6 Amplified products from Salmonella Typhimurium mutants using a) 
gyrAl primers (product size = 276 bp) and b) gyrA2 primers (product size = 347 
bp). Lane 1，OX 174DNA/i/a^III marker. Lane 2, negative control. Lane 3, parent 
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Figure 7 Amplified products from Salmonella Typhimurium mutants using a) gyrB 
primers (product size = 210 bp), b) parC primers (product size = 347 bp), and c) 
parE primers (product size = 273 bp). Lanel, OX 174DNA/^a^III marker. Lane 2, 
negative control. Lane 3, parent strain Salmonella Typhimurium ATCC 13311. 
Lanes 4-7, ？and 4^^-step mutants respectively. 
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Figure 8 Multiplex PGR amplimer conformation (MPAC) analysis of gyrA 
genes in Salmonella Typhimurium 1^ -^step strains. Lane 1, Salmonella 
Typhimurium standard strain ATCC 13311 as a control. Lanes 2-8, Tmox-1, 
Tlev-1, Tnor-1, Tofl-2, Tcip-2, Tnor-2 and Tcip-3, respectively. 
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1 2 3 4 
Figure 9 Multiplex PCR amplimer conformation (MPAC) analysis of gyrB 
genes in 1^ -^step mutants. Lane 1, Salmonella Typhimurium standard strain 
ATCC 13311 as a control. Lane 2, Salmonella Typhimurium I'^-step mutant 
Tlev-3. Lane 3, Salmonella Hadar 1739 as a control. Lane 4, Salmonella 
Hadar 1^ -^step mutant Hofl-2. 
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(GAC—AAC) in Tnor-1 of type III; and Asp87—His (GAC->CAC) mutation in 
Tlev-1 of type IV. 
The only mutant (Tlev-3) that exhibited a gyrB MPAC pattern different 
from that of the parent had a Glii466—Asp (GAA—GAC) mutation. No mutation 
was detected in the parC or parE genes of all mutants. 
No mutation was detected in all 1^ -^step strains that developed in the 
presence of gemifloxacin or moxifloxacin. 
3.1.1.3 Mutations and fluoroquinolone susceptibilities 
A) Mutants with gyrA mutation 
The MICs of gemifloxacin for six 1^ -^step mutants with a gyrA mutation 
were 4- to 8-fold higher (0.03 - 0.06 |ig/ml) than those for the parent strain while 
those of ofloxacin, moxifloxacin and levofloxacin were all 8-fold higher (0.25 |ig/ml, 
0.12 iig/ml and 0.25 jig/ml, respectively). In contrast, the MICs of norfloxacin and 
ciprofloxacin were increased to up to 16-fold for these strains (4- to 16-fold [0.25 - 1 
|ig/ml] and 8- to 16-foki [0.06 - 0.12 |ig/ml], respectively) (Table 12). 
B) Mutant with gyrB mutation 
The MIC of norfloxacin (0.12 }ig/ml) and gemifloxacin (0.015 |Lig/ml) for 
the mutant with a gyrB mutation were 2-fold higher than that for the parent strain, 
that of ciprofloxacin (0.03 |ig/ml), ofloxacin (0.06 |ig/ml) and levofloxacin (0.06 
)ig/ml) were 4-fold higher, and that of moxifloxacin (0.25 |ig/ml) was 8-fold higher 
(Table 12). 
C) Strains without any detectable mutation 
The susceptibilities of the 13 1^ -^step strains (96.5%), in which no mutation 
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of target gene was detected, were in general decreased. 
The MICs of the six fluoroquinolones to moxifloxacin-selected strains 
were either the same or 2- to 8-fold higher than those for the parent. Similarly, the 
MICs of these fluoroquinolones to gemifloxacin-selected strains were 2- to 8-fold 
higher than those for the parent. However, for strains selected by norfloxacin, 
ciprofloxacin, ofloxacin and levofloxacin, the MICs might be increased to up to 
16-fold (Table 12). 
3.1.1.4 Mutations and nalidixic acid susceptibilities 
Eight strains were resistant to nalidixic acid (MICs >16 jig/ml). As 
compared to the MIC for the parent strain, the MICs for these strains were 64- to 
128-fold higher. Two of these strains did not harbour any detectable mutations in the 
target genes although MIC of nalidixic acid was 256 |ig/ml while the remaining six 
harboured an Asp87—Asn/Gly/Tyr/His mutation in the gyrA gene and MICs for 
these strains were 64 - 128 |ig/mL 
For the other 12 strains, they were sensitive to nalidixic acid (<16 |ig/ml) 
although the MICs were still 2- to 8-fold higher than those for the parent strain. All 
except one, Tlev-3 with a Glu466—Asp mutation in gyrB, did not harbour detectable 
mutations in the target genes. 
3.1.2 Characterization of Instep mutants 
Six of the seven l® -^step mutants with non-identical mutation or with the 
same mutation but selected by different fluoroquinolones (Tnor-1, Tnor-2, Tcip-2, 
Tofl-2, Tlev-1, Tlev-3) were subjected to another round of selection by the 
fluoroquinolone that was used to select individual 1^ -^step mutants (Figure 3). Strains 
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that did not have any detectable mutation were not subjected to further selection. 
Mutants that developed in this round were referred to as 2"^-step mutants 
and they were obtained on antibiotic plates containing Ix or 2x MIC of the selecting 
drug (Table 13). Using the same selection criterion for I'^-step mutants, 21 2"'^ -step 
mutants were further characterized. They were similarly named as Txxx-n-m, where 
Txxx-n stands for the parent strain and m the number of the 2"^-step mutant. 
3.1.2.1 Antimicrobial susceptibilities 
As for ist-step strains, the susceptibilities of step mutants to all the six 
fluoroquinolones and nalidixic acid were tested by determining the MICs (Table 13). 
A) Susceptibilities of 2"^-step mutants 
a) Second-step norfloxacin mutants 
The MIC of ofloxacin, moxifloxacin and gemifloxacin for all 2"^-step 
norfloxacin mutants was 4- to 16-fold higher than that for the parent strain while the 
MIC of norfloxacin, ciprofloxacin and levofloxacin was 2- to 8-fold higher than that 
for the parent strain (Table 13). 
Four of the six step norfloxacin mutants were resistant to the 
breakpoint concentration of moxifloxacin for sensitive strains (1 fig/ml, BSAC, 2004) 
while none was resistant to that of ciprofloxacin or levofloxacin (1 |Lig/ml and 2 
|ig/ml, respectively, NCCLS, 2002). One and two mutants were resistant to 
norfloxacin (4 |ag/ml, NCCLS, 2002), ofloxacin (2 |ig/ml, NCCLS, 2002) and 
gemifloxacin (0.25 |ag/ml, BSAC, 2004), respectively. However, all were resistant to 
nalidixic acid (16 昭/ml, NCCLS, 2002). 


































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































The MICs of all the fluoroquinolones tested except gemifloxacin were 2- to 
4-fold higher for 2"'^ -step ciprofloxacin mutants than those for the parent strain (Table 
13). These MICs ranged from a low of 0.12 |ig/ml of ciprofloxacin to a high of 1 
|ig/ml of norfloxacin, ofloxacin and moxifloxacin which were below the breakpoint 
concentrations for sensitive strain (NCCLS, 2002; BSAC, 2004). However, the MIC 
of nalidixic acid was >512 |ig/ml which was 32-fold higher than the breakpoint 
concentration of 16 昭/ml (NCCLS, 2002). 
c) Second-step ofloxacin mutants 
Fluoroquinolone MICs for step ofloxacin mutants were 2- to 8-fold 
higher than those for the parent, ranging from a low of 0.25 jig/ml of ciprofloxacin 
and gemifloxacin (4-fold higher) to a high of 2 |ig/ml of norfloxacin and ofloxacin 
(4- and 8-fold higher, respectively) (Table 13). 
Except for three mutants that were resistant to gemifloxacin (MIC = 0.5 
|ig/ml), none was resistant to the fluoroquinolones tested. As for 2"^-step 
ciprofloxacin mutants, 2"^-step ofloxacin mutants were resistant to high 
concentrations of nalidixic acid (>512 |ig/ml). 
d) Second-step levofloxacin mutants 
For 2"^-step levofloxacin mutants, the fluoroquinolone MICs were 2- to 
8-fold higher than those for the parent strain (Table 13). The MICs ranged from 0.03 
jig/ml of gemifloxacin to 2 jig/ml of moxifloxacin. Only one strain (Tlev-1-1) was 
resistant to the fluoroquinolones tested (MIC of moxifloxacin and gemifloxacin was 
2 jig/ml and 0.5 |ag/ml, respectively), but all were resistant to nalidixic acid (MICs 
32 - 512 |ag/ml). 
B) Activities of fluoroquinolones against 2" -^step mutants 
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The MICs of the fluoroquinolones to the 2"^-step mutants ranged from 0.03 
|ig/ml to 8 }ig/ml which were 2- to 16-fold higher than those for their respective 
parents (Table 13). Second-step mutants that developed in the presence of 
norfloxacin were less susceptible (MICs of ofloxacin or moxifloxacin = 1 - 4 jig/ml 
to 2 - 8 |ig/ml of norfloxacin) to most of the fluoroquinolones tested than those that 
developed in the presence of ciprofloxacin or ofloxacin (MICs of ofloxacin or 
moxifloxacin = 1 - 2 |ig/ml to 0.5 - 2 昭/ml of norfloxacin). In contrast, 2"^-step 
mutants that developed in the presence of levofloxacin was more susceptible (MICs 
of ofloxacin and norfloxacin = 0.25 - 1 |ig/ml). 
3.1.2.2 Characterization of gene mutations 
A) MPAC analysis 
The QRDR of gyrA, gyrB, parC and parE of all the 21 2"'^ -step mutants 
was amplified, and the presence of mutation was detected by MPAC analysis. 
Five mutants (Tnor-2-1, Tcip-2-2, Tlev-1-5, Tlev-3-1 and Tlev-3-2) had 
gyrA MPAC patterns different from their respective parents although the pattern of 
Tnor-2-1 and Tcip-2-2 was the same (Figure 10). 
The gyrB, parC and parE MPAC patterns of all 2"^-step mutants were 
identical to those of their respective parents. 
B) Gene mutations 
The QRDR of gyrA of all except one of these five step mutants with an 
MPAC pattern different from that of their parents that was sequenced had a 
Ser83-^Phe (TCC^TTC) mutation that was absent in their parents in addition to the 
mutation that was originally present. The remaining mutant (Tlev-3-1) had an 
85 
礫 _ _ _ 峰 _ • 德 l^m 
袖 • • 特 • • 縫 謹 
• . . ^  ... 一 丄 m i H B ^ ' -
1 2 3 4 5 6 7 8 9 
Figure 10 Multiplex PGR amplimer conformation (MPAC) analysis of gyrA 
genes in Salmonella Typhimurium mutants. Lanes 1-3, Tlev-3, 
Tlev-3-2 and Tlev-3-1, respectively. Lanes 4-5, Tnor-2 and Tnor-2-1, 
respectively. Lanes 6-7，Tlev-1 and Tlev-1-5, respectively. Lanes 8-9, Tcip-2 
and Tcip-2-2, respectively. 
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Asp87—Gly (GAC->GGC) mutation in addition to a Glu466—Asp mutation in gyrB 
that was present in its parent. 
Although the gyrB, parC and parE MPAC patterns of 2"'^ -step mutants 
were the same as those of their parents, the sequence of their QRDRs was determined 
and absence of mutation was confirmed. 
3.1.2.3 Mutations and fluoroquinolone susceptibilities 
The MICs of norfloxacin (0.5 - 2 ^ig/ml) for three 2"^-step mutants with 
double gyrA mutations were 2-fold higher than those for the parent, and those of 
ofloxacin and moxifloxacin (0.5 - 1 昭/ml) were 2- to 4-fold higher (Table 13). In 
contrast, the MICs of ciprofloxacin (0.25 - 0.5 |ig/m), levofloxacin (0.25 - 1 jig/ml) 
and gemifloxacin (0.25 |Lig/ml) increased 2- to 8-fold for these strains. 
The susceptibilities of the 14 mutants which had the same single gyrA 
mutation as their respective parents also decreased, with MICs being up to 16-fold 
higher (0.12 - 8 |ig/ml). Of these, only one and two strains were resistant to 
norfloxacin and ofloxacin, respectively, while five and six strains were resistant to 
moxifloxacin and gemifloxacin, respectively. The three strains with two gyrA 
mutations had fluoroquinolone MICs similar to those of strains with single gyrA 
mutations. 
In contrast, the two mutants with the same gyrB mutation as their parent 
had MICs increased 2- to 4-fold only. 
3.1.2.4 Nalidixic acid susceptibilities 
All 2nd-step mutants were resistant to nalidixic acid with MICs ranging 
from 32 fig/ml to >512 jig/ml which were >4-fold higher than those of the respective 
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parents (Table 13). 
The MIC of nalidixic acid to mutants with an additional mutation and that 
of mutants without additional mutation was similar, except for Tlev-3-1 and Tlev-3-2 
which had a gyrA mutation in addition to a gyrB mutation and could only be 
inhibited by >256 jig/ml of nalidixic acid, as compared to Tlev-3-3 and Tlev-3-4 that 
had only a gyrB mutation and could be inhibited by 32 jig/ml of nalidixic acid. 
3.1.3 Characterization of mutants 
All five step mutants with double mutations (Tnor-2-1, Tcip-2-2, 
Tlev-1-5, Tlev-3-1 and Tlev-3-2) were subjected to another round of selection by the 
same fluoroquinolone as used in 2"^-step selection (Figure 3). 
Mutants that developed in this round were referred to as 3^^-step mutants 
and were obtained on antibiotic plates containing Ix - 8x MIC. Finally, 27 mutants 
were characterized and similarly they were named as Txxx-n-m-y, where Txxx-n-m 
stands for the parent and y the number of the S'^ -^step mutant. 
3.1.3.1 Antimicrobial susceptibilities 
The susceptibilities of 3^ -^=step mutants to all the six fluoroquinolones and 
nalidixic acid were tested by determining the MICs as described in Materials and 
Methods. 
A) Susceptibilities of mutants 
a) Third-step norfloxacin mutants 
The MIC of levofloxacin for all 3^ -^step norfloxacin mutants was identical 
to that for the parent while that of gemifloxacin was much higher (4- to 8-fold 
higher). The MICs of the other four fluoroquinolones were 2- to 4-fold higher than 
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those for the parent (Table 14). 
All four 3rd-step norfloxacin mutants were resistant to both moxifloxacin 
and gemifloxacin (MICs = 1 - 4 jig/ml) but susceptible to ofloxacin or levofloxacin 
(MICs = 1 - 2 |ig/ml). One and three strains were resistant to ciprofloxacin (MIC = 2 
|ig/ml) and norfloxacin (MIC = 8 |ig/ml), respectively. 
b) Third-step ciprofloxacin mutants 
For all except Tcip-2-2-5, the MICs of ofloxacin, levofloxacin and 
moxifloxacin were 4-fold higher, those of ciprofloxacin were 8-fold higher, and those 
of norfloxacin and gemifloxacin were 16-fold higher than those for the parent (Table 
14). The MICs of norfloxacin, ciprofloxacin and ofloxacin for Tcip-2-2-5 were 2-fold 
higher than those for the other 3^^-step ciprofloxacin mutants. 
All five 3^^-step ciprofloxacin mutants were resistant to the breakpoint 
concentration for susceptible strains of fluoroquinolones except levofloxacin, 
although the MICs of levofloxacin were 2 |Lig/ml which was 4-fold higher than that 
for the parent. 
c) Third-step levofloxacin mutants 
A total of 18 3^ -^step levofloxacin mutants were obtained (Table 14). They 
varied considerably in susceptibilities, ranging from 2- to 32-fold decreased 
susceptibilities as compared to their parents. The MICs ranged from 0.25 |ig/ml of 
gemifloxacin to 16 |ig/ml of norfloxacin and moxifloxacin. 
All were resistant to moxifloxacin and all except two were resistant to 
gemifloxacin. Two-thirds of these mutants were resistant to ofloxacin. Three to six 
mutants were resistant to norfloxacin, levofloxacin or ciprofloxacin. 






























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































In general, all B'^ -^step mutants were resistant to 1 jig/ml of moxifloxacin 
and all but two were resistant to 0.25 jig/ml of gemifloxacin (Table 14). In contrast, 
only five (1.9%) were resistant to levofloxacin. 
Third-step mutants that developed in the presence of norfloxacin had the 
least decrease in susceptibilities to all six fluoroquinolones than those developed in 
the presence of other fluoroquinolones. This is shown by the low MICs which were 
the same or up to 4-fold higher than those for the parent except for Tnor-2-1-4 which 
could only be inhibited by a concentration of gemifloxacin at 8x MIC for the parent. 
3.1.3.2 Characterization of gene mutations 
C) MPAC analysis 
The QRDR of gyrA, gyrB, parC and parE of 27 S'^ -^step mutants was 
amplified, followed by MPAC analysis. 
Eleven of these mutants (Tnor-2-1-2, Tcip-2-2-1 to Tcip-2-2-5, Tlev-1-5-2, 
Tlev-1-5-4, Tlev-1-5-5, Tlev-1-5-6 and Tlev-1-5-7) had parC patterns different from 
their respective parents (Figure 11). The pattern of Tcip-2-2-1 and Tcip-2-2-4; 
Tcip-2-2-2 and Tcip-2-2-3; and Tlev-1-5-4, Tlev-1-5-6 and Tlev-1-5-7 were identical. 
The MPAC patterns of gyrA, gyrB and parE genes of these 3^^-step mutants 
were identical to those of their respective parents. 
B) Gene mutations 
Amplified products were also subjected to DNA sequencing. The QRDR of 
parC gene of 11 3'^-step mutants with parC MPAC pattern different from the parent 
was found to have an additional mutation. A Glii51—Asp (GAG—>GAT) mutation 
was present in one mutant that developed in the presence of norfloxacin; a 
Ser80-^Arg (AGC-^AGG or AGC-^CGC) and a Glii84—Lys (GAA^AAA) 
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Figure 11 Multiplex PGR amplimer conformation (MPAC) analysis of parC 
genes in Salmonella Typhimurium S '^^ -step mutants. Lane 1, Salmonella 
Typhimurium ATCC 13311. Lane 2, Tnor-2-1-2. Lanes 3-7, Tlev-1-5-5, 
Tlev-1-5-7, Tlev-1-5-6, Tlev-1-5-4 and Tlev-1-5-2, respectively. Lanes 8-12, 
Tcip-2-2-5, Tcip-2-2-3, Tcip-2-2-2, Tcip-2-2-4 and Tcip-2-2-1, respectively. 
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mutation were present in four mutants and one mutant, respectively, that developed 
in the presence of ciprofloxacin. Three different parC mutations were present in 
rd 
3 -step mutants that developed in the presence of levofloxacin. These were a 
Gly78->Asp (GGC^GAC) in three mutants, a Ser80^Ile (AGC^ATC) and a 
Glu84->Gly (GAA -^GGA) in one mutant each. 
No additional gyrA, gyrB and parE mutation was found in all 3^^-step 
mutants. 
3.1.3.3 Mutations and fluoroquinolone susceptibilities 
The MICs of the fluoroquinolones tested except gemifloxacin for all the 
four norfloxacin mutants were similar (within 2-fold difference), regardless of 
whether a parC Glu51-^Asp mutation was present or not (Table 14). However, they 
were up to 8-fold higher (except for those of levofloxacin) than those for the parent, 
although all strains had the same gyrA mutation. 
Similarly, ciprofloxacin mutants had comparable susceptibilities regardless 
of the type of parC mutation they had. However, the MICs of the fluoroquinolones 
were 4- to 16-fold higher than those for the parent which differed only in having no 
parC mutation. 
The MICs of fluoroquinolones for Tlev-1-5-2 with a parC Glii84—Gly 
mutation were similar to those for Tlev-1-5-1 and Tlev-1-5-3 which did not have the 
parC mutation, although they were 2 - 8 times higher than those for the parent. In 
contrast, the MICs for Tlev-1-5-4 - Tlev-1-5-7 with a Gly78->Asp or Ser80->Ile 
mutation were 8- to 32-fold higher than those for the parent and only two (Tlev-1-5-5 
and Tlev-1-5-6) were susceptible to levofloxacin or norfloxacin, but resistant to all 
other fluoroquinolones tested. 
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All Tlev-3-1 and Tlev-3-2 3'^-step mutants, with an Asp87->Gly/His and a 
gyrB Glu466—Asp mutation as their parents, were susceptible to 4 jig/ml of 
norfloxacin and all but two were susceptible to 2 jig/ml of levofloxacin. 
3.1.3.4 Nalidixic acid susceptibilities 
Most of the 3^^-step mutants were resistant to 512 |ig/ml of nalidixic acid, a 
concentration which could inhibit the parents (MICs 256 - >512 |ig/ml). In contrast, 
the MIC of nalidixic acid decreased to 8 - 32 |Lig/ml for three levofloxacin mutants 
(Tlev-1-5-4, Tlev-1-5-6 and Tlev-1-5-7). These strains had double gyrA mutations 
(Asp87-> His and Ser83—Phe) andparC Gly78—Asp mutation (Table 14). 
3.1.4 Characterization of 4 -step mutants 
Seven (Tnor-2-1-2, Tcip-2-2-3, Tcip-2-2-4, Tcip-2-2-5, Tlev-1-5-2, 
Tlev-1-5-5 and Tlev-1-5-6) of the 11 3^^-step mutants that had a unique mutation in 
addition to the mutations that were present in their respective parents were subjected 
to a further round of selection (Figure 3). 
Strains that grew in this round were referred to as 4^^-step mutants and 
were given a similar nomenclature of Txxx-n-m-y-z, where Txxx-n-m-y represents 
the parent strain and z the number of the 4^ -^step mutant. Thirty-one such mutants 
that developed in the presence of Ix to 4x MIC of the fluoroquinolones were 
characterized. No colonies grew at higher concentrations of fluoroquinolones. 
3.1.4.1 Antimicrobial susceptibilities 
The MICs of fluoroquinolones and nalidixic acid for these step mutants 
were determined as described previously. 
A) Susceptibilities of 4^ -^step mutants 
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a) Fourth-step norfloxacin mutants 
The MICs of all fluoroquinolones for all but one (Tnor-2-1-2-3) 
norfloxacin mutants ranged from 4 jig/ml to 32 [ig/m\ which were 4- (ofloxacin, 
levofloxacin and moxifloxacin) to 8-fold (norfloxacin, ciprofloxacin and 
gemifloxacin) higher than those for the parent (Table 15). Besides, all were resistant 
to all these six fluoroquinolones. 
b) Fourth-step ciprofloxacin mutants 
For all these 4^^-step mutants except Tcip-2-2-4-2 and Tcip-2-2-5-5, the 
MICs were 2 - 8 times those for their respective parent (Table 15). They were also 
resistant to all the six fluoroquinolones. 
c) Fourth-step levofloxacin mutants 
Among the 11 4^ ^^ -step levofloxacin mutants, those that developed from 
Tlev-1-5-5 had the highest MICs (16-64 |ag/ml which were 4- to 16-fold higher than 
those for their parent), while the two that developed from Tlev-1-5-2 had the lowest 
MICs (2 - 8 |ig/ml which were the same or 4-fold higher than those for their parent) 
(Table 15). 
Except for two strains that were susceptible to levofloxacin, one of which 
was also susceptible to norfloxacin, the others were resistant to all the six 
fluoroquinolones. 
B) Activities of fluoroquinolone against 4 '^'-step mutants 
Fourth-step mutants that developed from Tlev-1-5-5 which had two gyrA 
mutations (Asp87^His and Ser83->Phe) and one parC mutation (Ser80->Ile) had 
their MICs increased most as compared to its parent (8- to 16-fold) than 4 '^^ -step 
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Table 15 Characterization of Salmonella Typhimurium 4 '^'-step mutants selected by  
fluoroquinolones  
Strain Selecting (no. of fold increase cl'J^ared with their parents) Mutotion at  
conc.a NA Nor Cip Ofl Lev Mox Gem gyrA parC 
Breakpoint' ()ig/ml) 16 4 1 2 2 1 0.25 
Parent: Tnor-2-1-2 >512 4 1 2 1 2 1 Asp87~K}ly，Ser83—Phe GluSl^Asp 
Tnor-2-1-2-1 2x MIC >512 32 (8) 8 (8) 8 (4) 4 (4) 8 (4) 8 (8) Asp87^Gly, Ser83->Phe GluSl^Asp 
Tnor-2-1-2-2 2x MIC >512 32 (8) 8 (8) 8 (4) 4 (4) 8 (4) 8 (8) Asp87->Gly, Ser83^Phe Glu51->Asp 
Tnor-2-1-2-3 2x MIC >512 32 (8) 8 (8) 8 (4) 4(4) 4 (2) 8 (8) Asp87->Gly, Ser83^Phe Glu51—Asp 
Tnor-2-1-2-4 2x MIC >512 32 (8) 8 (8) 8 (4) 4 (4) 8 (4) 8 (8) Asp87->Gly, Ser83^Phe Glu51->Asp 
Tnor-2-1-2-5 4x MIC >512 32 (8) 8 (8) 8 (4) 4 (4) 8 (4) 8 (8) Asp87->Gly, Ser83^Phe Glu51-^Asp 
Parent: Tcip-2-2-3 >512 8 2 4 2 4 4 Asp87->G]y, Ser83-^Phe Ser80^Arg 
Tcip-2-2-3-1 IxMIC >512 32 (4) 8 (4) 8 (2) 4 (2) 8 (2) 8 (2) Asp87^Gly, Ser83^Phe Ser80—Arg 
Tcip-2-2-3-2 IxMIC >512 16(2) 8(4) 16(4) 8(4) 32(8) 16(4) Asp87^Gly, Ser83->Phe Ser80—Arg 
Tcip-2-2-3-3 IxMIC >512 16(2) 4(2) 8(2) 4(2) 8(2) 8(2) Asp87—Gly，Ser83—Phe Ser80->Arg 
Tcip-2-2-3-4 2x MIC >512 16(2) 8(4) 8(2) 4(2) 8(2) 8(2) Asp87->Gly, Ser83->Phe Ser80->Arg 
Tcip-2-2-3-5 2x MIC >512 32 (4) 16 (8) 16 (4) 8 (4) 16 (4) 16 (4) Asp87^Gly, Ser83^Phe SerSO^Arg 
Parent: Tcip-2-2-4 >512 8 2 4 2 4 4 Asp87^Gly, Ser83^Phe Ser80—Arg 
Tcip-2-2-4-1 IxMIC >512 16(2) 8(4) 16(4) 8(4) 16(4) 16(4) Asp87^Gly, Ser83->Phe Ser80-^Arg 
Tcip-2-2-4-2 IxMIC >512 64 (8) 8 (4) 8 (2) 4 (2) 8 (2) 4 (1) Asp87->G]y, Ser83->Phe Ser80->Arg 
Tcip-2-2-4-3 IxMIC >512 16(2) 4(2) 8(2) 4(2) 8(2) 8(2) Asp87^Gly, Ser83^Phe Ser80—Arg 
Tcip-2-2-4-4 2x MIC >512 32 (4) 8 (4) 8 (2) 4 (2) 8 (2) 8 (2) Asp87—Gly, Ser83~>Phe Ser80->Arg 
Tcip-2-2-4-5 2x MIC >512 16(2) 8(4) 8(2) 4(2) 8(2) 8(2) Asp87^Gly, Ser83^Phe Ser80->Arg 
Parent: Tcip-2-2-5 >512 16 4 8 2 4 4 Asp87—Gly, Ser83~>Phe Glu84—Lys 
Tcip-2-2-5-1 IxMIC >512 32 (2) 8 (2) 16 (2) 4 (2) 8 (2) 8 (2) Asp87^Gly, Ser83^Phe Glu84—Lys 
Tcip-2-2-5-2 2x MIC >512 64 (4) 16 (4) 16 (2) 8 (4) 16 (4) 16 (4) Asp87—Gly, Ser83—Phe Glu84->Lys 
Tcip-2-2-5-3 2x MIC >512 32 (2) 8 (2) 16 (2) 4 (2) 8 (2) 8 (2) Asp87^Gly, Ser83-^Phe Glu84—Lys 
Tcip-2-2-5-4 2x MIC >512 32 (2) 8 (2) 16 (2) 8 (4) 16 (4) 8 (2) Asp87^Gly, Ser83^Phe Glu84->Lys 
Tcip-2-2-5-5 2x MIC >512 32 (2) 8 (2) 8 (1) 4 (2) 4 (1) 4 (1) Asp87^Gly, Ser83^Phe Glu84^Lys 
Parent: Tlev-1-5-2 >512 4 1 2 1 2 0.5 Asp87->His, Ser83^Phe Glu84->Gly 
Tlev-1-5-2-1 IxMIC >512 8(2) 2(2) 4(2) 2(2) 4(2) 2(4) Asp87—His，Ser83—Phe Glu84—Gly 
Tlev-1-5-2-2 IxMIC >512 4(1) 2(2) 4(2) 2(2) 4(2) 2(4) Asp87~>His，Ser83—Phe Glu84~^Gly 
Parent: Tlev-1-5-5 >512 16 4 8 2 4 4 Asp87—His, Ser83—Phe SerSO^Ile 
Tlev-1-5-5-1 2x MIC >512 64 (4) 16 (4) 32 (4) 16 (8) 32 (8) 32 (8) Asp87-^His, Ser83^Phe Ser80—lie 
Tlev-1-5-5-2 2x MIC >512 64(4) 16 (4) 32 (4) 16 (8) 32 (8) 32 (8) Asp87—His, Ser83—Phe SerSO^Ile 
Tlev-1-5-5-3 2x MIC >512 64 (4) 32 (8) 32 (4) 16(8) 64 (16) 64 (16) Asp87—His，Ser83—Phe Ser80^Ile 
Tlev-1-5-5-4 2x MIC >512 64 (4) 32 (8) 32 (4) 16(8) 64(16) 64 (16) Asp87—His，Ser83—Phe Ser80—lie 
Tlev-1-5-5-5 2x MIC >512 64 (4) 32 (8) 32 (4) 16 (8) 64(16) 32 (8) Asp87^His, Ser83->Phe Ser80—lie 
Parent: Tlev-1-5-6 8 4 4 8 4 4 2 Asp87—His, Ser83—Phe Gly78 —Asp 
Tlev-1-5-6-1 IxMIC 32 (4) 16 (4) 4 (1) 32 (4) 16 (4) 32 (8) 4(2) Asp87->His, Ser83^Phe Gly78 — Asp 
Tlev-1-5-6-2 IxMIC 64(8) 16(4) 8(2) 16(2) 8(2) 16(4) 8(4) Asp87-^His, Ser83^Phe Gly78 —Asp 
Tlev-1-5-6-3 IxMIC 32(4) 16(4) 8(2) 16(2) 8(2) 16(4) 8(4) Asp87—His, Ser83—Phe Gly78—Asp 
Tlev-1-5-6-4 IxMIC 16 (2) 8 (2) 4 (1) 32 (4) 16 (4) 32 (8) 4(2) Asp87->His, Ser83-^Phe Gly78—Asp 
''Concentration of drug at which 4'''-step mutants appeared expressed as multiples of MIC for the parent strain. 
''NA-nalidixic acid, Nor-norfloxacin, Cip-ciprofloxacin, Ofl-ofloxacin, Lev-levofloxacin, Mox-moxifloxacin, Gem-gemifloxacin. 
^Breakpoint of NA,Nor, Cip, Ofl, Lev for susceptible strains (|ig/ml) as recommended by NCCLS (2002) and of Mox, Gem as 
recommended by BSAC (Andrews, 2004). 
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mutants that developed from other parents (Table 15). 
In contrast, the mutants that developed from Tlev-1-5-2 that had the same 
two gyrA mutations as Tlev-1-5-5 but a different parC mutation (Glu84^Gly) 
showed the least resistance to all six fluoroquinolones (MIC = 2 - 8 |ig/ml being only 
the same or up to 4 times the MIC of the parent). 
3.1.4.2 Characterization of gene mutations 
Although 4^^-step mutants were resistant to high concentrations of 
fluoroquinolones, their MPAC patterns of the QRDR of gyrA, gyrB, parC and parE 
genes were identical to those of their parents. DNA sequencing also confirmed that 
there was no additional mutation of target genes in these 4^^-step mutants. 
3.1.4.3 Nalidixic acid susceptibilities 
All except step levofloxacin mutants that developed from Tlev-1-5-6 
had nalidixic acid MICs >512 jig/ml. The MICs of nalidixic acid for Tlev-1-5-6-1 to 
Tlev-1-5-6-4 ranged from 16 |ig/ml to 64 jig/ml, which were 2- to 8-fold higher than 
the MIC for their parent (Table 15). 
3.2 Salmonella Hadar 
3.2.1 Characterization of 1^ -^step strains 
Using the same procedures and selecting criteria for selection of 1^^ -step 
strains of S. Typhimurium, 24 strains of SHI739 that developed in the presence of 
the six fluoroquinolones were characterized (Figure 4). They were named as Hxxx-n, 
where H represents SHI739, xxx the abbreviation for the fluoroquinolone used for 
selection and n the number of the strain. Their colonial and microscopic morphology 
were similar to those of resistant strains that developed from S. Typhimurium (please 
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refer to 3.1.1). 
3.2.1.1 Antimicrobial susceptibilities 
The susceptibilities of I'^-step strains that developed in the presence of one 
fluoroquinolone to all six fluoroquinolones and nalidixic acid were tested by 
determining the MICs. 
A) Susceptibilities of 1^ -^step strains 
a) First-step norfloxacin strains 
The MICs of the six fluoroquinolones tested to all except three (Hnor-1, 
Hnor-5 and Hnor-7) 1^ -^step norfloxacin strains were 2- to 16-fold higher than those 
for the parent (Table 16). Hnor-1 and Hnor-5 were as susceptible to levofloxacin as 
their parent (MIC 二 0.06 iig/ml), while Hnor-7 was 32 times less susceptible to 
gemifloxacin than its parent (MIC — 1 jig/ml). 
The MICs for all these strains ranged from a low of 0.06 |ig/ml of 
ciprofloxacin, levofloxacin and gemifloxacin to a high of 2 |ig/ml of norfloxacin and 
ofloxacin (Table 16). Only two (Hnor-4 and Hnor-7) were resistant to gemifloxacin 
while the others were sensitive to all fluoroquinolones tested. In contrast, all except 
two (Hnor-1 and Hnor-5) were resistant to a high concentration of nalidixic acid 
(MICs = 512 |ig/ml). 
b) First-step ciprofloxacin strains 
The MICs of the fluoroquinolones for these strains were 8-fold higher than 
those for the parent except for Hcip-1 which was only 4-times less susceptible to 
levofloxacin than that for the parent. The MICs reached to a maximum of 1 |Lig/ml of 
norfloxacin，ofloxacin and moxifloxacin (Table 16). 





























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































to nalidixic acid (MICs >256 |ig/ml). 
c) First-step ofloxacin strains 
The susceptibility of the four 1^ -^step ofloxacin strains to the majority of 
fluoroquinolones decreased 8 times that for the parent (Table 16). Exceptions 
included Hofl-l which was 16-times less susceptible to norfloxacin, and Tofl-2 
which was only 2-times less susceptible to gemifloxacin and 4-times less susceptible 
to norfloxacin, ciprofloxacin, ofloxacin and levofloxacin than its parent. 
All remained susceptible to the fluoroquinolones but all were resistant to 
nalidixic acid (MICs >32 jig/ml). 
d) First-step levofloxacin strains 
The susceptibility of 1^^ -step levofloxacin strains decreased from a low of 
2-times that of their parent to ciprofloxacin (Hlev-1, MIC = 0.06 [xg/ml) to a high of 
16-times to norfloxacin, ofloxacin and gemifloxacin (Hlev-2, MIC = 2 jig/ml, 2 
jig/ml and 0.5 |ig/ml, respectively) (Table 16). 
Except for gemifloxacin to which only Hlev-2 was resistant, all were 
susceptible to the fluoroquinolones tested. Only Hlev-1 was susceptible to nalidixic 
acid while the other two could only be inhibited by 512 |ig/mL 
e) First-step moxifloxacin strains 
The susceptibility to ciprofloxacin and levofloxacin; and norfloxacin, 
ofloxacin and moxifloxacin, was decreased to the same or similar degree in all 
ist-step moxifloxacin strains (4- to 32-times and 8- to 32- times lower than that of the 
parent, respectively) (Table 16). Of these I'^-step strains, the MIC of all the 
fluoroquinolones, except gemifloxacin, for Hmox-3 was higher (MICs = 1 - 4 |ig/ml 
being 16- to 32-fold higher than that for the parent). 
101 
None was resistant to norfloxacin, ciprofloxacin and levofloxacin while 
one, two and four strains were resistant to ofloxacin, gemifloxacin and moxifloxacin, 
respectively. All were resistant to nalidixic acid (MICs = 32 to >512 jig/ml). 
f) First-step gemifloxacin strains 
The MIC of gemifloxacin for 1^ -^step gemifloxacin strains was 16-fold 
higher than that for the parent, while that of the other five fluoroquinolones was 8- to 
16-fold higher (Table 16). The MICs were in the range of 0.25 - 2 [ig/ml 
None was resistant to norfloxacin, ciprofloxacin, ofloxacin and 
gemifloxacin while two and all three were resistant to moxifloxacin and 
gemifloxacin, respectively. All were also resistant to nalidixic acid (MICs = 32 - 128 
l^g/ml). 
B) Activities of fluoroquinolone against 1^ -^step strains 
None of the 24 1^^ -step strains were resistant to norfloxacin, ciprofloxacin 
or levofloxacin but one to eight were resistant to ofloxacin, moxifloxacin or 
gemifloxacin (Table 16). Only three were susceptible to 16 |ag/ml of nalidixic acid. 
Most of these 1^^ -step strains had similar MICs except for those that 
developed in the presence of moxifloxacin or gemifloxacin which were much less 
susceptible especially to norfloxacin and moxifloxacin as the MICs were usually 8-
to 32-fold higher than those for the parent. 
3.2.1.2 Characterization of gene mutations 
Before characterization of gene mutations, the QRDR of gyrA, gyrB, parC 
and parE genes of SHI739 was determined and compared with that of ST13311 
(Figure 12). 
The QRDR sequence of gyrA and gyrB genes of both ST13311 and 
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Figure 12 Multiplex PCR amplimer conformation (MPAC) analysis of the 
QRDR of gyrA, gyrB, parC and parE genes of Salmonella Hadar 1739 
compared with that of Salmonella Typhimurium ATCC 13311. Lanes 1-2, parE 
gene of Salmonella Hadar and Salmonella Typhimurium, respectively. Lanes 
3-4, parC gene of Salmonella Hadar and Salmonella Typhimurium, 
respectively. Lanes 5-6, gyrB gene of Salmonella Hadar and Salmonella 
Typhimurium, respectively. Lanes 7-8, one fragment of gyrA gene of 
Salmonella Hadar and Salmonella Typhimurium, respectively. Lanes 9-10, the 
other fragment of gyrA gene of Salmonella Hadar and Salmonella 
Typhimurium, respectively. 
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SHI739 was identical. However, differences were detected in the QRDR of parC 
gene at nucleotide positions 183, 214, 238, 244 and 334 (Table 17). Compared to 
ST 13311, SHI739 had a C—G transversion at nucleotide position 183 leading to a 
substitution of threonine for serine at amino acid position 51. The other three-base 
difference, a T->C transversion at 214 and 244 and a C—T transversion at 238 and 
334, did not lead to changes in amino acid. 
The QRDR of the parE gene of SH1739 differed from that of ST13311 at 
nucleotide position 1399 (G—A transversion), 1420 (G—T transversion) and 1432 
(A—G transversion) (Table 17). These base differences also did not lead to changes 
in amino acid. 
A) MPAC analysis 
The QRDR of gyrA, gyrB, parC and parE genes in the 24 l® -^step strains 
was characterized by PCR followed by MPAC analysis. 
Five different gyrA MPAC patterns were found (Type I - V) (Figure 13). 
Nine strains had the same pattern (Type V) as SHI739 while the other 15 strains 
exhibited four different patterns (Type I - IV). However, only one isolate showed a 
gyrB pattern that was different from that of the parent (Figure 9). The parC and parE 
patterns of all 1^^ -step strains were identical to those of the parent. 
B) Gene mutations 
The DNA sequence of the QRDR of gyrA, gyrB, parC and parE genes of 
all 24 strains was determined. 
No mutation was found in the gyrA gene of nine strains that had the same 
gyrA MPAC pattern as that of the parent (Type V) while the other 15 mutants with an 
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Table 17 Base difference of target genes between Salmonella Typhimurium  
ATCC 13311 and Salmonella Hadar 1739 
_ S. Typhimurium S. Hadar 
Gene Site* 
13311 1739 
1 NA183 ACC AGC 
AA57 Thr Ser 
2 NA214 GTT GTC 
AA67 Val Val 
3 NA238 CAC CAT 
parC 
AA 75 His His 
4 NA244 CAT CAC 
AA 77 His His 
5 NA334 GGC GGT 
AA107 Gly Gly 
1 NA1399 GAG GAA 
AA449 Glu Glu 
2 NA1420 CTG CTT 
parE 
AA456 Leu Leu 
3 NA 1432 GAA GAG 
AA460 Glu Glu 








































































































































































































































































MPAC pattern different from that of the parent were found to have gyrA mutations. 
Three mutants (Hmox-1, Hmox-3, Hmox-5) of type I MPAC pattern had a 
Asp87—Gly (GAC^GGC) mutation; four (Hnor-3, Hnor-6, Hofl-3, Hofl-4) of type 
II had Asp87—Asn (GAC—AAC); five (Hnor-2，Hcip-2, Hlev-S, Hmox-2, Hgem-3) 
of type III had Asp87—Tyr (GAC—TAC); and three (Hnor-4, Hnor-7, Hlev-2) of 
type IV had Ser83-^Phe (TCC^TTC). 
The only mutant (Hofl-2) showing a different gyrB pattern from the parent 
had a Glu466—Asp (GAA^GAC) mutation on gyrB gene. No mutation was found 
in the parC or parE genes of all 1^ -^step mutants (Table 16). 
The Asp87—>Gly gyrA mutation was found only in moxifloxacin mutants 
(n = 3) while Asp87^Asn was found in two each of norfloxacin and ofloxacin 
mutants. Asp87—>Tyr was detected in one each of the mutants except ofloxacin 
mutants while Ser83—>Phe was detected in norfloxacin (n = 2) and levofloxacin (n 二 
1) mutants. The gyrB mutation was present in the ofloxacin mutant. 
3.2.1.3 Mutations and fluoroquinolone susceptibilities 
A) Mutants with gyrA mutation 
The MICs of fluoroquinolones for S. Hadar 1^ -^step mutants with a gyrA 
mutation were 4 - 32 times those for the parent. They ranged from 0.12 \iglm\ to 4 
|ig/ml (Table 16). 
Mutants that had a Asp87->Gly mutation were least fluoroquinolone-
susceptible since their MICs (except those for Hmox-5) were 16- to 32-fold higher 
than those for the parent, followed by those that had a Ser83—>Phe mutation, for 
which the MICs were usually 8- to 16-fold higher than those for the parent. All the 
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four mutants that had a Asp87—Asn mutation and most mutants with a Asp87—Tyr 
mutation had their susceptibilities decreased 8-times those of their parent. 
B) Mutant with gyrB mutation 
The MIC of gemifloxacin (0.06 jig/ml) and moxifloxacin (1 )ig/ml) for the 
mutant with a gyrB mutation was 2- and 8-fold higher than that for the parent while 
the MIC of the other four fluoroquinolones was 4-fold higher (0.12 jig/ml of 
ciprofloxacin; 0.25 |ig/ml of levofloxacin; 0.5 |ig/ml of norfloxacin and ofloxacin) 
(Table 16). 
C) Strains without any detectable mutation 
Eight S. Hadar 1^ -^step strains (33%) had no detectable mutation. However, 
their susceptibilities still decreased as compared to those of the parent. 
The susceptibilities to levofloxacin or norfloxacin were either the same or 
decreased 4 - 1 6 times as compared to their parent while those of the other four drugs 
decreased 2 - 1 6 times. The MICs ranged from 0.06 i^g/ml to 2 iig/ml (Table 16). 
3.2.1.4 Mutations and nalidixic acid susceptibilities 
All 15 S. Hadar 1^^ -step mutants with a gyrA mutation were resistant to 
nalidixic acid (MICs = 128 - 512 |ig/ml). Although the mutant with a gyrB mutation 
was also resistant to nalidixic acid, the MIC was much lower (32 jug/ml). These 
MICs were >16-fold and 4-fold, respectively higher than those for the parent. 
For the eight strains which did not have any detectable mutations, two 
which developed in the presence of norfloxacin and one which developed in the 
presence of levofloxacin were sensitive to nalidixic acid (MIC — 8 jig/ml and 16 
|ag/ml, respectively) while the other six were resistant (MICs = 32-512 |ig/ml). 
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3.2.2 Characterization of l^ '^ -step mutants 
Seven 1^ -^step mutants that had different gyrA mutation and were selected 
by each of the six fluoroquinolones (Hnor-4, Hcip-2, Hofl-4, Hlev-2, Hmox-3 and 
Hgem-3) and the one that had a gyrB mutation (Hofl-2) were subjected to another 
round of selection by the fluoroquinolones which was used to select individual 
ist-step mutants (Figure 4). Mutants that subsequently developed were referred to as 
S. Hadar 2"^-step mutants and they were obtained on antibiotic plates containing Ix -
4x MIC of the selecting drug (Table 18). Twenty-five 2"^-step mutants, named as 
Hxxx-n-m, where Hxxx-n stands for the parent strain and m the number of the 
2"^-step mutant, were characterized. 
3.2.2.1 Antimicrobial susceptibilities 
As for ist-step mutants, the susceptibilities of 2"^-step mutants to all the six 
fluoroquinolones and nalidixic acid were tested by determining the MICs. 
A) Susceptibilities of 2"^-step mutants 
a) Second-step norfloxacin mutants 
The MIC of gemifloxacin, moxifloxacin and ciprofloxacin for these five 
2"'^ -step norfloxacin mutants were 1 - 4, 2 - 4 and 4 - 8 times that for the parent, 
respectively, while that of the other three fluoroquinolones were 2 - 8 times (Table 
18). All were resistant to both moxifloxacin and gemifloxacin and one to three 
mutants were resistant to the other four fluoroquinolones tested. 
b) Second-step ciprofloxacin mutants 
The MICs of levofloxacin for 2"^-step mutants that developed from Hcip-2 

























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































fluoroquinolones increased 4- to 8-fold as compared to those for the parent (Table 
18). However, they remained susceptible to ciprofloxacin or levofloxacin but were 
resistant to the remaining four fluoroquinolones. 
c) Second-step ofloxacin mutants 
The MICs of all fluoroquinolones for 2"^-step ofloxacin mutants developed 
from Hofl-4 increased 8- to 16-fold as compared to those for the parent (ranging 
from 2 |ig/ml to 16 )ig/ml) (Table 18). Besides, these mutants were resistant to all six 
fluoroquinolones. 
However, the MICs of all fluoroquinolones for 2"'^ -step ofloxacin mutants 
that developed from Hofl-2 increased only 2- to 8-fold (ranging from 0.12 |ig/ml to 4 
jig/ml). One and two mutants were resistant to ofloxacin and gemifloxacin, 
respectively, while all were resistant to moxifloxacin. None was resistant to 
norfloxacin, ciprofloxacin or levofloxacin. 
d) Second-step levofloxacin mutants 
The MIC of ofloxacin, moxifloxacin and gemifloxacin for these two 
2nd-step levofloxacin mutants was 2- to 4-fold higher than that for the parent, while 
that of norfloxacin, ciprofloxacin and levofloxacin was 4- to 8-fold higher (Table 18). 
All except one (Hlev-2-2, sensitive to ciprofloxacin and levofloxacin) were resistant 
to low concentrations (1 -8 |ag/ml) of the fluoroquinolones. 
e) Second-step moxifloxacin mutants 
Compared to that for the parent, the MIC of ciprofloxacin (2 ^ig/ml), 
ofloxacin (8 |ag/ml), levofloxacin (4 |ig/ml) and moxifloxacin (8 |Lig/ml) for the 
2"^-step moxifloxacin mutant increased 2 times while that of gemifloxacin (2 ^g/ml) 
increased 4 times and that of norfloxacin (32 |ig/ml) increased 8 times. It was 
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resistant to all six fluoroquinolones (Table 18). 
f) Second-step gemifloxacin mutants 
The MIC of norfloxacin was increased to the highest level (8- to 32-fold) 
as compared to that for the parent except for Hgem-3-4, while that of the other 
fluoroquinolones was usually increased 2- to 8-fold (Table 18). The susceptibility of 
one and three mutants to ciprofloxacin and levofloxacin, respectively, was the same 
as that of the parent. 
The MICs were in the range of 0.5 - 32 [ig/ml. All were resistant to 
moxifloxacin and gemifloxacin, but one to four were susceptible to the other four 
fluoroquinolones. 
C) Activities of fluoroquinolone against 2"^-step mutants 
All 25 of the 2"^-step mutants were resistant to moxifloxacin (Table 18). 
Only four and seven were susceptible to gemifloxacin and ofloxacin, respectively, 
while 10 or more were susceptible to norfloxacin, ciprofloxacin or levofloxacin. The 
susceptibility of step mutants that developed from Hofl-2 decreased relatively 
less as compared to mutants that developed from other parents. 
3.2.2.2 Characterization of gene mutations 
MPAC analysis and sequencing results showed that no additional mutation 
developed in all S. Hadar mutants. 
3.2.2.3 Mutations and fluoroquinolone susceptibilities 
The MICs of all fluoroquinolones except moxifloxacin for the 2"^-step 
mutants with gyrB mutation (Tofl-2-1 to Tofl-2-6) were lower than those with gyrA 
mutation (Table 18). In contrast, the MICs for the step mutants with gyrA 
Asp87—>Asn mutation in general were higher than those for mutants with other gyrA 
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mutations. 
3.2.2.4 Nalidixic acid susceptibilities 
The MICs of nalidixic acid for all the 2"'^ -step mutants with a gyrA 
mutation were >512 |ig/ml while those for 2"'^ -step mutants with a gyrB mutation 
were lower (MIC = 32 - 128 )ig/ml) (Table 18). 
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Discussion 
1. Susceptibility of salmonellae to fluoro-
quinolones 
All salmonellae isolates selected for this study were very sensitive to the 
six fluoroquinolones tested. The MICs of all the fluoroquinolones were 8- to 64-fold 
lower than susceptible breakpoints recommended by the NCCLS (2002) and BSAC 
(Andrews, 2004). The geometric mean MICs of ciprofloxacin for all the strains were 
lowest (0.015 - 0.03 )Lig/ml), closely followed by those of gemifloxacin (0.016 - 0.03 
jLig/ml) (Tables 6 and 7). The MICs of norfloxacin and moxifloxacin were highest 
(the geometric mean MIC being up to 0.11 |Lig/ml). This indicated that ciprofloxacin 
was most active against our Salmonella strains, while norfloxacin and moxifloxacin 
were least active. These results were similar to those reported by workers in other 
parts of the world (Blondeau, 1999; Tankovic et aL, 1999; Wise and Andrews, 1999). 
Although levofloxacin and ofloxacin had similar activity against 
salmonellae, levofloxacin was sometimes more active than ofloxacin. This is 
probably due to the fact that levofloxacin is the L-enantiomer (the active form) of 
ofloxacin while ofloxacin is a racemic mixture (Walker, 1999). 
2. The potential of fluoroquinolones to restrict 
the development of Salmonella resistant 
strains 
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2.1 MPC and MPC/MIC of fluoroquinolones 
The objective of traditional treatment was to clear infection and was based 
on the susceptibilities of pathogen to antimicrobial agents in terms of MICs. 
However, MIC can only inhibit the growth of susceptible pathogens but not mutants 
which will be eliminated by the host defense systems. As a result, in 
immunocompromised patients, resistant mutants will not be killed (Zhao and Drlica, 
2002). 
Due to various factors contributing to the development of resistance such 
as inappropriate antibiotic use and overuse including in veterinary practice, a new 
strategy, MPC-based strategy, was developed to combat the resistance problem (Zhao 
and Drlica, 2002). The idea of MPC is based on the fact that above this concentration, 
resistant mutants need to acquire two mutations before being able to grow. A large 
number of cells at the infection sites, which is difficult to reach, is required before 
this will happen. Thus, MPC represents a threshold above which mutants will not 
flourish (Blondeau et al., 2001). MPC-based dosing strategy is a promising way to 
restrict the development of the resistant mutants (Drlica and Schmitz, 2002). 
Thus, the importance of determining MPC lies in the fact that it can be 
used to predict the rate at which an organism develops resistance to an antibiotic. The 
amount of drug administered to patients should preferably be higher than the MPC so 
that resistance development can be delayed. 
MFCs of fluoroquinolones have been determined for Mycobacterium sp. 
(Dong Qt al., 2000; Sindelar et al., 2000), S. aureus (Dong Qt al., 1999; Zhao et al., 
2003), S. pneumoniae (Blondeau et al., 2001; Hansen et al., 2003) and E. coli (Zhao 
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and Drlica, 2002). However, up to now, the MFCs of fluoroquinolones have not 
been determined for Salmonella strains. 
Although fluoroquinolone MICs for S. Typhimurium strains were lower 
than those for S. Hadar, the MFCs for the former were comparatively higher (Tables 
8 and 10). The MPC ranges of all the fluoroquinolones tested for S. Typhimurium 
were higher than those for S. Hadar except for ofloxacin MPC for one S. Hadar strain. 
The MFCs of ciprofloxacin for both S. Typhimurium and S. Hadar were lowest while 
those of ofloxacin were highest. 
To determine whether MPC was related to MIC, the MPC/MIC ratio was 
determined. This ratio is an indication of the size of the MSW and can reflect the 
potential of an antibiotic to select mutants. The smaller the ratio, the narrower is the 
MSW and easier for the drug to restrict development of resistant mutants. By having 
drug concentration higher than the MPC, the possibility of resistance development 
will be reduced (Dong et al., 2000). 
Interestingly, the ratio of ciprofloxacin for S. Typhimurium was the second 
highest (17 times higher than that of MIC) while that for S. Hadar was the second 
lowest (both the MPC and MPC/MIC ratio were low) (Tables 8 and 10). This 
indicated that the exact value of MPC was not the only parameter that should be 
looked at since it depended on the MIC for a particular strain. Rather, the MPC/MIC 
ratio, or the number of times the MPC was higher than the MIC of each drug should 
be evaluated. In terms of restricting development of resistant mutants, a low MPC 
value, as well as a low MPC/MIC ratio were desirable since the concentration of the 
drug required to stop or reduce the growth of mutants was low despite the MIC was 
also low. 
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Similarly, although the MPC of moxifloxacin for both S. Typhimurium and 
S. Hadar was higher than that of ciprofloxacin, the MPC/MIC ratio was the lowest 
among the six fluoroquinolones tested (Tables 8 and 10), indicating that 
moxifloxacin could efficiently inhibit the growth of resistant mutants at a rather low 
concentration. It has been shown that C-8-methoxy fluoroquinolones (such as 
moxifloxacin) are more potent in restricting the development of resistant mutants of 
mycobacteria, S. pneumoniae, S. aureus and E. coli (Ito, Matsumoto and Nishino, 
1995; Zhao et al., 1998; Dong et al., 1999 & 2000; Lu, Zhao and Drlica, 1999; 
Sindelar et al., 2000; Dalhoff, 2001; Ince, Zhang and Hooper, 2003). 
As for gemifloxacin, although the MPC was comparable to that of 
moxifloxacin, the MPC/MIC ratio for both S. Typhimurium and S. Hadar was the 
highest (Tables 8 and 10). Using the reasoning detailed above, it could be postulated 
that gemifloxacin could select resistant mutants more readily than other 
fluoroquinolones. 
There was no difference in the MPC/MIC ratios for the standard strain and 
those for the clinical strains of S. Typhimurium (Table 8). Blondeau et al (2001) also 
have reported that the ratios for both clinical and standard S. pneumoniae strains are 
similar. Thus, whether the strains were wild-type or standard, a drug had the same 
potential to restrict the development of resistant mutants. 
2.2 Cmax/MPC of fluoroquinolones 
The MPC of a drug must be below the maximum serum concentration 
(Cmax) and tissue concentration in order that the drug can restrict the growth of 
resistant mutants clinically (Sindelar et al., 2000). Since fluoroquinolone 
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concentration in serum is usually lower than that in tissues, a MPC that is lower than 
C m a x should also be lower than the concentration achievable in tissues (Blondeau et 
a l , 2001). Thus, Cmax/MPC could be used as a measure of the ability of a drug to 
restrict the development of resistant mutants. 
Our results showed that for both S. Typhimurium and S. Hadar 
ciprofloxacin had the highest Cmax/MPC ratio while norfloxacin had the lowest ratio 
(Tables 8 and 10), indicating that ciprofloxacin was the most effective while 
norfloxacin was the least effective among the fluoroquinolones tested in restricting 
the development of resistant mutants. 
As compared to the MFCs of first-line anti-tuberculous agents for M. 
tuberculosis (Dong et al., 2000) and the MPC of ciprofloxacin for S. aureus which 
were above Cmax (Zhao et al.’ 2003), the MFCs of all six fluoroquinolones for our 
Salmonella strains were below Cmax: ciprofloxacin MPC was 22- to 33-fold lower 
than Cmax while norfloxacin was just under 2-fold lower than Cmax (Tables 8 and 10). 
This indicated that theoretically, fluoroquinolones other than norfloxacin could be 
used in monotherapy since they had the ability to restrict selection of resistant 
Salmonella and there was only a slim chance of development of resistance if the 
recommended dosing regimen is strictly followed. Since only two serotypes were 
tested, strains of other serotypes should be tested to determine whether the same 
phenomenon holds true. Animal studies followed by clinical studies should be 
performed to test this hypothesis. 
2.3 Selection frequency of fluoroquinolones 
S. Typhimurium first-step resistant strains could develop at a frequency of 
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IQ-ii - 10—6 on plates containing Ix - 32x MIC of fluoroquinolones (Table 9). Among 
the six fluoroquinolones tested, gemifloxacin could select resistant strains at 
frequencies (10"^ ® - l O ’ that were higher than moxifloxacin (lO—u - lO’，indicating 
that S. Typhimurium could develop fluoroquinolone-resistance more readily in the 
presence of gemifloxacin than moxifloxacin. 
S. Hadar 1^ -^step resistant strains developed at frequencies similar to or 
different from those for S. Typhimurium (Table 11). As for S. Typhimurium, 
gemifloxacin least readily while moxifloxacin most readily restricted development of 
S. Hadar resistant strains. Therefore, selection frequencies could be an indicator of 
the potential of a fluoroquinolone to select resistant bacteria. 
2.4 Effects of fluoroquinolones on the development of 
resistance in Salmonella Typhimurium and 
Salmonella Hadar 
Since ciprofloxacin had the lowest MIC and MPC to both S. Typhimurium 
and S. Hadar and the MFCs were more than 20 times lower than the maximum 
achievable concentration in the blood, this antibiotic had good antibacterial activity 
as well as great potential to restrict development of resistant strains. In contrast, 
gemifloxacin had the widest MSW and the second lowest Cmax/MPC ratio (Tables 8 
and 10), indicating that this drug could readily select for resistance. Moxifloxacin 
had the narrowest MSW among the fluoroquinolones tested. However, the MPC was 
only about seven times lower than the maximum serum concentration (Tables 8 and 
10). 
S. Typhimurium has been found to be the Salmonella serotype that has 
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more resistant strains or more strains that have decreased susceptibilities to the 
fluoroquinolones than other serotypes in many parts of the world (Piddock et al” 
1993; Threlfall et aL, 1997a; Threlfall, Ward and Rowe, 1997; Cruchaga et al., 2001; 
Guerra et al., 2003; Threlfall et al., 2003). Whether our preliminary in vitro results 
reflected resistance development in S. Typhimurium in vivo requires more 
confirmatory studies to be carried out. 
3. Characterization of in vitro fluoroquinolone-
resistant Salmonella strains 
3.1 Development of resistance phenotype 
3.1.1 Microbiology 
Some of the fluoroquinolone-resistant mutants that developed from 
sensitive Salmonella strains in the presence of increasing fluoroquinolone 
concentrations formed smaller colonies and were more slow-growing (requiring 48 
to 72 h to grow) than their parents. This might probably be a result of adaptation to 
antimicrobial agents. Bagel et al (1999) and Giraud et al. (1999 & 2003) also 
noticed that some high-level resistant E. coli and Salmonella showed altered growth 
rates and shapes, and that they did not colonize guts of chickens. Whether these 
contribute to high-level resistance to develop more readily in vitro than in vivo 
requires further investigation. 
3.1.2 Antimicrobial susceptibilities 
3.1.2.1 First-step strains 
In general, l® -^step strains of both S. Typhimurium and S. Hadar were less 
120 
susceptible to most of the fluoroquinolones tested than their parents, regardless of 
whether target gene mutations developed or not. Such decreased susceptibilities 
could be as much as 32-fold as compared to the parents (Tables 12 and 16). However, 
all strains of S. Typhimurium and most of those of S. Hadar remained susceptible to 
the fluoroquinolones. In contrast, 40% and 88% of these strains that developed from 
S. Typhimurium and S. Hadar, respectively, were resistant to up to 512 |ig/ml or more 
of nalidixic acid. 
3.1.2.2 Second-step mutants 
As for ist-step strains, the susceptibilities to fluoroquinolones of 2"^-step 
mutants were further decreased even though not all became resistant and had the 
same mutations as their parents (Tables 13 and 18). In contrast, all 2"'^ -step mutants 
of both S. Typhimurium and S. Hadar became resistant to nalidixic acid (MICs = 32 -
>512 |ig/ml). 
It appeared that S. Typhimurium norfloxacin mutants were least susceptible 
as the MICs of most fluoroquinolones for these mutants were higher and 
levofloxacin mutants were most susceptible while for S. Hadar, norfloxacin mutants 
were most susceptible. Therefore, MICs might not only depend on which 
fluoroquinolone was used for selecting mutants but also the mutation harboured by 
mutants. Mutants with high fluoroquinolone MICs harboured a single Asp87—Asn 
mutation while those with low MICs had either a gyrB Glu466—Asp mutation or a 
gyrA Asp87—His mutation. Therefore, the Asp87—>Asn mutation might be important 
in conferring reduced susceptibilities to fluoroquinolones. 
3.1.2.3 Third-step mutants 
Another round of selection was not carried out on S. Hadar 2"^-step 
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mutants since they did not have an additional mutation. The susceptibilities further 
decreased in S. Typhimurium S'^ -^step mutants as they became resistant to at least one 
fluoroquinolone (Table 14). Besides, all were resistant to moxifloxacin and nalidixic 
acid. The MICs of most fluoroquinolones were increased much more for those 
mutants that had an additional parC mutation. 
3.1.2.4 Fourth-step mutants 
Susceptibilities of S. Typhimurium mutants to fluoroquinolones continued 
to decrease in step mutants as MICs reached to a high of 64 昭/ml of norfloxacin, 
moxifloxacin or gemifloxacin (Table 15). All except two mutants became resistant to 
all the fluoroquinolones tested. However, none had additional target gene mutations. 
3.2 Contribution of target gene mutations to resistance 
development 
3.2.1 First-step mutants 
All ist-step mutants developed a single gyrA mutation except one each of S. 
Typhimurium and S. Hadar which developed di gyrB mutation (Tables 12 and 16). All 
the gyrA mutations were on position 87 or 83. Mutations at these two positions were 
commonly reported to be related to fluoroquinolone-resistance in Salmonella sp. 
(Heisig et al, 1995; Reyna et al., 1995; Brown et al., 1996; Piddock et al., 1998; 
Ling et al., 2003) and E. coli (Cullen et al, 1989, Yoshida et al., 1990; Oram and 
Fisher, 1991; Heisig, Schedletzky and Falkenstein-Paul, 1993). 
The gyrA mutations (Asp87—Asn/Gly/Tyr) that developed in this study 
have been reported in clinical Salmonella isolates with decreased susceptibilities 
(Griggs, Gensberg and Piddock, 1996; Piddock, 2002; Casin et al” 2003; Guerra et 
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a l . 2003; Ling et al., 2003; Nakaya et al., 2003) and in in vitro stepwise-selected 
mutants (Reyna et al., 1995; Giraud et al., 1999; Hansen and Heisig, 2003). These 
mutations have also been reported in other organisms such as M tuberculosis (Takiff 
et al., 1994, Alangaden et al., 1995；, N. gonorrhoae (Lindback et al, 2002), P. 
aeruginosa (Kureishi et al., 1994) and C. jejuni (Wang, Huang and Taylor, 1993) and 
were shown to contribute to fluoroquinolone-resistance. However, the Asp87->His 
mutation in a S. Typhimurium mutant that developed in the presence of levofloxacin 
(Tlev-1) had not been reported previously. 
All 1 St-step mutants of S. Typhimurium with an Asp87 mutation 
(Asp87—Asn/Gly/His/Tyr) remained susceptible to all the fluoroquinolones tested 
although MICs increased (Table 12). All except one of the 1^ -^step mutants of S. 
Hadar with an Asp 87 mutation were also susceptible to the fluoroquinolones other 
than moxifloxacin and gemifloxacin (Table 16). However, they were all resistant to 
up to >512 |ig/ml of nalidixic acid. 
The Ser83—Phe mutation was present in 1^^ -step mutants of S. Hadar only 
and Asp87—>His in those of S. Typhimurium only while Asp87^Tyr/Gly was present 
in those of both Salmonella serotypes. All these mutations caused a 2- to 32-fold 
reduced susceptibilities to fluoroquinolones (Tables 12 and 16). Although Giraud et 
al (1999) reported that Ser83—Phe caused strains to be more resistant than other 
single gyrA mutations, whether this is related to strain specificity or presence of other 
resistance mechanisms remains to be determined. 
Both our findings of a single gyrB gene mutation in salmonellae and such a 
mutation being at amino acid 466 (Glu466—Asp) have not been reported previously. 
Other workers have also noted that gyrB mutation is uncommon in salmonellae and 
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other bacterial species (Ling et al., 2003). To the best of our knowledge, only two 
gyrB mutations have been found in salmonellae and all these occurred in S. 
Typhimurium (Heisig, 1993; Piddock et al., 1993; Gensberg, Jin and Piddock, 1995; 
Casin et aL, 2003). However, these mutations (Ser463->Tyr or Ser464—>Phe) were 
always present together with one or more gyrA mutations. Although gyrB was 
thought to decrease the binding ability of quinolones to the gyrase-DNA complex, 
the exact role of gyrB mutation in the development of resistance was still unclear 
(Heddle and Maxwell, 2002). 
A single gyrB mutation was indeed uncommon as it was found in only two 
out of 23 of our 1^ -^step mutants with a target gene mutation (Tables 12 and 16). Its 
effect on fluoroquinolone susceptibilities of these mutants was also less than that of 
gyrA mutation as MICs could be increased to as low as only twice those of the parent 
strain. 
Gyrase gene mutations were shown to be directly related to resistance by 
complementation tests that recovered complete or partial fluoroquinolone 
susceptibilities by wild-type gyrA or gyrB plasmids (Heisig, 1993; Heisig et aL, 1995; 
Piddock et al, 1998). Our findings were consistent with those of other workers that 
gyrA mutations were associated with resistance or decreased susceptibility to 
fluoroquinolones in Gram-negative bacteria, while gyrB played only a secondary role 
and was uncommon (Griggs, Gensberg and Piddock, 1996; Ouabdesselam, Tankovic 
and Soussy, 1996; Ruiz et al., 1997a; Wiuffe^ aL, 2000). 
It is interesting to note that of the 44 1^ -^step strains studied, 21 did not 
have any detectable mutations in the target genes gyrA, gyrB, parC and parE. 
However, their fluoroquinolone susceptibilities were decreased as compared to their 
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parents despite remaining susceptible to most fluoroquinolones and nalidixic acid. 
The exact mechanism(s) leading to such a reduced susceptibility require(s) further 
investigation. 
3.2.2 Second-step mutants 
Previous studies have emphasized the important contribution of Ser83 
mutation to the fluoroquinolone-resistance (Griggs, Gensberg and Piddock, 1996; 
Ouabdesselam, Tankovic and Soussy, 1996; Wain et al., 1997; Chu et al., 1998; 
Tankovic et al., 1999; Kristiansen, Sandvang and Rasmussen, 2003; Ling et al., 
2003). Three out of the 17 2"^-step mutants of S. Typhimurium with a gyrA mutation 
but none of the 19 of S. Hadar characterized developed an additional gyrA mutation, 
Ser83->Phe (Tables 13 and 18). 
Although 2"^-step mutants with two gyrA mutations were less susceptible 
than their 1^ -^step mutants with a single gyrA mutation, their susceptibilities were 
similar to those of 2"^-step mutants without any additional gyrA mutation (Table 13). 
This was probably due to the fact that other resistance mechanisms were involved. 
Other explanations included mutations existed outside of the QRDR on the fragments 
that were sequenced and were therefore not detected. The exact resistance 
mechanisms remain to be investigated. 
An additional gyrA mutation (Asp87—Gly or Ser83->Phe) developed in 
two of the four step mutants that developed from the 1^^ -step mutant with a gyrB 
mutation (Table 13). Their susceptibilities to fluoroquinolones, though decreased as 
compared to those of their parent, were comparable to those of the 2"^-step mutants 
that did not have an additional gyrA mutation. However, the mutants with an 
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additional gyrA mutation were more resistant to nalidixic acid than those without an 
additional gyrA mutation. Resistance mechanisms in these mutants had to be further 
investigated. 
3.2.3 Third-step mutants 
AparC mutation (Glu51/Gly78—Asp, Ser80—Arg/Ile or Glu84—Lys/Gly) 
developed in 3^^-step mutants from 2"'^ -step mutants with two gyrA mutations (Table 
14). Although fluoroquinolone susceptibilities of 3^^-step mutants with Glu51—Asp 
or Glu84->Gly mutation decreased further, they were similar to those without a parC 
mutation. It should be noted that Hiasa (2002) found that Glu84 was critical for 
interactions of topoisomerase IV, DNA and fluoroquinolones. Therefore, it is difficult 
to determine the contribution of these parC mutations towards 
fluoroquinolone-resistance. In contrast, S '^^ -step mutants with a Gly78—Asp, 
Ser80->Arg/Ile or Glu84^Lys mutation were more resistant, suggesting that these 
mutations might contribute towards fluoroquinolone-resistance. 
SerSO^Arg and Glu84—Lys mutations have been reported to be the most 
common mutations that contribute towards decreased fluoroquinolone susceptibilities 
in E. coli (Vila et al., 1996; Wang et al., 2001, Hirose et al., 2002), N. gonorrhoeae 
(Ser88 and Glu91 of N. gonorrhoeae equivalent to SerSO and Glu84, respectively of 
E. coli) (Belland et al., 1994) and S. aureus (Ferrero et al., 1994; Ferrero, Cameron 
and Crouzet, 1995; Takahashi et al., 1998; Jones et al., 2002). 
Four 3^^-step ciprofloxacin mutants of S. Typhimurium had an additional 
mutation, a parC Ser80->Arg (Table 14). However, they had either a C—G or an 
A->C transversion. Such nucleotide changes did not affect their susceptibilities as 
126 
the MICs of all six fluoroquinolones tested for these mutants were identical. 
Three 3^^-step levofloxacin mutants developed an additional parC mutation 
(Gly78—>Asp) (Table 14). They were resistant to most fluoroquinolones tested but 
one was susceptible to nalidixic acid while the other two had nalidixic acid MIC of 
32 |ig/ml which was 8-fold lower than that for the parent. This has not been reported 
previously in Salmonella. 
Whether the parC mutation caused an increased susceptibility to nalidixic 
acid remains to be determined. Possible explanations include the structure of 
aspartate at residue 78 being more stable and more sensitive to nalidixic acid than 
glycine; and change in amino acid at parC residue 78 might interact with gyrA 
residue 87 and 83 resulting in diminished effect of these gyrA mutations on nalidixic 
acid susceptibilities. Crystallography studies could be used to test these hypotheses. 
Nalidixic acid-susceptible and fluoroquinolone-resistant strains have been 
reported in E. coli strains with a gyrA Gly81->Asp mutation (Moniot-Ville et al., 
1991; Cambau et al” 1993; Troung et al., 1997; Ruiz, 2003). Since nalidixic acid has 
no cyclic constituent at C-7 position which is important in binding to gyrase, 
mutation involving the gene coding for this enzyme probably did not affect its 
activity. Alterations of outer membrane proteins or LPS might also be responsible for 
decreased uptake of fluoroquinolones leading to fluoroquinolone-resistance 
(Moniot-Ville et al., 1991). 
No additional mutation developed in S '^^ -step mutants from 2"^-step 
mutants with a gyrB Glu466 mutation and a gyrA mutation (Asp87—Gly or 
Ser83->Phe) although susceptibilities to fluoroquinolones continued to decrease 
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(Table 14). Most remained susceptible to the fluoroquinolones except moxifloxacin 
and gemifloxacin. Mechanisms other than target gene mutations were probably 
involved. 
3.2.4 Fourth-step mutants 
Although no additional mutations were detected in all 4^^-step mutants, all 
had decreased susceptibilities as compared to their parents and almost all were 
resistant to breakpoint concentrations for resistant strains of all fluoroquinolones 
except levofloxacin (Table 15). However, 4^^-step mutants that developed from 
Tlev-1-5-5 that harboured two gyrA mutations (Asp87—His and Ser83—Phe) and a 
parC mutation (SerSO^Ile) were most resistant as compared to other 4^^-step 
mutants as the MICs were usually 16 - 64 |ig/ml. In contrast, 4^^-step mutants that 
developed from Tlev-1-5-2 harboring the same gyrA mutations but another parC 
mutation (Glu84->Gly) were the least resistant. Mechanisms of resistance in these 
strains are interesting topics for further investigation. 
It is not surprising to find no additional gyrA or parC mutation in step 
mutants as previous studies have shown that only one parC mutation existed in 
Salmonella isolates usually with one or two gyrA mutations (Casin et al., 2003; 
Guerra et al, 2003; Ling et al., 2003; Nakaya et al., 2003). Although double parC 
mutations were reported in E. coli, they usually existed in those strains that were 
resistant to very high concentrations of fluoroquinolones (Vila et al., 1996). However, 
the most common mutations involved in high level resistance are usually double 
gyrA mutations and a singleparC mutation (Everett et al., 1996; Bagel et al., 1999). 
It is also not surprising that we did not detect any parE mutation since such mutation 
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is rare and does not seem to play a major role in fluoroquinolone-resistance (Vila et 
al., 1994; Ruiz et al., 1997a; Tavio et al., 1999; Ling et al； 2003). 
The role of parC mutations in conferring fluoroquinolone-resistance has 
been demonstrated by the introduction of a plasmid with wild-type parC genes that 
decreased the resistance level of recipient strains of Salmonella (Hansen and Heisig, 
2003). Thus, topoisomerase IV is also a target enzyme in Gram-negative bacteria 
(Belland et al., 1994; Khodursky, Zechiedrich and Cozzarelli, 1995). 
3.3 The sequential development of gene mutations 
GyrA and gyrB mutation occurred first in our Salmonella mutants 
irrespective of which fluoroquinolone was used for selection. Changes of amino acid 
at Ser83 and Asp87 were the only mutations that we detected on gyrase A although 
other gyrA mutations such as Ala67—Pro, Gly81—Ser/Cys or Alall9->Glu/Val have 
been reported (Reyna et al., 1995; Griggs, Gensberg and Piddock, 1996; Piddock, 
2002; Giraud et al., 2003). A parC mutation developed subsequent to the 
development of these two gyrA mutations leading to high-level 
fluoroquinolone-resistance. Other workers have also reported that clinical Salmonella 
strains with high-level resistance had Ser83 and Asp87 double mutations as well as 
topoisomerase IV gene mutations (Hirose et al., 2002; Casin et al., 2003; Nakaya et 
al, 2003; Ling et a/., 2003). 
Only a few studies have been reported on the in vitro sequential 
accumulation of target gene mutations in salmonellae (Reyna et al., 1995; Giraud et 
al., 1999; Hirose et al., 2002; Hansen and Heisig, 2003). These laboratory 
observations including ours together with clinical findings indicated that gyrase is the 
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primary target of fluoroquinolones in salmonellae while topoisomerase IV is the 
secondary target (Walker, 1999; Hooper, 2000a; Bearden and Danziger, 2001). This 
is also true for other Gram-negative bacteria such as N. gonorrhoeae, E. coli and 
Klebsiella pneumoniae (Belland et al., 1994; Yasuda et al., 2000; Khodursky, 
Zechiedrich and Cozzarelli, 1995; Deguchi et al., 1997). In contrast, Gram-positive 
bacteria have topoisomerase IV as their primary target and gyrase as their secondary 
target (Ferrero et al., 1994; Ferrero, Cameron and Crouzet, 1995; Anderson et al, 
1999). 
GyrA mutations Asp87^Asn/Gly/Tyr were found in 1^ -^step mutants of 
both Salmonella serotypes, however, Ser83—>Phe was found in those of S. Hadar 
only and Asp87-^His in those of S. Typhimurium only. GyrA Ser83一Phe mutation 
was detected in l® -^step mutants of S. Hadar but only in 2"^-step mutants of S. 
Typhimurium. Besides, no mutations were detected in 1^ -^step strains of S. 
Typhimurium in the presence of moxifloxacin or gemifloxacin while mutations could 
be detected in 1^ -^step mutants of S. Hadar in the presence of all the six 
fluoroquinolones tested. There were also more strains of S. Typhimurium without 
detectable mutation than those of S. Hadar. No additional mutation appeared in all 
2"^-step mutants of S. Hadar while two different gyrA mutations (Ser83^Phe and 
Asp87—Gly) developed in 2"'^ -step mutants of S. Typhimurium. Whether these were 
due to serotype difference again requires further investigation. 
3.4 Other fluoroquinolone-resistance mechanisms 
It is obvious from our study that mechanisms of fluoroquinolone-resistance 
other than target gene mutations played an important role in our resistant strains. 
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Strains that developed in the presence of fluoroquinolones but without any detectable 
mutation were much less susceptible than their parent but were similar to those 
mutants with target gene mutation(s) (Tables 12 and 16). Besides, mutants with the 
same mutation(s) had different MICs especially if they were subjected to another 
around of selection (Tables 15 and 18). Thirdly, the MICs for mutants with double 
gyrA mutations were not much higher than those for mutants with a single mutation 
(Table 13). 
Other mechanisms that have been reported include enhanced expression of 
efflux pumps and decreased permeability (Kohler et al., 1997; Poole, 2000a; 
Mazzariol et al., 2000; Lomovskaya et al., 2001; Jellen-Ritter and Kem, 2001; 
Webber and Piddock, 2003). AcrAB-TolC efflux system and marRAB/soxRS regulons 
have been reported to be responsible for fluoroquinolone-resistance in Salmonella 
(Sulavik, Dazer and Miller, 1997; Giraud et al., 2000; Piddock et al., 2000; 
Pomposiello and Demple, 2000; Koutsolioutsou et al., 2001; Randall and Woodward, 
2001). 
Several workers have suggested that these mechanisms play only a 
complementary role, have a lesser effect on the development of resistance and 
probably mainly act to facilitate development of multiple-antibiotic-resistant (MAR) 
phenotypes than gene mutations (Tavio et al, 1999; Su and Lind, 2001). Inhibitors of 
efflux pumps such as Phe-Arg-P-naphthylamide have been suggested to be used in 
combination with antimicrobial agents to provide enhanced antimicrobial activity 
(Renau et al., 2002; Ribera et al., 2002). Design of new and safe inhibitors of 
antibiotic efflux transporters have been advocated for the control of resistance (Van 
Bambeke, Balzi and Tulkens, 2000; Van Bambeke et al., 2003). 
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4. Mutations and susceptibilities to fluoro-
quinolones and nalidixic acid 
4.1 Nalidixic acid - a marker for resistance to 
fluoroquinolones 
Although salmonellae that are resistant to fluoroquinolones (ciprofloxacin 
MICs >1 jig/ml) are not commonly isolated, those that have decreased 
susceptibilities with ciprofloxacin MICs >0.125 |ig/ml have continuously been 
reported and have been found to be related to delayed response or treatment failure 
(Pers, Sogaard and Pallesen; 1996; Herikstad et al., 1997; Vasallo et aL, 1998; Asna, 
Haq and Rahman, 2003). Most of these salmonellae are resistant to the prototypic 
quinolone, nalidixic acid, and have a gyrA mutation (Piddock et aL, 1993; Hakanen 
et al., 1999; Poutanen and Low, 2003). 
All our S. Typhimurium 1^^ -step mutants which had a gyrA mutation were 
resistant to nalidixic acid (MICs = 64 - 128 |ig/ml) while all except two that did not 
have any detectable gyrA mutation were susceptible to nalidixic acid (Table 12). 
These two strains were resistant to a high concentration of nalidixic acid (MICs = 
256 iig/ml) and had decreased susceptibility to all the fluoroquinolones tested (MICs 
>0.12 |ig/ml). The mutant with a gyrB mutation was susceptible to nalidixic acid 
(MIC = 8 jig/ml) and ciprofloxacin (MIC = 0.03 |ig/ml) although much less so 
(4-fold increase in MICs) than its parent. 
Similarly, all S. Hadar I'^-step mutants that had a gyrA mutation were 
resistant to nalidixic acid (Table 16). However, only three out of the eight 1^^ -step 
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strains that had no detectable mutation were susceptible to nalidixic acid (MICs = 8 -
16 |ig/ml) and the one with a gyrB mutation were resistant (MIC = 32 |ig/ml). They 
were also less susceptible to the fluoroquinolones tested. Thus, our finding further 
adds to the view that strains that are resistant to nalidixic acid have reduced 
susceptibility to the fluoroquinolones and thus nalidixic acid-resistance could be used 
as an indication of treatment failure with fluoroquinolones (Hakanen et al., 1999; 
Kapil and Renuka, 2002; Wiuff al., 2000; Crump et al., 2003). 
It is interesting to note that three 3''^ -step mutants that had two gyrA 
mutations and one parC Gly78—Asp mutation had their MIC of nalidixic acid 
reduced from 256 |ig/ml for their parent to 8 - 32 }ig/ml but were resistant to all the 
fluoroquinolones tested (Table 14). Susceptibilities to ciprofloxacin or other 
fluoroquinolones should be tested in order to detect such strains in vivo. Crump and 
his colleagues (2003) found that using nalidixic acid to screen for salmonellae with 
reduced fluoroquinolone susceptibility can not identify all Salmonella strains that are 
associated with treatment failure. 
4.2 Breakpoint and clinical efficiency 
Our results are in agreement with findings of other workers that 
salmonellae that are susceptible to the breakpoint concentration of fluoroquinolones 
for sensitive strains may not respond to treatment if the MICs are higher than those 
for wild-type strains (Howard et al., 1990; Gibb, Lewin and Garden, 1991; Lewin, 
Nandivada and Amyes, 1991; Le Lostec et al., 1997; Wain et al., 1997; Vasallo et al., 
1998; Hakanen et al, 1999; Dutta et al., 2001). Using the current breakpoints of 
fluoroquinolones would thus defeat the purpose of relating results to clinical 
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response. 
Several workers have proposed to change fluoroquinolone breakpoints 
especially for salmonellae (Aarestrup et al., 2003; Crump et al., 2003). Although the 
NCCLS has not yet revised the breakpoints, it commented that susceptibility to 
nalidixic acid might be tested to detect reduced fluoroquinolone susceptibility and 
that nalidixic acid-resistant but fluoroquinolone-susceptible salmonellae from 
patients with extraintestinal Salmonella infections might be associated with clinical 
failure if these patients were treated with fluoroquinolones (NCCLS, 2003). 
5. Strategies to reduce development of 
fluoroquinolone-resistance 
It is a general consensus that use of an antimicrobial agent will lead to 
development of resistance to this and/or other agents (Chen et al., 1999; Goldstein 
and Garabedian-Ruffalo, 2002; Neuhauser et al., 2003). Since fluoroquinolones have 
a wide spectrum of activity and few side effects, they have been extensively used for 
treatment. This has led to an increasing prevalence of fluoroquinolone-resistant 
bacteria. 
Several strategies have been proposed to prolong the lifespan of 
antimicrobial agents and these can be extended to the fluoroquinolones. MPC-based 
strategy is recently developed for this purpose (Drlica and Schmitz, 2002; Drlica and 
Malik, 2003; Drlica, 2003; Zhao, 2003). It advocates the use of a drug that has a low 
potential to select resistant mutants and that a drug should not be used alone unless it 
has the potential to have a MPC below maximum serum concentration (Drlica, 2000). 
An appropriate dosing regimen must be used in order to prevent the MPC to fall into 
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the MSW during which mutants flourish. If the fluoroquinolone can not achieve a 
serum concentration above the MPC, it should be used together with one or more 
drugs to close or narrow the MSW. Although Zhao and Drlica (2001) stressed that 
the MPC concept has not been subjected to animal or human studies, our MPC 
results for salmonellae could form a basis on which further work could be carried out 
to validate this new concept. 
With respect to development of new antimicrobial agents, one of the 
strategies is to manipulate the molecular structure so that they will have a low 
potential to select for resistance besides being active against target organisms. An 
example would be to substitute a methoxy group at the C8 site of the fluoroquinolone 
molecule that can enhance the potential of fluoroquinolones to restrict resistance 
development (Zhao et al., 1997; Dong et aL, 1999; Blondeau et al., 2001; Hansen et 
al., 2003). Another strategy is to design drugs that can evade the resistance 
mechanisms of organisms. This relies on the detailed understanding of the different 
mechanisms of resistance in various organisms. The stepwise accumulation of gene 
mutations demonstrated by our in vitro studies could be used to reflect what might 
occur in nature. 
Continuous surveillance of resistance and avoiding inappropriate use or 
overuse of drugs in man and animals are strategies that can be applied to all 
antimicrobial agents to reduce development and spread of resistance (Chen et aL, 
1999; Al-Lawati, Crouch and Elhag, 2000; Goldstein and Garabedian-Ruffalo, 2002; 
Neuhauser et al., 2003). In this study, we have screened S. Typhimurium and S. 
Hadar isolates in our hospital for fluoroquinolone-resistance or reduced susceptibility. 
This should be carried out on all salmonellae isolated on a regular basis so as to 
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monitor the development of fluoroquinolone-resistance in these organisms. 
6. Conclusion 
Salmonellae with decreased susceptibilities to fluoroquinolones and 
harbouring gyrA mutations played an important role in the development of resistance 
since high-level resistance developed by sequential accumulation of mutations in 
gyrA followed by those in parC gene. GyrB and parE gene mutations probably did 
not play an important role in fluoroquinolone-resistance in these organisms. All 
strains with decreased fluoroquinolone susceptibilities and habouring a gyrA 
mutation were resistant to nalidixic acid and nalidixic acid-resistance could be used 
as a marker of reduced fluoroquinolone susceptibility. Salmonella serotypes varied in 
their development of gene mutations and resistant mutants might more readily 
develop from S. Typhimurium than from S. Hadar. 
7. Areas for future research 
There are many questions relating to fluoroquinolone-resistance that 
remain unanswered in my project. 
1) Although MPC-based strategy is important towards determining whether 
a drug has the potential to select for resistance, the method used to determine MPC is 
time-consuming and labour-intensive. Efforts should be made to streamline the 
procedure so that it could be used routinely to study MPC of drug-organism 
combination. 
2) In this study, we have only determined the MFCs of different 
fluoroquinolones for two Salmonella serotypes. Whether other salmonellae behaved 
similarly requires to be investigated. 
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3) We managed only to select resistant mutants with both gyrA and parC 
mutations. It would be interesting to perform stepwise selection of more resistant 
mutants to detect the presence of parE mutation(s). This could be used as evidence to 
partially demonstrate the rarity of parE mutation in the clinical setting or that it 
developed late in the selection process or not at all. 
4) We have used a standard strain of S. Typhimurium for selection. It 
would be interesting to use some clinical isolates to see whether the sequential 
development of gene mutations would be similar. 
5) Since we focused only on the sequential development of target gene 
mutations, we did not subject 1^^ -step strains that did not have detectable gene 
mutations to another round of selection. These strains should be subjected to further 
selection to trace development of gene mutations, if any. 
6) Although resistant strains developed after the sensitive parent was 
grown in the presence of fluoroquinolones, some of these did not have any detectable 
mutations. Experiments such as accumulation studies using carbonyl cyanide 
w-chlorophenylhydrazone (CCCP) or ethidium bromide and efflux pumps expression 
analysis by ELISA and blotting method should be done on these strains to elucidate 
their resistance mechanisms. Further studies to determine these resistance 
mechanisms include DNA/RNA analysis on the relevant genes such as acrA, acrB, 
marR, marO, marA, marB, soxRS or tolC, and characterization of OMPs and LPS. 
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